Targeted cancer therapies

A bicistronic vector encoding shRNA targeting RASAL1 mRNA and a CAR with a LAIR hinge domain improves CAR-T cell efficacy by modulating signaling and function, overcoming limitations of current cancer immunotherapies by enhancing cytotoxicity and viability, and reducing T-cell exhaustion.

WO2026239165A1PCT designated stage Publication Date: 2026-11-19IMMUNAB RESEARCH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2026/000325
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-05-12
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current cancer immunotherapies using monoclonal antibodies for immune checkpoint blockade have limited efficacy and are hindered by mechanisms such as T-cell exhaustion and regulatory T-cell suppression, necessitating improved strategies for enhanced therapeutic outcomes.

Method used

A bicistronic vector encoding a short hairpin RNA (shRNA) targeting RASAL1 mRNA and a chimeric antigen receptor (CAR) with a LAIR hinge domain is introduced into immune cells, enhancing their therapeutic efficacy by modulating CAR-T cell signaling and function in collagen-rich tumor microenvironments.

Benefits of technology

The approach significantly enhances the cytotoxicity and viability of CAR-T cells, reducing tumor growth and achieving complete tumor clearance, while minimizing T-cell exhaustion and regulatory T-cell suppression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IB2026000325_19112026_PF_FP_ABST
    Figure IB2026000325_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The disclosure provides bicistronic vectors encoding a short hairpin RNA (shRNA) that binds specifically to RASAL1 mRNA and a chimeric antigen receptor that binds specifically to a tumor antigen or tumor neoantigen, such as the CD 19 or GD3 tumor antigen.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] TARGETED CANCER THERAPIES

[0002] RELATED APPLICATION

[0003] This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 63 / 805,045, filed May 13, 2025, the content of which is incorporated herein by reference in its entirety.

[0004] BACKGROUND

[0005] Cancer immunotherapy using monoclonal antibodies against PD-1 (and its ligand PD-Ll) has demonstrated unprecedented therapeutic benefits and long-term durable responses in patients with various cancers. Immune checkpoint blockade employs monoclonal antibodies that obstruct the binding of inhibitory receptors on T cells to their natural ligands, often expressed by cancer cells. Blockade of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) or the PD-1 ligand, PD-L1, have achieved survival rates of 20-30% in various cancers such as non-small cell lung carcinoma, melanoma, and bladder cancer. The efficacy of checkpoint blockade is mediated by several mechanisms that include classic blockade, receptor down-regulation, elimination of suppressive regulatory T-cells (Tregs) and altered contact times with presenting cells.

[0006] SUMMARY

[0007] Some aspects of the technology relate to a bicistronic vector encoding a short hairpin RNA (shRNA) that binds specifically to RASAL1 mRNA and a chimeric antigen receptor that binds specifically to a tumor-associated antigen.

[0008] In some embodiments, the tumor-associated antigen is selected from CD 19, CD20, CD22, CD33, CD38, CD123, CLL-1, GPRC5D, HER2 (ERBB2), EGFR, EGFRvIII, CEA (carcinoembryonic antigen), PSMA (pro state- specific membrane antigen), MUC1, mesothelin, Claudin 18.2, GPC3, B7-H3, AXL, GD2, GD3, FAP, WT1 (Wilms tumor 1), NY-ESO-1, PRAME (preferentially expressed antigen in melanoma), MAGE-A3, MAGE-A4, AFP, BCMA (B-cell maturation antigen), ROR1, and IL13Ra2.

[0009] Other aspects of the technology relate to a bicistronic vector encoding an shRNA that binds specifically to RASAL1 mRNA and a chimeric antigen receptor comprising a leukocyte-associated immunoglobulin-like receptor (LAIR) hinge domain.

[0010] Yet other aspects of the technology relate to a bicistronic vector comprising (a) a contiguous 10-40 nucleotide sequence reverse complementary to a RASAL1 gene, wherein theRASAL1 gene comprises the nucleotide sequence of SEQ ID NO: 22, and (b) a transgene encoding a polypeptide comprising a sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 14.

[0011] In some embodiments, a polypeptide further comprises a sequence having at least at least 90% identity to the amino acid sequence of SEQ ID NO: 6.

[0012] In some embodiments, a polypeptide further comprises a sequence having at least at least 90% identity to the amino acid sequence of SEQ ID NO: 16.

[0013] In some embodiments, a polypeptide further comprises a sequence having at least at least 90% identity to the amino acid sequence of SEQ ID NO: 17.

[0014] In some embodiments, a polypeptide further comprises a sequence having at least at least 90% identity to the amino acid sequence of SEQ ID NO: 21.

[0015] In some embodiments, a polypeptide comprises a sequence having at least at least 90% identity to the amino acid sequence of SEQ ID NO: 23.

[0016] Further aspects of the technology relate to a bicistronic vector comprising: (a) a contiguous 10-40 nucleotide sequence reverse complementary to a RASAL1 gene, wherein the RASAL1 gene comprises the nucleotide sequence of SEQ ID NO: 22; and (b) a nucleotide sequence encoding a chimeric antigen receptor that comprises a LAIR hinge domain.

[0017] Still other aspects of the technology relate to a bicistronic vector comprising: (a) a contiguous 10-40 nucleotide sequence reverse complementary to a RASAL1 gene, wherein the RASAL1 gene comprises the nucleotide sequence of SEQ ID NO: 22; and (b) a nucleotide sequence encoding a polypeptide comprising a CD 19 antibody domain and a LAIR hinge domain.

[0018] In some embodiments, a contiguous 10-40 nucleotide sequence encodes the sequence of SEQ ID NO: 25 or 26.

[0019] Some aspects of the technology relate to a bicistronic vector encoding: (a) an shRNA targeting RASAL1 and (b) a chimeric antigen receptor comprising (i) a CD 19 single-chain variable fragment (scFv) region and (ii) a LAIR hinge domain.

[0020] In some embodiments, a vector is a viral vector.

[0021] In some embodiments, a bicistronic vector comprises a vector backbone sequence selected from a retroviral vector, a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, or a herpes viral vector.

[0022] In some embodiments, an shRNA targeting RASAL1 comprises a sequence having at least 90%, at least 95%, or 100% identity to a sequence that binds to mRNA encoded by the sequence of SEQ ID NO: 22. In some embodiments, an shRNA targeting RASAL1 comprisesa sequence having at least 90%, at least 95%, or 100% identity to the sequence of SEQ ID NO: 25 or SEQ ID NO: 26.

[0023] In some embodiments, a CD 19 scFv region comprises a heavy chain comprising an amino acid sequence of SEQ ID NO: 7, an amino acid sequence of SEQ ID NO: 8, and an amino acid sequence of SEQ ID NO: 9. In some embodiments, a CD 19 scFv region comprises a light chain comprising an amino acid sequence of SEQ ID NO: 10, an amino acid sequence of SEQ ID NO: 11, and an amino acid sequence of SEQ ID NO: 12. In some embodiments, a CD19 scFv region comprises the sequence of SEQ ID NO: 6.

[0024] In some embodiments, a LAIR hinge domain comprises an amino acid sequence having at least 90%, at least 95%, or 100% identity to the amino acid sequence of SEQ ID NO: 14.

[0025] In some embodiments, a chimeric antigen receptor comprises an amino acid sequence having at least 90%, at least 95%, or 100% identity to the amino acid sequence of SEQ ID NO: 23.

[0026] Other aspects of the technology relate to a bicistronic vector encoding an shRNA targeting RASAL1 mRNA, a CD 19 scFv, a LAIR hinge domain, a CD28 transmembrane domain, a CD28 intracellular domain, and a CD3<^ intracellular domain.

[0027] In some embodiments, a bicistronic vector comprises: a first nucleic acid comprising a first promoter operably linked to a coding sequence encoding the shRNA targeting RASAL1 mRNA; and a second nucleic acid comprising a second promoter operably linked to a coding sequence encoding a chimeric antigen receptor comprising the CD 19 scFv, LAIR hinge domain, CD28 transmembrane domain, CD28 intracellular domain, and CD3<^ intracellular domain.

[0028] Still other aspects of the technology relate to a bicistronic vector encoding an shRNA targeting RASAL1 mRNA, a CD 19 scFv, a CD28 hinge domain, a CD28 transmembrane domain, a CD28 intracellular domain, and a CD3<^ intracellular domain.

[0029] In some embodiments, a bicistronic vector comprises: a first nucleic acid comprising a first promoter operably linked to a coding sequence encoding the shRNA targeting RASAL1 mRNA; and a second nucleic acid comprising a second promoter operably linked to a coding sequence encoding a chimeric antigen receptor comprising the CD 19 scFv, CD28 hinge domain, CD28 transmembrane domain, CD28 intracellular domain, and CD3<^ intracellular domain.Further aspects of the technology relate to a cell comprising the bicistronic vector of any preceding paragraph.

[0030] In some embodiments, a cell is selected from immune cells.

[0031] In some embodiments, immune cells are selected from T cells, B cells, Natural Killer (NK) cells, and dendritic cells.

[0032] In some embodiments, a cell is a T cell.

[0033] In some embodiments, a cell is selected from stem cells.

[0034] In some embodiments, stem cells are induced pluripotent stem cells (iPSCs).

[0035] Yet other aspects of the technology relate to a method for enhancing immunotherapy, comprising introducing into T cells, NK cells, or other immune cells an expression vector comprising a nucleic acid sequence encoding a RNA interference molecule or a CRISPR / CRISPR-associated (Cas) protein system, wherein the RNA interference molecule or CRISPR / Cas system is targeted to inhibit expression of the Rasall gene, wherein the T cells, NK cells, or other immune cells having reduced Rasall expression exhibit enhanced therapeutic efficacy for use in adoptive cell therapy or chimeric antigen receptor (CAR) therapy.

[0036] Some aspects of the technology related to a method of modulating (e.g., activating) CAR-T cell signaling and / or function in a collagen-rich tumor microenvironment, comprising providing a T cell expressing a chimeric antigen receptor comprising a LAIR hinge domain, wherein the LAIR hinge domain binds to collagen in the tumor microenvironment and transduces an activation signal to the T cell.

[0037] In some embodiments, the activation signal results in upregulation of CD69 on the T cell.

[0038] Other aspects of the technology related to a method of manufacturing CAR-T cells with enhanced viability, comprising introducing into T cells a nucleic acid encoding a chimeric antigen receptor comprising a LAIR hinge domain, and expanding the T cells ex vivo in the presence of IL-7 and IL- 15, wherein the T cells exhibit greater viability compared to T cells expressing a chimeric antigen receptor comprising a CD28 hinge domain under the same conditions. In some embodiments, the nucleic acid further encodes a short hairpin RNA (shRNA) targeting RASAL1 mRNA.

[0039] Further aspects of the technology related to a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of Tcells expressing a chimeric antigen receptor comprising a LAIR hinge domain and a short hairpin RNA (shRNA) targeting RASAL1 mRNA.

[0040] Some aspects of the technology related to a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of T cells expressing any one of the bicistronic vectors described herein.

[0041] Other aspects of the technology related to a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a population of cells comprising any one of the cells described herein.

[0042] In some embodiments, the cancer is a hematologic cancer or a solid tumor.

[0043] In some embodiments, the chimeric antigen receptor further comprises an anti-CD19 scFv or an anti-GD3 scFv.

[0044] In some embodiments, the T cells exhibit synergistically enhanced cytotoxicity against tumor cells compared to T cells expressing a chimeric antigen receptor comprising a CD28 hinge domain with the same shRNA targeting RASAL1 mRNA.

[0045] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 depicts the design of the scr-scFv CD19-mCD28-CD3z and scr-scFv CD19-mLAIRl-CD3z chimeric antigen receptors (CARs). The two CARs share an identical structure, except for the different hinge regions employed. Both constructs include a CD 19 single-chain variable fragment (scFv) region followed by a FLAG tag, the respective hinge domain, a mCD28 transmembrane region, a mCD28 cytoplasmic tail, and a mCD3zeta cytoplasmic region containing immunoreceptor tyrosine-based activation motifs (IT AMs).

[0046] FIGs.2A-2D illustrate the flow cytometric analysis of chimeric antigen receptor (CAR) expression profiles following viral transduction in murine splenic T cells. The experimental procedure involved activating murine splenic T cells by stimulating them with anti-CD3 and anti-CD28 monoclonal antibodies for 24 hours. The activated T cells were subsequently transduced with viral supernatant containing the CAR constructs, facilitated by the addition of the polycation Polybrene during the spinoculation process. Following transduction, the cells were cultured in RPMI 1640 medium supplemented with fetal bovine serum, penicillin-streptomycin, and the cytokines interleukin (IL)-7 and IL- 15 to support T cell proliferation and survival. The transduced T cell population was stained with an anti-Flag-BV421 antibody to detect the expression of the CARs on the cell surface. The flowcytometry data depicted in Figures 2A-D show the similar expression levels of the respective CARs within the transduced T cell population, as quantified by the anti-Flag-BV421 staining.

[0047] FIGs. 3A-3B illustrate the EL4-CD19tumor growth curves in mice treated with scr-scFv CD19-mCD28-CD3z and scr-scFv CD19-mLAIRl-CD3z CARs. FIGs. 3A and 3B provide examples of two experiments conducted on mice, with 4-5 mice per treatment group. EL4-CD19 tumors were subcutaneously implanted, and after 6 days, the CARs were injected. Tumor volumes (mm3) were monitored, and the tumors were harvested on day 14 (FIG. 3 A) or day 9 (FIG. 3B) post-injection. The scr-scFv CD19-mCD28-CD3z CAR reduced tumor growth from day 6 to day 14 post-injection, which did not lead to tumor clearance. By contrast, the scr-scFv CD19-mLAIRl-CD3z CAR demonstrated a significantly better reduction in tumor growth and unexpectedly, the treatment cleared implanted tumors by day 9.

[0048] FIG. 4 shows photographs of the EL4-CD19 tumors. Tumor cell were subcutaneously implanted for 6 days, after which CARs were injected. Tumor growth was monitored, and the tumors were harvested on day 9 post-injection as in FIG. 3B. The control tumor showed 3 large tumors together with a blank which corresponds to a 4th even larger tumor that killed the mouse before the harvest time point. The scr-scFv CD19-CD28-CD3z CAR reduced the size of the tumor but was unable to eliminate the tumors. By contrast, the scr-scFv CD 19-LAIRl-CD3z CAR successfully cleared three out of the four implanted tumors.

[0049] FIG. 5 depicts a bar graph illustrating the efficacy of the LAIR1 hinge domain CD28 CAR in eradicating solid EL4-CD19 tumors. The control group and the scr-scFv CD19-mCD28-CD3z CAR treated group were unable to eliminate the tumors. In contrast, the scr-scFv CD19-mLAIRl-CD3z CAR successfully cleared three out of the four implanted tumors.

[0050] FIGs. 6A-6C show expression of markers on the CD8+LAIR1 CARs. TILs were extracted from tumors and stained by flow cytometry for CD8, granzyme B (GZMB) and Ki67 within the CD8+ CD45.2+ cells. FIG. 6A shows a greater number of CD8+ TILs expressing CD45.2 and FLAG induced by scr-scFv CD19-mLAIR-CD3z CAR injection relative to scr-scFv CD19-CD28-CD3z CD8+ CARs. FIG. 6B shows that the percentage of CD8+ TILs expressing GZMB was greater with scr-scFv CD19-mLAIR-CD3z CARs treatment as opposed to treatment with scr-scFv CD19-CD28-CD3z CD8+ CARs. The percentage of scr-scFv CD19-mLAIR-CD3z CARs were also increased in the percentage of CD8+ TILs expressing the cell cycle marker Ki67 relative to that seen with the scr-scFv CD19-CD28-CD3z CD8+ CAR-Ts (FIG. 6C). CD8+ tumor- infiltrating lymphocytes (TILs) derived from an injected spleen typically comprise a heterogeneous population of cells,including cytotoxic T cells, natural killer (NK) cells, dendritic cells, macrophages, and, in some cases, B cells, all of which contribute to the anti-tumor immune response.

[0051] FIGs. 7A-7B depict LAIR1 CARs show lower levels of expression of PD-1 and CD 101 markers of T-cell exhaustion. TILs were extracted from tumors and stained by flow cytometry wither CD45.2, CD8, PD1 and TIM-3. scr-scFv CD19-mLAIR-CD3z CARs showed reduced PD-1 expression relative to scr-scFv CD19-CD28-CD3z CD8+ CARs (FIG.

[0052] 7 A). scr-scFv CD19-mLAIR-CD3z CARs also showed reduced CD 101 expression relative to scr-scFv CD19-CD28-CD3z CD8+ CARs (FIG. 7B). The reduction in PD-1 and CD101 indicate reduced immune cell exhaustion needed for more effective and sustained cellular responses against tumors.

[0053] FIG. 8 depicts Bar graph illustrating the efficacy of the LAIR1 vs the tLAIRl hinge domains in CARs in controlling the growth of solid EL4-CD19 tumors. scr-scFv CD 19-CD28-CD3z CAR was able to reduce tumor growth from 1200 to 320mm3 at day 14 while the scr-scFv CD19-LAIR-CD3z CAR reduced growth from 1200 to 40mm3. The scr-scFv CD19-tLAIR-CD3z CAR, lacking the binding sites for collagen reduced tumor growth to 280mm3, statistically comparable to the scr-scFv CD19-CD28-CD3z CAR. Collagen binding sites are found on the surface of the LAIR1 Ig domain. The deletion of the collagen binding sites present on the LAIR1 CAR but not in the tLAIRl domain. These data support that notion that the collagen binding sites contribute to the efficacy of the LAIR CAR in reducing tumor growth.

[0054] FIGs. 9A-9B show a schematic representation of the shRNA vector and CRISPR constructs targeting Rasall. FIG. 9A: Schematic representation of the shRNA vector. A CAR targeting mouse CD19, based on the 1D3 antibody, was constructed by cloning the CD19-specific scFv into the pMKO.l-GFP retroviral vector. However, the vector could be another retroviral or lenti viral system, such as the lenti viral vectors derived from HIV-1 (e.g., pLenti-EFla, pLVX-EFla), murine leukemia virus (e.g., pMX, pMSCV), or gammaretroviral vectors (e.g., pQCXIH, pMSCV). These vectors can employ scFvs against various tumor antigens in mouse or human models, including GD2 (disialoganglioside), GD3 (trisialoganglioside), HER2 (human epidermal growth factor receptor 2), mesothelin, and others. The construct includes a Flag tag (DYKDDDDK), a hinge domain, the CD28 transmembrane and intracellular regions, and the CD3(^ signaling domain. Different hinge lengths can be evaluated, such as a 36-amino-acid CD28 hinge or a 123-amino-acid LAIR1 (leukocyte- associated immunoglobulin-like receptor l)-based hinge or other hinges, transmembrane (TM) or intracellular regions such as 4- IBB, 0X40, ICOS, and othersignaling molecules. FIG. 9B: Schematic representation of the Rasall shRNA vector or Rasall CRISPR-Cas9 as an isolated cassette. Each cassette is used alone or is combined in transduction of cells with a separate cassette encoding CARs with different hinge regions. The left panel shows the Rasall shRNA vector (upper) or an equivalent cassette using CRISPR / Cas9 (lower) to target Rasall expression. The right panel shows the design of the scr-scFv CD19-CD28-CD3z and scr-scFv CD19-EAIRl-CD3z CARs as in Fig. 1.

[0055] FIG. 10 depicts FACs plots showing the expression levels of the various CARs in spleen cells. Spleen immune cells were activated with anti-CD3 / CD28, cultured in IE7 / 15 and transduced with virus to induce CAR expression (see Methods) This culture condition preferentially supports the expansion of T-cells but could include other cell cells such as NK and dendritic cells (DCs) sustained by the culture conditions. After one week of cell culture, the cells were stained with tagged anti-Flag and subjected to analysis by flow cytometry. Each of CARs were expressed at 37-43% of the expanded cell population In certain cases, cells were subsequently sorted by FACs to derive populations of cell cultures expressing some >95% CAR+ cells. While the FACS plots of cells activated with anti-CD3 / CD28 are CAR-T cells, the presence of CAR-NK cells or other CAR-expressing cells is also possible.

[0056] FIGs. 11A-11B show downregulation of Rasall expression in T-cells expressing shRNA 1 or shRNA4 targeting Rasall. (FIG. 11A) T-cells were activated with anti-CD3 / CD28 antibodies, cultured in IE-7 / IE-15, and transduced with lentivirus to express a CD19-targeted chimeric antigen receptor (CAR). After one week, the cells were stained intracellularly with a FITC-labeled anti-Rasall antibody and analyzed by flow cytometry. Both the shRNA 1 -CD 19 CAR and shRNA4-CD19 CAR showed reduced Rasall expression compared to the scrambled control (scr-CD19 CAR). (FIG. 11B) Immunoblot analysis confirmed the downregulation of Rasall protein levels. Transduced T-cells were lysed in 1% Triton lysis buffer, and lysates were denatured, separated by SDS-PAGE, transferred to nitrocellulose, and blotted with an anti-Rasall antibody (upper panel) or anti-beta- actin loading control (lower panel). The Rasall band intensity was reduced in lysates from shRNA 1 -CD 19 CAR and shRNA4-CD19 CAR expressing cells compared to non-transduced and scr-CD19 CAR control cells.

[0057] FIGs. 12A-12E shows that the shRasall CARs with anti-CD19 scFv of anti-CD19 enhances tumor killing in in vitro killing assays. ID3 is a synthetic antibody engineered to specifically target the mouse CD 19 antigen. Chimeric antigen receptors (CARs)were expanded and maintained in vitro by culturing them in the presence of interleukin-7 (IE-7) and interleukin- 15 (IE-15), which are cytokines important for T cell proliferation andsurvival. After this ex vivo / in vitro expansion step, the CAR cells were co-cultured with their target cancer cells for a period of 4 hours. Subsequently, the cytotoxic activity of CARs against the target cells were evaluated by measuring the release of lactate dehydrogenase (LDH) by target cells, an enzyme present in the cytosol of cells (see Methods). FIG. 12A: Rasall Sh4-scFv CD19-CD28-CD3z is superior to scr-scFv CD19-CD28-CD3z CAR in killing targets at all CAR to target ratios. At 5:1 and 2.5:1, the Rasall Sh4-scFv CD19-CD28-CD3z killing was 2-fold greater than the scr-scFv CD19-CD28-CD3z CAR. FIG. 12B: A second experiment showing that Rasall shRNAl-scFv ID3-CD28-CD3z CARs are more effective in killing EL4-CD19 cells than scr-scFv ID3-CD28-CD3z. In this experiment, a control was included with CARs lacking the cytoplasmic domains CD28ex failed to mediate killing. This indicates that the superior killing of targets by Rasall shRNAl-scFv CD19-CD28-CD3z is dependent on the presence of the cytoplasmic signaling domain of the CAR.

[0058] FIG. 12C: The Rasall shRNAl-scFv CD19-CD28-CD3z and Rasall shRNA4-scFv CD19-CD28-CD3z CARs show an unexpected synergistic augmentation in the expression of the effector cytokine IFN-y. IFN-y can directly induce apoptosis (programmed cell death) in tumor cells by activating various pro-apoptotic signaling pathways and increasing the expression of apoptosis-related genes. IFN-y also enhances the expression of major histocompatibility complex (MHC) class I molecules on tumor cells, making them more visible to cytotoxic T lymphocytes (CTLs). This increased antigen presentation facilitates the recognition and destruction of tumor cells by CTLs. IFN-y also activates macrophages, enhancing their cytotoxic activity against tumor cells. FIG. 12D: The Rasall shRNAl-scFv CD19-CD28-CD3z and Rasall shRNA4-scFv CD19-CD28-CD3z CARs exhibit an unexpected synergistic increase in the mean fluorescence intensity (MFI) expression of the effector cytolytic killer factor granzyme B (GZMB). GZMB is a serine protease enzyme released by cytotoxic T cells and natural killer cells, which induces apoptosis in targeted cells. FIG. 12E: The Rasall shRNAl-scFv CD19-CD28-CD3z and Rasall shRNA4-scFv CD19-CD28-CD3z CARs exhibit an unexpected synergistic increase in the mean fluorescence intensity (MFI) expression of the effector receptor FasL. FasL is a type II transmembrane protein that belongs to the tumor necrosis factor (TNF) family and plays a crucial role in inducing apoptosis (programmed cell death) in target cells by binding to its receptor, Fas.

[0059] FIGs. 13A-13B illustrate the EL4-CD19 tumor growth curves in mice treated with Rasall KD CARs. Tumor volumes (mm3) were monitored, and the tumors were harvested on day 18 (FIG. 13A) or day 8 (FIG. 13B) post-injection. While the conventional scr-scFvCD19-CD28-CD3z showed a trend to reduce tumor growth, the Rasall Shl-scFv CD 19-CD28-CD3z and Rasall Sh4-scFv CD19-CD28-CD3z had significant and potent effects on tumor growth. In a second example, the Rasall Shl-scFv CD19-CD28-CD3z and Rasall Sh4-scFv CD19-CD28-CD3z CARs reduced tumor growth while the scr-scFv CD19-CD28-CD3z had no effect.

[0060] FIGs. 14 shows that Rasall shRNA on CD 19 CARs induces an unexpected tumor clearance and survival not seen with conventional CD 19 CARs. CARs were transferred to mice bearing EL4-OVA tumors on day 7 followed by a monitoring of tumor clearance and mouse survival until day 20. (FIG. 14A) Rasall shRNA on CD19 CARs cleared tumors. While no tumor clearance was observed with conventional CD 19 scFv CD28 CARs, both the Rasall shRNA 1 and shRNA2 CARs cleared tumors. In the case of Rasall shRNA 1, one out of four mice was tumor free, while in the case of shRNA2 CARs, a remarkable three out of four mice were free of tumors.

[0061] FIG. 15 shows Rasall shRNA on CD 19 CARs promotes 100% mouse survival. While 0% of wild-type mice survived by day 15, 50% of scr-CD19 scFv CD28 CAR treated mice survived by day 20 and 100% of shRNA 1 -CD 19 scFv CD28 CAR and shRNA4-CD19 scFv CD28 CAR mice survived by day 20. These data indicate that reducing Rasall expression in CAR T cells provides a synergistic advantage for the survival of mice implanted with tumors.

[0062] FIG. 16 shows FAC profiles showing increased CAR T-cell filtration into tumors by the Rasall shRNA-CD28 hinge constructs relative to the scrambled-CD28 hinge constructs. Mouse splenic T cells were activated with anti-CD3 (2 pg / ml) and anti-CD28 (2 pg / ml) for 24 hours. Activated cells were then transduced via spinoculation with viral supernatant and Polybrene (8 pg / ml) mix, followed by incubation. CAR-T cells were then injected into mice that had previously been injected SC with EG7 tumor cells. The extracted TILs at day 18 were then assessed for the presence CD45.2 and GFP, both markers for injected CARs.

[0063] While mice injected with scr-scFv CD19-CD28-CD3z were found to comprise 10.7 of TILs, Rasall Shl-scFv CD19-CD28-CD3z comprised 22.1 andRasall Sh4-scFv CD19-CD28-CD3z made up 36 percent of TILs.

[0064] FIG. 17 depicts FAC profiles showing that Rasall shRNA increases the presence of memory CARs in the TIL population of tumors. CAR-T cells were then injected into mice that had previously been injected SC with EL4-CD19 tumor cells. The extracted CD45.2 CD8+ TILs at day 18 were then assessed for the expression of CD44 and CD62L. While mice injected with scr-scFv CD19-CD28-CD3z were found to comprise 4.65 of TILs, Rasall Shi-scFv CD19-CD28-CD3z comprised 9.48 and Rasall Sh4-scFv CD19-CD28-CD3z made up 12.3 percent of TILs. The KD of Rasall therefore increased the presence of memory TILs.

[0065] FIG. 18 shows FAC profiles showing that Rasall shRNA markedly reduces exhaustion in the CD8+ TIL population in tumors. CAR-T cells were then injected into mice that had previously been injected SC with EG7 tumor cells. The extracted CD45.2 CD8+ TILs at day 18 were then assessed for the expression of TIM-3 and PD-1 expression. While mice injected with scr-scFv CD19-CD28-CD3z were found to comprise 46.3 of TIM3+PD1+ TILs, Rasall Shl-scFv CD19-CD28-CD3z comprised 18.8 and Rasall Sh4-scFv CD19-CD28-CD3z made up 15.4 percent of TILs. The KD of Rasall therefore decreased the presence of CD8+ exhausted TILs.

[0066] FIG. 19 demonstrates a reduction in the frequency of PD-lhiTIM-3+ CD8+ CAR T cells upon knockdown of Rasall expression. The Rasall shRNA 1 and shRNA4 CAR T cell products isolated from tumor samples exhibited a significantly diminished percentage of cells expressing high levels of PD-1 and TIM-3, which are hallmark markers of T cell exhaustion, compared to the conventional scr-scFv CD19-CD28-CD3(^ CAR T cell control.,

[0067] FIG. 20 depicts FAC profiles showing that Rasall shRNA increases the presence of in the CD8+ Ki67+ TCF1+ TILs in tumors. CAR-T cells were injected into mice that had previously been injected subcutaneously (SC) with EG7 tumor cells. The extracted PD-1+ CD45.2 CD8+ tumor-infiltrating lymphocytes (TILs) at day 18 were then assessed for the expression of the cell cycle marker Ki67 and the progenitor stem cell marker TCF1. While mice injected with scrambled control (scr-scFv CD19-CD28-CD3z) CAR-T cells comprised 3.96% of Ki67+TCF1+ TILs, Rasall knockdown (Rasall Shl-scFv CD19-CD28-CD3z) CAR-T cells comprised 6.19%, and Rasall knockdown (Rasall Sh4-scFv CD19-CD28-CD3z) CAR-T cells made up 16.5% of Ki67+TCF1+ TILs. Similarly, the mice injected with scr-scFv CD19-CD28-CD3z CAR-T cells comprised 10.0% of Ki67-TCF1+ TILs, Rasall Shl-scFv CD19-CD28-CD3z CAR-T cells comprised 14.4%, and Rasall Sh4-scFv CD19-CD28-CD3z CAR-T cells made up 22.5% of Ki67-TCF1+ TILs. The knockdown of Rasall increased the presence of dividing (Ki67+) and non-dividing (Ki67-) TCF1+ progenitor stemlike CD8+ TILs.

[0068] FIG. 21 present viSNE (visual Stochastic Neighbor Embedding) profiles for CAR-T cells derived from tumor-infiltrating lymphocytes (TILs) expressing different markers. CAR CD8+ T cells were extracted from EG7 tumors as previously indicated and analyzed by multi-dimensional viSNE analysis. The viSNE analysis revealed several distinct clusters or "islands" of expression, denoted as i, ii, and iii. There is an enrichment of CD45.2+ TILs incluster i. The same cluster i also showed an increased presence in the Rasall Sh4-scFv CD19-CD28-CD3z CAR-T cell subsets relative to the scrambled control (scr-scFv CD 19-CD28-CD3z) subset. Additionally, this cluster exhibited increased expression of CD69, Ki67 (a marker of cell proliferation), and the progenitor stem cell marker TCF1. These data confirm that the Rasall Sh4-scFv CD19-CD28-CD3z CARs maintain or develop a subpopulation which are stem-like progenitor T-cells, needed to sustain an immune response.

[0069] FIG. 22 shows the effect of Rasall shRNA on the production of effector cytokines in CD8+ CARs within tumors. CARs were injected into mice previously inoculated with EL4-CD19 tumor cells. On day 18, the extracted CD45.2+ CD8+ CAR TILs were analyzed for intracellular expression of the effector cytokines IFN-y and TNF-a. The results demonstrate that the control group (scr-scFv CD19-CD28-CD3z) had 4.26% of TILs expressing the exhaustion markers TIM3 and PD1. In contrast, the Rasall knockdown groups exhibited significantly higher proportions of TILs expressing these markers. Specifically, the Rasall Shl-scFv CD19-CD28-CD3z group had 38.7% of TILs expressing TIM3 and PD1, and the Rasall Sh4-scFv CD19-CD28-CD3z group had 33.2%. These findings indicate that the knockdown of Rasall in CAR cells increased the presence of CD8+ CARs expressing the effector cytokines IFN-y and TNF-a within the tumor microenvironment, indicative of an enhanced anti-tumor immune response.

[0070] FIG. 23 shows that Rasall shRNA CAR-T cells are unexpectedly potent in promoting the presence of endogenous CD45.1+ CD8+ T-cells within the EL4-CD19 tumor. The scFv CD19-CD28-CD3z CAR (CD45.2) were injected into SJL mice (CD45.1) that had been previously inoculated with EL4-CD19 tumor cells for 7 days. The extracted CD45.1+CD8+ T cells represent endogenous TILs. Any effect on CD45.1+CD8+ T cells would indicate a trans-regulatory effect where the CARs alter the endogenous T cells in the tumor. FIG. 23 shows Rasall shRNA-expressing CARs Rasall Shi and Sh4) increased the presence of CD8+ endogenous CD45.1 T cells in the TIL population relative mice treated with control scrambled shRNA (Scr) CARs.

[0071] FIG. 24 shows Rasall shRNA reduces the endogenous memory T cell population while increasing the presence of endogenous CD45.1 effector CD8+ T cells. At day 18, TILs were assessed for the expression of CD44 and CD62L on CD45.1+CD8+ T cells. While mice injected with Scr CARs had 27.1% CD45.1+CD44+ CD62L+ memory CD8+ TILs, those receiving Rasall Shi and Sh4 CARs had markedly reduced memory CD44+CD62L+ populations (5.56% and 5.10%, respectively) and increase in endogenous CD8+CD44+CD62L- CD45.1+ effector cells (from 12.7% in scFv CD19-CD28-CD3z CAR(CD45.2) treated mice to 93.3 and 94% in tumor from Rasall Shl-scFv CD19-CD28-CD3z (CD45.2) and Rasall Sh4-scFv CD19-CD28-CD3z (CD45.2) treated mice.

[0072] FIG. 25 illustrates that Rasall knockdown potentiates the anti-tumor efficacy of CD19 scFv CD28 CAR T cells against a second tumor model, B16 F10 CD19+ solid tumors. The B16 F10 murine melanoma cell line was engineered to express human CD19 via retroviral transduction. shRNA4-CD19 scFv CD28 CAR T cells, exhibiting reduced Rasall expression, mediated complete tumor regression in 4 out of 5 mice by day 18 post- tumor inoculation. In contrast, the conventional scr-CD19 scFv CD28 CAR T cell control failed to eradicate tumors in any of the mice. These results demonstrate that downregulating Rasall expression in conventional CD28-costimulated CAR T cells confers an enhanced anti-tumor response, leading to the unexpected complete elimination of established B16 F10 CD 19+ solid tumors, an outcome not achieved with standard CAR T cell therapy.

[0073] FIG 26 shows that Rasall shRNA4-scFv CD19-CD28-CD3(^ CAR T cells exhibit attenuated interleukin-6 (IL-6) production compared to conventional scrambled shRNA-scFv CD 19-CD28-CD3(^ CAR T cells, potentially mitigating the cytokine release syndrome (CRS) frequently associated with CAR T-cell therapy. Transduced CAR T cell products were sampled from culture, and quantitative PCR analysis was performed to evaluate IL-6 transcript levels in blood, lung, and liver tissue samples. The Rasall shRNA4-scFv CD19-CD28-CD3(^ CAR T cells demonstrated significantly reduced IL-6 expression relative to the scrambled shRNA-scFv CD19-CD28-CD3(^ CAR T cell control.

[0074] FIGs. 27A-27H: Rasall mutant mice show enhanced tumor clearance. FIG. 27A: CRISPR-based endonuclease technology was employed to target the Rasall gene leading to the deletion of 481 base pairs that resulted in the removal of exons 4-5, an amino acid alteration after residue 41, and an early truncation occurring 14 amino acids downstream (termed Rasaic mutmice). Sequencing of the deletedregions showed the loss of the Cl domain and the partial loss of the C2 domain. FIG. 27B: The endogenous T-cells from Ras al 7c mutshow a loss of binding to ZAP-70. Spleen T-cells were stimulated for 15min with anti-CD3 (2C11) followed by detergent solubilization and precipitation with either anti-ZAP-70 or the isotype control followed by blotting with anti-Rasall (upper panel), anti-ZAP-70 (middle panel) or anti-actin (lower panel). In response to anti-CD3 activation, anti-ZAP-70 co-precipitated Rasall from wild- type T-cells but not from RasaH~cmutT-cells (upper panel, lanes 1, 2). Anti-ZAP-70 precipitated ZAP-70 equally from WT and Rasall^""" T-cells (middle panel, lanes 1-4). As a negative control, anti-actin failed to precipitate actin (lower panel). These data showed that the loss of the Cl / 2 domains in Rasall prevented its ability toassociated and inhibit ZAP-70. The loss of Rasall binding to ZAP-70 is indicative of a loss of function (Guo et al., 2021 iScience 24, 103295). FIG. 27C and 27D: the growth of MC38 and B 16 F10 tumors is reduced in Rasaic mutmice. We next conducted experiments involving the implantation of cells from various tumor models in WT versus RasaHc~mutand monitored their growth over 18 days. The B16 F10 melanoma cells were implanted intradermally, while MC38 cells were subcutaneously implanted. B16-F10 melanoma cells are a highly invasive and metastatic murine melanoma cell line widely used as an in vivo model for studying melanoma progression and metastasis. The MC38 tumor model is a syngeneic murine colon adenocarcinoma cell line that is also utilized to study colorectal cancer and investigate therapeutic interventions in an immunocompetent host. FIG. 27C: Notably, Ras allc mutmice exhibited a significant decrease in MC38 tumor volume throughout the implantation period of each of the tumors when measured over 18 days post- implantation. The weight was measured for each tumor at the end of treatment (right panel). FIG. 27D: 7toaZ7c mutmice exhibited a significant decrease in B16 F10 tumor volume throughout the implantation period of each of the tumors when measured over 18 days post-implantation. The weight was measured for each tumor at the end of treatment (right panel). This model supports the observations related to the efficacy of Rasall shRNA CARs in regressing tumor growth and suggest other modes of possible therapy by exploiting the Rasall pathway.

[0075] FIGs. 28A-28B show Rasall knockdown (KD) impairs regulatory T-Cell (Treg) suppression of CD8+ T-Cell proliferation. FIG 28A: CD4+CD25+ Tregs were isolated and added to cultures of wild-type CD8+ T-cells (pre-labeled with cell tracker Tagit) stimulated with anti-CD3 (2C11) at 0.5 pg / ml in vitro for 72 hours. Cell divisions were assessed. Wildtype T responder cells underwent multiple divisions (grey peaks). Addition of wild-type Tregs suppressed the proliferative response, as seen by a reduced number of peaks shifted to the left. In contrast, addition of Rasall knockdown Tregs failed to suppress proliferation to the same extent as wild-type Tregs (FIG. 18B).

[0076] FIGs. 29A-29H: Anti-PD-1 immunotherapy and genetic disruption of Rasall cooperatively promote tumor regression and enrich for progenitor TCF1+ CD8+ tumorinfiltrating lymphocytes (TILs). The B 16 F10 murine melanoma model was established via intradermal implantation, and tumors were allowed to progress for 6 days prior to initiation of treatment. Mice received intraperitoneal injections of either anti-PD-1 antibody (200 pg / ml, administered every 3 days) or saline control. FIGs. 29A-29H demonstrate the cooperative effects of anti-PD-1 immunotherapy and genetic disruption of Rasall in the B16 F10 murine melanoma model. Anti-PD-1 treatment further reduced tumor volume in Ras al 7c-mutantmice beyond the tumor growth inhibition observed in untreated Rasall c-mntant mice or wildtype mice receiving anti-PD-1 monotherapy (FIG. 29A). Moreover, anti-PD-1 treatment in Ras allc mutmice increased the percentage of CD8+ tumor-infiltrating lymphocytes (TILs) (FIG. 29B), which exhibited higher expression of the activation marker CD44 (FIG. 29C), along with decreased expression of the exhaustion markers PD-1 (FIG. 29D) and TIM-3 specifically on PD-1+ CD8+ TILs (FIG. 29E). Unexpectedly, anti-PD-1 therapy in Rasallc~mutmice also reduced the mean fluorescence intensity of CX3CR1 on CD8+ TILs (FIG. 29F), which is associated with a exhaustion phenotype. FIG. 29G showed an increase in the precent expression of the progenitor markers SLAMF6+ in CD8 TILs from anti-PDl treated Ras al Jc mutmice. SLAMF6 (Signaling Lymphocytic Activation Molecule Family member 6) is a surface marker that identifies progenitor or naive CD8+ T cells with enhanced selfrenewal capacity and the potential to differentiate into effector and memory subsets. FIG. 29H shows a synergistic increase in the number of PD1+TCF1+ CD8 TILs from anti-PDl treated Ras allc mutmice. Overall, in Rasai ~dommice, anti-PDl therapy increased the percentage of PD1 -expressing stem-like CD8+ TILs while reducing both transitory and terminally exhausted CD8+ TILs.

[0077] FIGs. 30A-30D illustrates the EL4-CD19 tumor growth curves in mice treated with Rasall shRNA4-scFv CD19-mCD28-CD3z and Rasall shRNA4-scFv CD19-mLAIRl-CD3z CARs. EL4-CD19 tumors were subcutaneously implanted, and after 7 days, CARs were injected (n=5 for each group). Tumor volumes (mm3) were monitored over 12 days after CAR injection. FIG 30A: The Rasall shRNA4-scFv CD19-mCD28-CD3z CAR controlled tumor growth from day 6 to 8 post-injection with a trend to show an increase in tumor size from day 8-12. In contrast, the Rasall shRNA4-scFv CD19-mLAIRl-CD3z CAR treated mice showed a significantly better reduction in tumor growth as early as day 4 post-injection, sustained over 12 days with no evidence of an escape from tumor surveillance. FIG. 30B trend towards an increase in the % of CD8 CARs in mice treated with Rasall shRNA4-scFv CD19-mLAIRl-CD3z CARs relative to Rasall shRNA4-scFv CD19-mCD28-CD3z CARs.

[0078] FIG. 30C: A trend towards an increase in the % of Ki67+ CD8 CARs in mice treated with Rasall shRNA4-scFv CD19-mLAIRl-CD3z CARs relative to Rasall shRNA4-scFv CD19-mCD28-CD3z CARs. FIG. 30D:A trend towards a decrease in the % of PD1+ CD8 CARs in mice treated with Rasall shRNA4-scFv CD19-mLAIRl-CD3z CARs relative to Rasall shRNA4-scFv CD19-mCD28-CD3z CARs.

[0079] FIG. 31 shows the effect of expressing a cassette for mRasall 1 shRNA4 on the control of tumor growth when expressed in OT-1 spleen cells, expanded in the presence of IL-7 andIL- 15 and adoptively transferred into mice. The tumor volume was decreased relative to untreated controls when assessed as day 16. These data show that the mRasall 1 shRNA4 cassette alone can also be used to potentiate T-cell responses against tumors.

[0080] FIG. 32: Human CARs expressing Rasall shRNA potentiate killing of RBD-expressing targets. Human CARs were generated from donor T cells and lentivirally transduced with bicistronic vectors co-expressing an shRNA (Scr o Rasall shRNAl) and a CR3022 scFv-based CAR with either a CD28 hinge or LAIR1 hinge, along with CD28 and CD3(^ signaling domains. 293-ACE2 cells loaded with RBD peptide were used as targets. Coculture of effector CARs with targets at a 10:1 ratio for 4-5 hours showed enhanced target cell killing by Rasall shRNAl CARs compared to Scr controls. Notably, incorporation of the LAIR1 hinge further increased the cytotoxic potency of the Rasall shRNAl CAR, reaching 82% killing versus 59% for the Scr CD28 hinge CAR. Data demonstrate the cooperative effect of Rasall knockdown and LAIR1 hinge optimization in augmenting CAR T cell antitumor functionality.

[0081] FIG. 33A shows a schematic representation of the pMKO.1 GFP retroviral vector encoding GFP, a Rasall -targeting shRNA, and an anti-GD3 scFv-CD28-CD3(^ chimeric antigen receptor (CAR), indicating the relative positions of each expression cassette. FIG. 33B shows that Rasall shRNA expression enhances T-cell-mediated control of EL4-GD3 lymphoma growth in vivo. Primary splenic T cells were activated, transduced with Rasall shRNA retroviral vector or an anti-GD3 scFv-CD28-CD3^ CAR, expanded for 5 days, and adoptively transferred into C57BL / 6 mice bearing established subcutaneous EL4-GD3 tumors. Tumor volumes (mm3) were monitored over 6 days post-injection. Mice receiving Rasall shRNA-transduced T cells exhibited a statistically significant reduction in tumor growth compared to both the untreated control and the anti-GD3 scFv-CD28-CD3^ CAR group (****P<0.0001 and **P<0.01, respectively), demonstrating that Rasall knockdown alone is sufficient to enhance T-cell-mediated anti-tumor activity against a GD3-expressing tumor.

[0082] FIG. 34 shows that Rasall shRNA synergistically cooperates with the anti-GD3 scFv-LAIR I -CD28(^ CAR to limit EL4 lymphoma growth. Rasall shRNA was cloned into the pMKO.l GFP retroviral vector together with an anti-GD3 scFv-LAIR l-CD28(^ CAR or expressed alone, and used to transduce murine T cells for 5 days. C57BL / 6 mice implanted subcutaneously with EL4 lymphoma cells received adoptive transfer of the expanded CAR-T cells after tumor establishment. Tumor growth was monitored over 6 days. The anti-GD3 scFv-LAIR l-CD28(^ CAR alone demonstrated a modest, non- statistically significantreduction in tumor growth. In contrast, co-expression of Rasall shRNA with the anti-GD3 scFv-LAIR l-CD28(^ CAR resulted in a marked and statistically significant reduction in tumor volume compared to both control and CAR alone (****P<0.0001), with tumors reduced to approximately 180-250 mm3at day 6, representing a substantial synergistic improvement in anti-tumor efficacy. These data demonstrate that Rasall shRNA functionally cooperates with the anti-GD3 scFv-LAIR l-CD28(^ CAR to substantially improve anti-tumor efficacy, consistent with findings using anti-CD19 CAR constructs.

[0083] FIG. 35 demonstrates an unexpected and preferential functional cooperation between Rasall suppression and the LAIR1 hinge domain that markedly enhances anti-CD19 CAR-mediated cytotoxicity beyond conventional CAR architectures. Primary effector T cells were engineered using a bicistronic vector system encoding anti-CD19 CAR constructs containing either a conventional CD28 hinge domain or a LAIR 1 -derived hinge domain, with or without concurrent expression of shRNA targeting Rasall. CAR-modified effector cells were evaluated in an in vitro cytotoxicity assay against CD19-expressing EG7 target cells. At a 1:2 effector-to-target ratio, Rasall shRNA+LAIRl hinge CAR T cells demonstrated the highest level of target cell killing among all groups tested, including Rasall shRNA alone, Rasall shRNA+CD28 hinge CAR, and LAIR1 hinge CAR alone, demonstrating a synergistic interaction between Rasall suppression and the LAIR1 hinge platform.

[0084] FIGs. 36A-36D demonstrates the efficacy of human LAIR1 hinge-containing CARs in killing human tumor cells. FIG. 36A shows a schematic of second-generation human antiCD 19 CAR constructs containing either a CD28 hinge domain or a LAIR 1 -derived hinge domain, both incorporating CD28 transmembrane and costimulatory domains and a CD3(^ signaling domain. FIG. 36B shows flow cytometric analysis of human CAR expression on the surface of transduced primary mouse T cells using a BV421 -conjugated anti-FLAG antibody, demonstrating comparable surface expression levels (18.5% for CD28-CAR and 14.4% for LAIR 1 -CAR). FIG. 36C shows flow cytometric analysis of CD 19 expression on NALM6 human B-cell lymphoma cells, confirming high surface expression (98.1%). FIG.

[0085] 36D shows in vitro cytotoxicity of mouse T cells transduced with human anti-CD19 CAR constructs against NALM6 human tumor targets at a 2:1 effector-to-target ratio. LAIR1 hinge CAR T cells demonstrated significantly greater killing (-30%) compared to CD28 hinge CAR T cells (-20%) and non-transduced controls (-10%), confirming the superior cytotoxic activity of the human LAIR1 hinge CAR platform. FIG. 36D displays similar human CAR potency data as FIG. 32, but provided here for comparison within the context of the LAIR1 hinge platform analysis.FIG. 37 demonstrates that the LAIR1 hinge domain enhances CAR-T cell viability during ex vivo generation and expansion under IL-7 / IL-15 culture conditions. Primary splenic T cells were isolated from C57BL / 6 mice, activated, and retrovirally transduced with CD28-hinge or LAIR 1 -hinge CAR constructs, then expanded for three days in the presence of IL-7 and IL-15. Cell viability was assessed by flow cytometry using a Fixable Viability Dye (LIVE / DEAD Near-IR). CD28-hinge CAR expression was associated with marked reduction in viable cell frequency relative to non-transduced controls (78.6% in control vs.

[0086] 41.5% in CD28 CAR cells). ShRoro 7-CD28 CAR cells showed similarly reduced viability (41.8%). In contrast, incorporation of the LAIR1 hinge significantly increased viable cell frequencies in both ShRoro 7-LAIRl CAR cells (61.7%) and LAIR1 CAR cells (66.1%), demonstrating an intrinsic pro-survival property conferred by the LAIR1 hinge domain, independent of Rasall knockdown.

[0087] FIGs. 38A-38C shows that the LAIR1 hinge reprograms multiple dimensions of CAR-T cell activation, differentiation, and functional state following expansion in IL-7 / IL-15. FIG. 38A shows flow cytometric analysis of surface marker expression (CAR+, CD8, CDlla / LFA-1, CD69, CD25) across Scr-CD28 CAR, ShRasall-CD28 CAR, ShRasall-LAIR1 CAR, and LAIR1 CAR T cells, demonstrating broadly comparable CAR expression but distinct biological effects including decreased CD69 in LAIRl-hinge constructs. FIG.

[0088] 38B depicts CD62L vs. CD44 profiles on CAR-T cells, showing that LAIR1 hinge incorporation promotes a shift in differentiation trajectory away from central memory programming toward a more activated or transitional state. FIG. 38C shows exhaustion marker profiling (TIM-3, PD-1), proliferative status (Ki67), TCF1 expression, and effector cytokine production (IFNy, TNFa) across CAR constructs. LAIRl-hinge CAR T cells exhibited reduced co-expression of PD-lhi and TIM-3, reduced Ki67 compared to CD28-hinge controls, and preserved polyfunctional cytokine production, indicating reduced exhaustion during in vitro expansion while maintaining effector competence. All constructs include human sequences.

[0089] FIGs. 39A-39D demonstrate that the LAIR1 hinge domain in anti-CD19 LAIR1 CAR T cells binds to collagen and transduces collagen-dependent activation signals. FIG. 39A shows flow cytometry plots confirming high purity of CD3+ T-cell populations (95-97%) following activation and retroviral transduction with indicated CAR constructs. FIG. 39B shows selective adhesion of LAIR1 hinge CAR T cells but not CD28 hinge CAR T cells or control T cells to Collagen Lcoated microtiter plates at 20 pg / cm2, as demonstrated by representative bright-field microscopy images (left panels) and quantitative bar graphsshowing significantly higher numbers of adherent LAIR1 CAR T cells (-4,000 cells / well) compared to CD28 CAR T cells or controls (p<0.01). FIG. 39C shows equivalent selective adhesion of LAIR1 hinge CAR T cells to Collagen IV-coated surfaces (-9,000 cells / well), confirming LAIR1 hinge-mediated collagen-binding across multiple collagen subtypes. FIG.

[0090] 39D shows that collagen engagement by the LAIR1 hinge induces CD69 upregulation (23.5% on Collagen I and 31.7% on Collagen IV, compared to -1-3% for CD28 CAR and control T cells) and suppresses Ki67 expression (reduced from 63.6% on uncoated plates to 29.9% on Collagen I and 28.4% on Collagen IV), demonstrating that the LAIR1 hinge functions as a biologically active signaling module capable of sensing and responding to the collagen-rich tumor microenvironment.

[0091] Construct Glossary:

[0092] CD19 scFv CD28 hinge (also known as scr-scFv CD19-CD28-CD3z; scr-scFv CD19-CD28; Scr-scFv CD19-CD28 CAR; SRC; CD28 CARs; CD28-CAR)

[0093] CD19 scFv LAIR1 hinge (also known as scr-scFv CD19-mLAIR-CD3z; scr-scFv CD19-mLAIRl; Scr-scFv CD19-LAIR1 CAR; Scr-scFv CD19-LAIRl-CD3z; LAIR CAR; LAIR1 CARs; LAIR1-CAR)

[0094] Src-CD19 scFv CAR (also known as Scr-scFv CD19-CD28-CD3z; CAR-luciferase-shRNA; Src-CD19 scFv CD28 CAR; CD28 CAR Scr-CD19 scFv CAR; Src-CD19 scFv CAR; Luciferase-CAR)

[0095] shRNAl -CD 19 scFv CAR (also known as shRNAl-CD19 scFv CD28 CAR; shRNAl Rasall -CD 19 scFv CD28 CAR; shRNAl -CD 19 scFv CD28 hinge CAR; Rasall shRNA 1-scFv CD19, CD28, CD3z; CAR-Rasall -shRNAl; Rasall Shl-scFv CD19-CD28-CD3z; Shl-ScFv CD19-CD28-CD3z; Rasall ShRNAl-CD19 scFv CD28 CAR; Rasall Shi scFv CD19-CD28-CD3z; RASAL 1 scRNAl-CAR; shRNAl CAR; RASAL1 shRNAl-CAR) shRNA4-CD19 scFv CAR (also known as shRNA4-CD19 scFv CD28 CAR; shRNA4 Rasall -CD 19 scFv CD28 CAR; shRNA4-CD19 scFv CD28 hinge CAR; CAR-Rasall-shRNA4; Rasall Sh4-scFv CD19-CD28-CD3z; Sh4-ScFv CD19-CD28-CD3z; Rasall ShRNA4-CD19 scFv CD28 CAR; Rasall Sh4 scFv CD19-CD28-CD3z; RASAL 1 scRNA4-CAR; shRNA4 CAR; RASAL1 shRNA4-CAR; Rasall shRNA + CD28 CAR)

[0096] shRNA RASAL 1 (also known as mRasall shRNA) (vector only expressing shRNA RASAL1)DETAILED DESCRIPTION

[0097] The development and use of chimeric antigen receptor (CAR) is an effective immunotherapy against hematologic cancers. CARs combine an antigen recognition domain of a specific antibody with an intracellular domain of the CD3-(^ chain or FcyRI protein into a single chimeric protein. The inclusion of intracellular motifs from the co-receptors CD28 and CD 137 (4-1BB) extend the longevity of CAR-Ts. The remarkable achievement of anti-CD19 CAR-T cell therapy in treating patients with B-cell lymphoma has demonstrated the profound potential of genetically modifying T cells. This innovative approach facilitates the expeditious generation of tumor- specific T cells capable of exerting sustained and potent anti-tumor effects, marking a significant stride in the development of effective cancer therapies. The administered CAR-T cells exhibit potent antitumor effects through a dual mechanism. Firstly, they recognize and bind to the target antigen expressed on tumor cells via their engineered chimeric antigen receptor (CAR), triggering cytotoxic activity that directly kills the cancer cells. Secondly, these CAR-T cells possess the remarkable ability to proliferate and survive for an extended period within the body. Consequently, even a single dose of CAR-T cell therapy can elicit sustained and prolonged antitumor responses, continually eliminating malignant cells over an extended timeframe. CAR-Ts against relapsed acute lymphoblastic leukemia (ALL) have been associated with durable and sustained remissions for up to 24 months. Severe cytokine-release syndrome in a minority of patients has been effectively treated with the anti-interleukin-6 receptor antibody, tocilizumab. Multiple CAR-T based drugs such as Breyanzi, Yescarta and Kymriah have been approved by FDA, while other trials are presently underway in many academic medical centers. Many studies have validated the efficacy and safety of CAR-T cell therapy and made improvements by altering either the extracellular or intracellular regions. However, this therapy relies on individually constructed chimeric antigen receptors (CARs). Rationally engineered CARs with enhanced therapeutic capabilities. For example, the inclusion of different hinge regions has been shown to alter CAR function and killing.

[0098] In this context, the LAIR receptor, also known as the Leukocyte-Associated Immunoglobulin-like Receptor, is a type of immune receptor found on various immune cells, including B cells, T cells, and natural killer (NK) cells. It belongs to the immunoglobulin superfamily of proteins and plays a role in regulating immune responses. LAIR1 is a transmembrane protein with extracellular immunoglobulin-like domains that can interact with various ligands, such as cell surface molecules or soluble proteins. It can deliver co-stimulatory or co-inhibitory signals that modulate the activation state of immune cells, influencing their proliferation, cytokine production, and effector functions. LAIR1, which suppresses lymphocyticactivity through SHP-1 signaling, while LAIR-2 (CD306) is a soluble homolog of LAIR- 1 and can bind to the same ligands (collagens and Clq), acting as a decoy receptor that competes with LAIR-1. LAIR-2 antagonizes the collagen / LAIR- 1 inhibitory immune interaction. The binding of Clq to LAIR-1 suppresses the development and activation of dendritic cells, while the presence of LAIR-2 can counteract this suppressive effect. A LAIR-2-Fc fusion protein can enhance the anti-cancer efficacy of PD-1 / L1 checkpoint inhibitor therapy.

[0099] In the context of T-cell intracellular signaling, the activation of T cells is regulated by a balance between positive and inhibitory receptors and their respective signaling events(28-31). Specifically, the protein tyrosine kinase p561ck, upon binding to the CD4 or CD8 co-receptors, phosphorylates immunoreceptor tyrosine-based activation motifs (IT AMs) located on the CD3 and , chains associated with the T-cell receptor (TCR). This phosphorylation allows for the recruitment of zeta-chain-associated protein kinase 70 (ZAP-70) and subsequent phosphorylation of downstream enzymes and adaptor proteins, ultimately leading to the activation of various transcriptional pathways. T-cell activation also involves a metabolic transition from oxidative phosphorylation (OXPHOS) to glycolysis as well as the small GTP-binding protein p21ras and its regulation of the extracellular signal-regulated kinase (ERK) pathways. This pathway is modulated by guanine nucleotide exchange factors (GEFs) that activate p21ras by exchanging bound GDP (guanosine diphosphate) for GTP (guanosine triphosphate) and by GTPase-activating proteins (GAPs) that inactivate GTP-binding proteins by converting the active GTP-bound form to the inactive GDP-bound form.

[0100] One group of GAPs belongs to the RASA GAP subfamily, which includes NF1, RASA1-5, and RASAL1 -3. These family members typically consist of two N-terminal C2 domains, followed by the GAP catalytic domain, a pleckstrin homology (PH) domain, and a Bruton tyrosine kinase (BTK) motif. When intracellular calcium levels are elevated, the C2 domains facilitate binding to the plasma membrane, thereby initiating GAP activity.

[0101] Rasall (also known as Ras protein activator like 1) is a distinct protein that functions as a GTPase-activating protein (GAP) for the Ras family of small GTPases such as p21ras and RAP1. Ras family of small GTPases includes proteins like H-Ras, K-Ras, and N-Ras. In T cells, p21rasis activated with TCR ligation21. The regulation of NF AT by p21ras in T cells requires the activity of multiple effector pathways, including those regulated by MAPKK-l / ERK-2. Furthermore, inactive p21ras can deactivate the MAPK pathway, resulting in T cell anergy. T cell anergy is a state of functional unresponsiveness that develops when T cells receive stimulation through their TCR without adequate co- stimulation. Expressing constitutively active mutants of p21ras can overcome anergy induction by restoring IL-2 production and proliferation in anergized T cells.Unlike Rasall, Rasa2 (ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2) which is a GTPase- activating protein (GAP) that specifically targets and inactivates members of the Arf (ADP-ribosylation factor) and Rho (Ras homologous) families of small GTPases. It does not have any GAP activity towards the While both Rasa2 and Rasall are GAPs, they target different families of small GTPases and play distinct roles in cellular processes. Rasa2 regulates Arf and Rho GTPases, while Rasall specifically regulates Ras GTPases.

[0102] In this context, T-cell signaling proteins also regulate T-cell subsets and stages of differentiation in the T-cell compartment. Repeated chronic activation can exhaust T-cells leading to a loss of function. The transcription factor TCF1 determines the progenitor and memory responses of CD8+ T cells. PD-1, TIM-3, CX3CR1 and CD101 define further stages of exhaustion from transient to terminal exhaustion. Suppressive regulatory T cells (Tregs) safeguard against autoimmunity. Thymic Tregs originate from developing thymocytes that receive strong T cell receptor (TCR) signals through high-affinity interactions between the TCR and self-major histocompatibility complex (MHC) molecules. Our previous work identified Rasall as a binding partner of ZAP-70 within the TCR / CD3 complex, where its binding inhibited ZAP-70's catalytic activity and its GAP domain suppressed the p21ras-ERK pathways, exerting a double inhibitory role on T cell activation.

[0103] I. Certain Definitions

[0104] An “antibody” refers to a polypeptide or set of polypeptides that specifically recognizes and binds to an antigenic determinant, or epitope, on a target molecule. The term encompasses both full-length antibodies and antibody fragments that retain antigen-binding activity. A full-length antibody typically comprises two identical heavy chains and two identical light chains, each including a variable region and a constant region, assembled in a Y-shaped structure. The variable regions of the heavy and light chains form the antigenbinding sites, conferring specificity toward a target antigen.

[0105] As used herein, the term “antibody” also includes antigen-binding fragments and engineered derivatives of full-length antibodies that are capable of specifically binding to an antigen. Such fragments include, without limitation, Fab fragments (comprising the light chain and the variable and first constant domain of the heavy chain), F(ab')2 fragments (two Fab fragments joined by a disulfide bond), and Fv fragments (comprising the variable regions of both the heavy and light chains). Also encompassed are single-chain variable fragments (scFvs), in which the variable regions of the heavy and light chains are joined by a flexiblepeptide linker, and single-domain antibodies (sdAbs or nanobodies), which consist of a single monomeric variable domain and are often derived from camelid antibodies.

[0106] The term further includes diabodies, triabodies, and tetrabodies, which are multivalent constructs formed by non-covalent assembly or genetic fusion of multiple variable domains, as well as bispecific antibodies engineered to simultaneously bind two different antigens or epitopes. Antibody fragments may be derived from natural sources, produced by enzymatic cleavage of full-length antibodies, expressed recombinantly, or generated synthetically. These fragments may be modified to improve pharmacokinetics, stability, or effector function, and may include fusion to other proteins, tags, or therapeutic moieties.

[0107] Unless otherwise indicated, the term “antibody” as used herein is intended to include all of the above forms, provided that the molecule retains the ability to specifically bind to a target antigen, such as a tumor-associated antigen. Antibodies and antibody fragments of the invention may be used for therapeutic, diagnostic, research, or cell-engineering applications, including but not limited to incorporation into chimeric antigen receptors (CARs).

[0108] An “antigen-binding domain” includes the portion of a chimeric antigen receptor (CAR) or other receptor molecule that is responsible for specifically recognizing and binding to a target (e.g., tumor- associated) antigen, typically presented on the surface of a cell. An antigen-binding domain enables selective targeting of cells expressing the antigen, such as tumor-associated antigens, on cancer cells.

[0109] A “bicistronic vector” is a genetic construct (for example, a plasmid or viral vector) engineered to express two distinct molecules (e.g., shRNA and a CAR) from a single transcript within a host cell. The mechanism of bicistronic expression enables the coordinated translation of two distinct coding sequences from a single mRNA transcript. In some embodiments, a bicistronic vector contains a single promoter that drives transcription of an mRNA encoding both a first molecule (cistron) and a second molecule, separated by a regulatory element that facilitates downstream translation. This can be achieved, for example, using an internal ribosome entry site (IRES), which allows cap-independent initiation of translation at the second cistron, or a self-cleaving 2 A peptide sequence (e.g., P2A or T2A), which induces ribosomal skipping and co-translational cleavage, resulting in two discrete protein products.

[0110] A “chimeric antigen receptor,” also referred to as a “CAR,” is a synthetic, engineered receptor that enables immune cells, for example, T cells, to recognize and respond to specific antigens on the surface of target cells, such as cancer cells. CARs include modular domainsderived from different proteins, allowing immune cells to bypass conventional major histocompatibility complex (MHC) presentation and directly bind to antigens.

[0111] A “contiguous nucleotide sequence” refers to a linear sequence of nucleotides (e.g., bases: adenine, cytosine, guanine, and thymine or uracil) in which each nucleotide is directly adjacent to the next, with no gaps, interruptions, or unrelated sequence segments in between.

[0112] A “hinge (spacer) domain” includes a polypeptide segment positioned between the antigen-binding domain and the transmembrane domain of a chimeric antigen receptor (CAR) or other engineered receptor. A hinge domain provides structural flexibility and spatial separation, facilitating proper orientation and accessibility of the antigen-binding domain to its target epitope on the surface of a target cell.

[0113] An “intracellular signaling domain” includes a portion of a chimeric antigen receptor or other engineered receptor that resides within the cytoplasm of a host cell and is responsible for transducing activation signals following antigen engagement. This domain plays a role in initiating and regulating cellular responses such as activation, proliferation, cytokine production, cytotoxicity, and survival.

[0114] A “leukocyte-associated immunoglobulin-like receptor hinge domain,” also referred to as a “LAIR hinge domain,” includes a polypeptide segment derived from the extracellular portion of a LAIR protein, for example, from human LAIR-1 (CD305). In some embodiments, it is engineered into CAR constructs to modulate the length, flexibility, and orientation of the receptor for optimal antigen engagement. The hinge domain can provide flexibility and spatial separation between, for example, an extracellular antigen-binding domain (e.g., an scFv) and a transmembrane domain of the CAR.

[0115] “Percent identity” refers to the degree of sequence similarity between two nucleic acid sequences or two amino acid sequences, as determined by aligning the sequences and calculating the percentage of identical residues at corresponding positions over a defined region of comparison (e.g., via local alignment or global alignment). Percent identity can be calculated by comparing two sequences using a suitable alignment algorithm, such as the Needleman- Wunsch algorithm, with standard parameters (e.g., a gap opening penalty of 10 and a gap extension penalty of 0.5) and is expressed as the number of identical residues in the alignment divided by the total number of residues in the compared sequence, multiplied by 100. For nucleic acid sequences, percent identity refers to the number of identical nucleotide bases, while for amino acid sequences, it refers to the number of identical amino acids.

[0116] Unless otherwise stated, percent identity values are determined over the full length of the reference sequence or over a specified aligned region, and may be calculated usingcommercially available software, such as those provided by the Vector NTI Suite (Invitrogen) or Geneious (Biomatters) or using publicly available tools such as BLAST or EMBOSS Needle.

[0117] An “RNAi molecule” includes a nucleic acid-based agent that mediates RNA interference (RNAi) — a naturally occurring, sequence- specific mechanism for post-transcriptional gene silencing.

[0118] A “short-hairpin RNA,” also referred to as an “shRNA,” includes a single- stranded RNA molecule that folds back on itself to form a tight hairpin loop. It is typically expressed from a DNA vector within a cell and processed by cellular machinery into small interfering RNA (siRNA), which guides the RNA-induced silencing complex (RISC) to degrade or inhibit the translation of target mRNA.

[0119] A “transgene” includes a segment of nucleic acid — for example, DNA — that can be artificially introduced into the genome of a cell or organism and is not naturally present in that cell. A transgene can be engineered to encode a functional product, such as a protein or RNA, and can be stably or transiently expressed in a host cell. A transgene can originate from a different species (heterologous) relative to a host cell or may be a modified version of a gene from the same species (homologous but engineered) relative to a host cell. In some embodiments, a transgene is introduced via vectors such as plasmids, viruses (e.g., lentivirus, AAV), or by direct methods such electroporation or microinjection. Expression of a transgene can be driven by a promoter (often constitutive or inducible) included in the same construct, for example.

[0120] A “transmembrane domain” includes a portion of a chimeric antigen receptor or other engineered receptor that spans a cellular lipid bilayer and anchors the receptor to the plasma membrane, a transmembrane domain provides a structural link between an extracellular region — containing the antigen-binding and hinge domains — and an intracellular signaling region of the receptor.

[0121] A “tumor-associated antigen” includes a protein or other molecular structure that is expressed on the surface of tumor cells at levels significantly higher than on normal cells, or in a manner that is otherwise abnormal (e.g., ectopic expression, altered glycosylation, or expression of embryonic isoforms).

[0122] II. Bicistronic Vector Design

[0123] The technology, in some aspects, relates to a bicistronic vector configured to express two distinct functional genetic elements from a single vector construct: (1) a short hairpinRNA (shRNA) targeting the mRNA of a specified gene (e.g., RASAL1), and (2) a chimeric antigen receptor (CAR) e.g., for cell-based immunotherapy). The vector can be delivered to a host cell via a plasmid, lentiviral, retroviral, or other suitable gene delivery system.

[0124] A bicistronic vector of the disclosure enables simultaneous gene silencing (e.g., via the shRNA targeting mRNA encoded by RASAL1) and antigen- specific immune activation (e.g., via a CAR), and can be used to modify immune cells such as T cells, NK cells, or other effector cells for therapeutic applications, including the treatment of cancer or other diseases In some embodiments, a bicistronic vector comprises: (a) a contiguous 10-40 nucleotide sequence reverse complementary to a RASAL1 gene, wherein the RASAL1 gene comprises the nucleotide sequence of SEQ ID NO: 22; and (b) a nucleotide sequence encoding a chimeric antigen receptor that comprises a LAIR hinge domain.

[0125] In some embodiments, a bicistronic vector comprises: (a) a contiguous 10-40 nucleotide sequence reverse complementary to a RASAL1 gene, wherein the RASAL1 gene comprise the nucleotide sequence of SEQ ID NO: 22; and (b) a nucleotide sequence encoding a polypeptide comprising a CD 19 antibody domain and a LAIR hinge domain.

[0126] In some embodiments, a bicistronic vector comprises: (a) an shRNA targeting RASAL1 mRNA; and (b) a chimeric antigen receptor comprising (i) a CD 19 single-chain variable fragment (scFv) region and (ii) a LAIR hinge domain.

[0127] In some embodiments, a bicistronic vector encodes: (a) an shRNA targeting RASAL1 mRNA; and (b) a chimeric antigen receptor comprising (i) a CD 19 single-chain variable fragment (scFv) region and (ii) a LAIR hinge domain.

[0128] In some embodiments, a bicistronic vector encodes an shRNA targeting RASAL1 mRNA, a CD 19 scFv, a LAIR hinge domain, a CD28 transmembrane domain, a CD28 intracellular domain, and a CD3<^ intracellular domain.

[0129] In some embodiments, a bicistronic vector comprises a first nucleic acid comprising a first promoter operably linked to a coding sequence encoding the shRNA targeting RASAL1 mRNA; and a second nucleic acid comprising a second promoter operably linked to a coding sequence encoding a chimeric antigen receptor comprising the CD 19 scFv, LAIR hinge domain, CD28 transmembrane domain, CD28 intracellular domain, and CD3<^ intracellular domain.

[0130] In some embodiments, a bicistronic vector encodes an shRNA targeting RASAL1 mRNA, a CD 19 scFv, a CD28 hinge domain, a CD28 transmembrane domain, a CD28 intracellular domain, and a CD3<^ intracellular domain.In some embodiments, a bicistronic vector comprises a first nucleic acid comprising a first promoter operably linked to a coding sequence encoding the shRNA targeting RASAL1 mRNA; and a second nucleic acid comprising a second promoter operably linked to a coding sequence encoding a chimeric antigen receptor comprising the CD 19 scFv, CD28 hinge domain, CD28 transmembrane domain, CD28 intracellular domain, and CD3<^ intracellular domain.

[0131] In some embodiments, a CD 19 scFv region comprises a heavy chain comprising an amino acid sequence of SEQ ID NO: 7, an amino acid sequence of SEQ ID NO: 8, and an amino acid sequence of SEQ ID NO: 9. In some embodiments, a CD 19 scFv region comprises a light chain comprising an amino acid sequence of SEQ ID NO: 10, an amino acid sequence of SEQ ID NO: 11, and an amino acid sequence of SEQ ID NO: 12. In some embodiments, a CD19 scFv region comprises the sequence of SEQ ID NO: 6.

[0132] III. RNA Interference Molecules Targeting RASAL1

[0133] In some embodiments, a bicistronic vector comprises a first nucleotide sequence (e.g., a first transcriptional unit) comprising a promoter operably linked to a nucleotide sequence encoding an RNA interference (RNAi) molecule specific for RASAL1 mRNA. RNAi molecules function by guiding cellular RNA-induced silencing complexes (RISC) to complementary messenger RNA (mRNA) targets, resulting in degradation of the target mRNA or inhibition of its translation, thereby reducing or eliminating expression of the corresponding protein. RNAi molecules encompass several classes, including short hairpin RNA (shRNA), which are transcribed within the cell and form stem-loop structures that are processed by Dicer into small interfering RNA (siRNA); small interfering RNA (siRNA) itself, which are synthetic double- stranded RNA molecules typically 21-23 nucleotides in length and used for transient gene knockdown; and microRNA (miRNA) mimics or inhibitors, which modulate endogenous miRNA pathways to either enhance or inhibit gene silencing of natural targets. Additional examples include short interfering hairpin RNA and Dicer- substrate siRNA (DsiRNA), which are chemically modified or extended RNA duplexes designed for enhanced silencing potency and stability. In some embodiments, a bicistronic vector encodes an shRNA and a chimeric antigen receptor. In some embodiments, the bicistronic vector encodes an siRNA and a chimeric antigen receptor. In some embodiments, a bicistronic vector encodes a microRNA mimic and a chimeric antigen receptor. In some embodiments, a bicistronic vector encodes a DsiRNA and the chimeric antigen receptor. Insome embodiments, a bicistronic vector encodes a short interfering hairpin RNA or an antagomir (microRNA inhibitor) and a chimeric antigen receptor. Each of these RNAi molecules may be selected based on the desired gene- silencing mechanism, stability, and therapeutic application.

[0134] In some embodiments, a bicistronic vector comprises a first nucleotide sequence (e.g., a first transcriptional unit) comprising a promoter operably linked to a nucleotide sequence encoding an shRNA molecule specific for RASAL1 mRNA. shRNA molecules are singlestranded RNA sequences designed to form a stem-loop (hairpin) structure upon transcription, wherein a sense strand region is linked to an antisense strand region via a loop sequence. The stem (duplex) portion of the shRNA exhibits sequence complementarity to a target mRNA, resulting in gene knockdown through sequence- specific mRNA degradation.

[0135] The shRNA molecules of the disclosure can be encoded by DNA constructs, such as a bicistronic vector, and expressed intracellularly under the control of a promoter. Once transcribed, the shRNA is processed by cellular machinery, including the enzyme Dicer, into a functional siRNA duplex that is incorporated into RISC, thereby directing degradation of the complementary mRNA target.

[0136] The length of a duplex (stem) region of an shRNA can be varied to modulate silencing efficiency, stability, or cellular processing. The stem region can comprise, for example, between 16 and 29 base pairs, such as between 19 and 25 base pairs. In some embodiments, an shRNA comprises a duplex of 19, 21, 23, or 25 base pairs. The loop region can be 4 to 15 nucleotides in length, for example, and in some embodiments comprises a non-palindromic sequence such as UUCAAGAGA or GAAA.

[0137] An shRNA, in some embodiments, is designed to target RASAL1 (e.g., human RASAL1). In some embodiments, an shRNA binds to an mRNA sequence encoded by a sequence of SEQ ID NO: 22. Additionally, chemical modifications may be introduced at the 5' or 3' ends or within the loop region to improve RNA stability, reduce immune stimulation, or modulate processing by Dicer.

[0138] The disclosure also encompasses variants of the shRNA molecules, including those with mismatches within the stem region that preserve gene silencing activity, and short interfering hairpin RNAs that mimic pre-processed siRNA duplexes. The shRNA molecules can be incorporated into bicistronic vectors, as provided herein, co-expressed with a second therapeutic gene such as a chimeric antigen receptor (CAR), and / or delivered via viral vectors (e.g., lentivirus or AAV) for therapeutic applications.In some embodiments, an shRNA targeting an mRNA encoded by RASAL1 comprises a sequence having at least 90% identity to a sequence (e.g., a 10-40 nucleotide sequence) of SEQ ID NO: 22. In some embodiments, an shRNA targeting an mRNA encoded by RASAL1 comprises a sequence having at least 95% identity to a sequence (e.g., a 10-40 nucleotide sequence) of SEQ ID NO: 22. In some embodiments, an shRNA targeting an mRNA encoded by RASAL1 comprises a sequence having at least 98% identity to a sequence (e.g., a 10-40 nucleotide sequence) of SEQ ID NO: 22. In some embodiments, an shRNA targeting an mRNA encoded by RASAL1 comprises a sequence having 100% identity to a sequence e.g., a 10-40 nucleotide sequence) of SEQ ID NO: 22.

[0139] IV. Chimeric Antigen Receptors Targeting Tumor-associated Antigens

[0140] In some embodiments, a bicistronic vector comprises a second nucleotide sequence (e.g., a second transcriptional unit) encoding a chimeric antigen receptor (CAR), operably linked to a promoter suitable for expression in mammalian cells, such as the EFla, SFFV, or PGK promoter. CARs can include synthetic, modular receptors that redirect the antigen specificity of immune cells, such as T cells or natural killer (NK) cells, toward target cells expressing selected antigens, thereby facilitating targeted immune activation and cytotoxicity.

[0141] A CAR can be introduced into immune effector cells via viral or non- viral gene transfer methods, including lentiviral, retroviral, adenoviral, or adeno-associated virus (AAV) vectors, or via electroporation of DNA or mRNA. Engineered cells expressing the CARs can be used, for example, in adoptive cell therapy protocols for the treatment of cancer. In some embodiments, a CAR may be co-expressed with additional therapeutic elements, such as an shRNA targeting human RASAL1 to enhance therapeutic efficacy.

[0142] The technology herein encompasses CAR constructs wherein the antigen-binding domain comprises a variable region sequence having at least 90%, 95%, or 98% identity to a reference scFv specific for a given TAA, including sequences set forth herein. Variants with altered hinge length, transmembrane origin, and / or intracellular signaling configurations are also contemplated, provided that the CAR retains functional antigen- specific activation properties.

[0143] In some embodiments, a CAR comprises an anti-CD19 scFv, a LAIR (e.g., LAIR-1) or CD28 hinge domain, a CD28 or CD8a transmembrane domain, and intracellular signaling domains derived from CD28 and CD3(^. In some embodiments, a CAR targets CD 19 and is incorporated into a bicistronic expression vector encoding an shRNA targeting RASAL1.In some embodiments, a CAR comprises the following domains arranged in a single open reading frame: (i) an extracellular antigen-binding domain, in some embodiments comprising a single-chain variable fragment (scFv) specific for a tumor- associated antigen (TAA); (ii) a hinge (spacer) domain that provides structural flexibility and optimal spatial configuration for antigen engagement; (iii) a transmembrane domain that anchors the receptor in the plasma membrane; and (iv) one or more intracellular signaling domains that mediate immune cell activation upon antigen binding. In some embodiments, the intracellular domain comprises a CD3(^ activation motif in combination with one or more co- stimulatory domains such as CD28, 4-1BB (CD137), or 0X40 (CD134), depending on the desired signaling profile.

[0144] In some embodiments, a chimeric antigen receptor comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 23. In some embodiments, a chimeric antigen receptor comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 23. In some embodiments, a chimeric antigen receptor comprises an amino acid sequence having at least 98% identity to the amino acid sequence of SEQ ID NO: 23. In some embodiments, a chimeric antigen receptor comprises an amino acid sequence having 100% identity to the amino acid sequence of SEQ ID NO: 23.

[0145] A. Antigen Binding Domains

[0146] In some embodiments, an antigen-binding domain comprises a single-chain variable fragment (scFv), which includes the variable region of a heavy chain (VH) and the variable region of a light chain (VL) of an antibody, joined by a flexible peptide linker. An scFv retains the specificity and affinity of the original antibody from which the variable regions were derived and is engineered to be expressed as a single polypeptide chain.

[0147] Alternative forms of antigen-binding domains can include, but are not limited to, nanobodies, affibodies, Fab fragments, ligand-binding domains of native receptors, or synthetic binding scaffolds, provided they maintain specific binding affinity for the target antigen. The antigen-binding domain can be selected or engineered to recognize any extracellular epitope, including protein, carbohydrate, or glycolipid structures, and can be derived from monoclonal antibodies, phage display libraries, or synthetic sources.

[0148] In some embodiments, an antigen-binding domain is located at the N-terminal extracellular portion of a CAR.

[0149] In some embodiments, an antigen binding domain binds specifically to CD 19. In some embodiments, an antigen binding domain is an antibody (e.g., scFv) that binds toCD 19. Non-limiting examples of CD 19 antibodies (used interchangeably with the term “antiCD 19 antibodies” to mean antibodies that bind to CD19 antigen), or molecules from which a CD 19 antibody can be derived are known, many of which are commercially available, including Tafasitamab (Monjuvi® / Minjuvi®), Loncastuximab Tesirine (Zynlonta®), Blinatumomab (Blincyto®), Inebilizumab (Uplizna®), Denintuzumab Mafodotin (SGN-CD19A), and Taplitumomab Paptox. CD19 antibodies are also described in W02005012493A2, W02007002223A2, WO2010053716A1, W02016033570A1, WO2017055541A1, WO2017055328A1, W02018108106A1, and Davis JA et al. J Oncol Pharm Pract. 2022 Apr;28(3):686-690, the CD19 antibodies of which are incorporated herein by reference. The CDRs, variable regions, heavy and / or light chains, and / or full-length sequence of any CD 19 antibody of any of the preceding publications can be used as an antigen binding domain as described herein.

[0150] In some embodiments, a CD 19 scFv region comprises a heavy chain comprising an amino acid sequence of SEQ ID NO: 7, an amino acid sequence of SEQ ID NO: 8, and an amino acid sequence of SEQ ID NO: 9. In some embodiments, a CD 19 scFv region comprises a light chain comprising an amino acid sequence of SEQ ID NO: 10, an amino acid sequence of SEQ ID NO: 11, and an amino acid sequence of SEQ ID NO: 12.

[0151] In some embodiments, a CD 19 scFv region comprises: a heavy chain comprising an amino acid sequence of SEQ ID NO: 7, an amino acid sequence of SEQ ID NO: 8, and an amino acid sequence of SEQ ID NO: 9; and a light chain comprising an amino acid sequence of SEQ ID NO: 10, an amino acid sequence of SEQ ID NO: 11, and an amino acid sequence of SEQ ID NO: 12.

[0152] In some embodiments, a CD 19 scFv region comprises the sequence of SEQ ID NO: 6. In some embodiments, an antigen binding domain binds specifically to GD3. In some embodiments, an antigen binding domain is an antibody (e.g., scFv) that binds to GD3 (e.g., comprising or derived from SEQ ID NOs: 28 and / or 29, or sequences at least 85%, at least 90%, or at least 95% identical thereto). Non-limiting examples of GD3 antibodies (used interchangeably with the term “anti-GD3 antibodies” to mean antibodies that bind to GD3 antigen), or molecules from which a GD3 antibody can be derived, include R24, a murine IgG3 monoclonal antibody that has been evaluated in clinical trials for metastatic melanoma and is commercially available (Sigma-Aldrich, clone R24, catalog MABC1112; Abeam, clone R24, abll779), ecromeximab (KW-2871), a human-mouse chimeric IgGl monoclonal antibody targeting GD3 that has been evaluated in Phase Eli clinical trials in patients with metastatic melanoma, and KM-871, a humanized chimeric IgGl anti-GD3 antibody derivedfrom the murine KM-641 clone that has demonstrated binding to melanoma cell lines.

[0153] Additional research-grade anti-GD3 antibodies are commercially available, including clone GMR19 (TCI America) and clone MB3.6 (Santa Cruz Biotechnology). GD3 antibodies are also described in Shah J et al. Cancer Biother Radiopharm. 2006;21(3):187-197, the GD3 antibodies of which are incorporated herein by reference. The CDRs, variable regions, heavy and / or light chains, and / or full-length sequence of any GD3 antibody of any of the preceding publications can be used as an antigen binding domain as described herein. See, e.g., U.S. Patent No. 7,253,263 and U.S. Patent No. 9,205,157 (e.g., SEQ ID NOs: 28 and / or 29, or sequences at least 85%, at least 90%, or at least 95% identical thereto).

[0154] 1. Tumor-associated Antigens

[0155] In some embodiments, encode a chimeric antigen receptor that binds specifically to a tumor-associated antigen. Non-limiting examples of tumor-associated antigens include CD 19, CD20, CD22, CD33, CD38, CD123, CLL-1, GPRC5D, HER2 (ERBB2), EGFR, EGFRvIII, CEA (carcinoembryonic antigen), PSMA (pro state- specific membrane antigen), MUC1, mesothelin, Claudin 18.2, GPC3, B7-H3, AXL, GD2, GD3, FAP, WT1 (Wilms tumor 1), NY-ESO-1, PRAME (preferentially expressed antigen in melanoma), MAGE-A3, MAGE-A4, AFP, BCMA (B-cell maturation antigen), ROR1, and IL13Ra2. These antigens are overexpressed, mutated, or aberrantly expressed on the surface of various cancer cells.

[0156] CD 19 is a transmembrane glycoprotein expressed almost exclusively on B-lineage cells from early development through differentiation into memory B cells. It is commonly found on the surface of B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain non-Hodgkin lymphomas, making it a well- validated target for chimeric antigen receptor (CAR) T cell therapy.

[0157] CD20 is a non-glycosylated phosphoprotein expressed on the surface of pre-B and mature B lymphocytes but not on early progenitor B cells or plasma cells. It is highly expressed in B-cell lymphomas and leukemias, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL), and is the target of monoclonal antibody therapies such as rituximab.

[0158] CD22 is a B-cell-specific transmembrane sialoglycoprotein involved in regulating B cell signaling. It is expressed in mature B cells and B-cell malignancies, including hairy cell leukemia and ALL. Its restricted expression pattern makes it a candidate for targeted therapy with antibody-drug conjugates or CAR T cells.

[0159] CD33 is a myeloid cell surface antigen and a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. It is predominantly expressed on myeloid lineagecells, including monocytes and granulocyte precursors, and is a hallmark antigen in acute myeloid leukemia (AML), where it serves as a target for immunotherapies such as gemtuzumab ozogamicin.

[0160] CD38 is a type II transmembrane glycoprotein with receptor and enzyme functions that is highly and uniformly expressed on multiple myeloma cells and at lower levels on other hematopoietic cells. Its high expression in plasma cell dyscrasias and role in cell signaling and adhesion make it a validated therapeutic target, as demonstrated by the clinical success of anti-CD38 monoclonal antibodies such as daratumumab, and it is an emerging target for CAR T cell therapy.

[0161] CD 123 is the alpha chain of the interleukin-3 receptor (IL-3Ra) and is overexpressed in multiple hematologic malignancies, including AML, blastic plasmacytoid dendritic cell neoplasm (BPDCN), and high-risk myelodysplastic syndromes (MDS). Its expression on leukemic stem cells and relative absence on normal hematopoietic stem cells makes it an attractive therapeutic target.

[0162] CLL-1 (C-type lectin-like molecule- 1, also known as CLEC12A) is a myeloid inhibitory receptor expressed on AML blasts and leukemic stem cells but not on normal hematopoietic stem cells. Its selective expression pattern makes it a promising target for CAR T cell therapy and other immunotherapeutic approaches in AML, including in combination with CD33 or CD 123 targeting.

[0163] GPRC5D (G protein-coupled receptor class C group 5 member D) is an orphan receptor with highly restricted expression in normal tissues, primarily in hair follicles, but is aberrantly expressed at high levels on multiple myeloma cells. Its tumor- selective expression profile and cell surface localization make it an attractive target for CAR T cell therapy and bispecific antibodies in multiple myeloma, including in patients who have relapsed after BCMA-directed therapies.

[0164] HER2 (ERBB2) is a member of the epidermal growth factor receptor (EGFR) family and is overexpressed in various solid tumors, most notably breast and gastric cancers. HER2 overexpression or gene amplification is associated with aggressive tumor growth and poor prognosis, and it is targeted by multiple therapies including trastuzumab and HER2-specific CAR T cells.

[0165] EGFR (Epidermal Growth Factor Receptor) is a transmembrane tyrosine kinase receptor involved in cell proliferation and survival. It is frequently overexpressed or mutated in epithelial cancers such as non-small cell lung cancer (NSCLC), glioblastoma, andcolorectal cancer. EGFR-targeted therapies include tyrosine kinase inhibitors and monoclonal antibodies.

[0166] EGFRvIII (Epidermal Growth Factor Receptor variant III) is a tumor- specific deletion mutant of EGFR in which exons 2-7 are deleted, resulting in a constitutively active receptor that is not expressed on normal adult tissues. EGFRvIII is found predominantly in glioblastoma and, to a lesser extent, in other epithelial malignancies, and its tumor-restricted expression makes it a highly selective target for CAR T cell therapy and antibody-based approaches with minimal risk of on-target / off-tumor toxicity.

[0167] CEA (Carcinoembryonic Antigen) is a glycoprotein involved in cell adhesion that is normally expressed during fetal development but re-expressed in many adenocarcinomas, including colorectal, pancreatic, gastric, and breast cancers. Its limited expression in normal adult tissues makes it a viable target for cancer vaccines, antibody-based therapies, and CAR T cells.

[0168] PSMA (Prostate-Specific Membrane Antigen) is a type II transmembrane glycoprotein highly expressed in prostate cancer cells, particularly in advanced or metastatic disease. It has minimal expression in most normal tissues, making it an ideal target for radionuclide therapies, antibody-drug conjugates, and CAR T cell therapy in prostate cancer.

[0169] MUC1 (Mucin 1) is a transmembrane glycoprotein that is overexpressed and aberrantly glycosylated in a wide range of epithelial cancers, including breast, pancreatic, ovarian, and lung cancers. Tumor-associated MUC1 differs structurally from normal MUC1, providing a tumor- specific epitope for therapeutic targeting.

[0170] Mesothelin is a glycoprotein expressed at low levels in normal mesothelial cells but overexpressed in several malignancies, including mesothelioma, pancreatic cancer, and ovarian cancer. Its restricted expression in normal tissues and high expression in tumors makes it a favorable target for antibody-based and cell-based therapies.

[0171] Claudin 18.2 (CLDN18.2) is a tight junction protein whose expression in normal tissues is largely restricted to gastric mucosa, but which is aberrantly expressed and accessible on the surface of gastric, pancreatic, esophageal, and lung adenocarcinoma cells due to disruption of epithelial tight junction integrity in the tumor microenvironment. Its highly restricted normal tissue distribution and tumor surface accessibility make it an attractive target for CAR T cell therapy, bispecific antibodies, and antibody-drug conjugates in gastrointestinal and other solid tumors.

[0172] GPC3 (Glypican-3) is a heparan sulfate proteoglycan anchored to the cell surface via a glycosylphosphatidylinositol (GPI) linkage that is highly expressed in hepatocellularcarcinoma (HCC) and other malignancies including ovarian clear cell carcinoma and squamous cell lung cancer, but is largely absent from normal adult tissues. Its overexpression in HCC and other solid tumors, combined with its cell surface accessibility, makes it a well-validated target for CAR T cell therapy, antibody-drug conjugates, and bispecific antibodies.

[0173] B7-H3 (CD276) is an immune checkpoint molecule of the B7 family that is broadly overexpressed across a wide range of solid tumors, including glioblastoma, breast, lung, prostate, colorectal, and pancreatic cancers, as well as in pediatric solid tumors such as neuroblastoma and medulloblastoma. While minimally expressed on most normal tissues, B7-H3 promotes tumor immune evasion and is associated with poor prognosis. Its near-ubiquitous tumor expression and surface accessibility make it an attractive pan-tumor target for CAR T cell therapy and antibody-drug conjugates.

[0174] AXL is a receptor tyrosine kinase of the TAM family (TYRO3, AXL, MERTK) that is overexpressed in numerous solid tumors, including non-small cell lung cancer, glioblastoma, breast cancer, and pancreatic cancer. AXL signaling promotes tumor cell survival, epithelial-to-mesenchymal transition, metastasis, and immune evasion. Its overexpression in aggressive and therapy-resistant cancers, combined with its limited expression in most normal adult tissues, makes it a candidate for CAR T cell therapy and targeted kinase inhibition.

[0175] GD2 (Disialoganglioside GD2) is a glycolipid antigen expressed on neuroectodermal tumors such as neuroblastoma, melanoma, and osteosarcoma. It is minimally expressed in normal tissues, with the exception of peripheral nerves, which can lead to on-target / off-tumor toxicity. Nonetheless, GD2 is a validated target in pediatric and solid tumor immunotherapy.

[0176] GD3 (Trisialoganglioside GD3) is a glycolipid antigen expressed on neuroectodermal tumors such as melanoma, neuroblastoma, and glioblastoma. It is minimally expressed in most normal adult tissues, making it an attractive target for tumor- selective immunotherapy. GD3 is a validated target in melanoma and pediatric solid tumor immunotherapy, and its expression on the surface of tumor cells renders it accessible to CAR T-cell-mediated recognition and killing.

[0177] FAP (Fibroblast Activation Protein) is a type II transmembrane serine protease selectively expressed on cancer-associated fibroblasts (CAFs) within the tumor stroma of the majority of epithelial cancers, including colorectal, breast, pancreatic, and lung carcinomas, and is largely absent from normal adult tissues. Because FAP is expressed on stromal rather than cancer cells per se, targeting FAP-expressing CAFs offers a tumor- antigen- agnosticstrategy to remodel the immunosuppressive tumor microenvironment and enhance the efficacy of CAR T cells and other immunotherapies.

[0178] WT1 (Wilms Tumor 1) is a transcription factor normally expressed during development and involved in cell growth and differentiation. Aberrant expression of WT1 is observed in leukemias and various solid tumors, and it is considered a tumor-associated antigen suitable for T cell-based immunotherapy and cancer vaccines.

[0179] NY-ESO-1 is a cancer / testis antigen that is normally expressed only in germ cells of the testis but is aberrantly expressed in various cancers, including melanoma, sarcoma, and ovarian cancer. Because germ cells do not express MHC class I, NY-ESO-1 is effectively tumor- specific and has been the focus of TCR-based adoptive cell therapies and cancer vaccines.

[0180] PRAME (Preferentially Expressed Antigen in Melanoma) is another cancer / testis antigen expressed in multiple malignancies including melanoma, leukemia, and breast cancer. Its limited expression in normal tissues and frequent overexpression in cancer cells make it a candidate for TCR-based and other targeted immunotherapies.

[0181] MAGE-A3 (Melanoma Antigen Gene A3) is a cancer / testis antigen belonging to the MAGE-A family that is expressed in germ cells and trophoblasts under normal physiological conditions but is aberrantly activated in a broad range of malignancies, including melanoma, lung cancer, head and neck cancer, bladder cancer, and multiple myeloma. Because somatic cells do not express MAGE-A3, it represents a tumor- selective target for TCR-based adoptive cell therapies, cancer vaccines, and, where surface presentation allows, antibody-based approaches.

[0182] MAGE-A4 (Melanoma Antigen Gene A4) is a closely related cancer / testis antigen of the MAGE-A family with a similar expression pattern to MAGE- A3, being restricted to germ cells in normal tissues but aberrantly expressed in esophageal, lung, bladder, and ovarian cancers, among others. MAGE-A4 has emerged as a clinically actionable target, with TCR-engineered T cell therapies demonstrating therapeutic activity in synovial sarcoma and other MAGE-A4-expressing solid tumors.

[0183] AFP (Alpha-Fetoprotein) is an oncofetal glycoprotein produced abundantly during fetal liver development and normally present at only trace levels in healthy adults, but is markedly re-expressed in hepatocellular carcinoma (HCC) and certain germ cell tumors, where elevated serum AFP serves as a diagnostic and prognostic biomarker. Intracellularly processed AFP peptides are presented on MHC class I molecules at the tumor cell surface,enabling targeting by AFP- specific TCR-engineered T cells and making AFP a relevant antigen for adoptive cell therapy approaches in HCC.

[0184] BCMA (B-cell Maturation Antigen) is a member of the TNF receptor superfamily and is selectively expressed on plasma cells and multiple myeloma cells. It plays a role in B cell development and survival, and has become a validated target for CAR T cells, bispecific antibodies, and antibody-drug conjugates in the treatment of multiple myeloma.

[0185] R0R1 (Receptor Tyrosine Kinase-like Orphan Receptor 1) is an oncofetal protein expressed during embryogenesis and re-expressed in a variety of malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and breast cancer. It has limited expression in normal adult tissues, making it a promising target for immune-based therapies.

[0186] IL13Ra2 (Interleukin- 13 Receptor Alpha 2) is a high-affinity receptor for IL-13 that is overexpressed in glioblastoma, pancreatic cancer, and other solid tumors. Unlike the physiological IL13Ral / IL-4R complex, IL13Ra2 has limited signaling function and is largely tumor- specific, making it an attractive target for CAR T cell therapy and other modalities.

[0187] B. Hinge Domains

[0188] A hinge domain can serve several functions, including (i) enhancing the mobility and reach of the antigen-binding domain, particularly when the target epitope is membrane-proximal or buried within a complex tissue microenvironment; (ii) minimizing steric hindrance between the receptor and the target cell surface; and / or (iii) enabling more efficient receptor activation and signaling following antigen engagement.

[0189] Hinge domains can be derived from various naturally occurring or synthetic sources. Non-limiting examples include hinge regions from human CD8a, CD28, IgGl, IgG4, or leukocyte-associated immunoglobulin-like receptors (LAIRs) such as LAIR-1. A hinge domain can vary in length, composition, and glycosylation state, depending on the desired functional properties of the CAR construct. In some embodiments, a hinge domain includes part or all of an immunoglobulin Fc region, while in other embodiments, it includes a minimal peptide linker sufficient to provide flexibility without contributing significant bulk.

[0190] The selection of a hinge domain can influence the expression, stability, antigen accessibility, and signaling efficiency of the CAR, and may be based on the intended therapeutic application or the nature of the target antigen.

[0191] 1. LAIR Hinge DomainsIn some embodiments, a hinge region is a LAIR hinge region. In the context of the present disclosure, LAIR hinge domains include flexible polypeptide spacer regions derived from leukocyte-associated immunoglobulin-like receptors (LAIRs), for example, LAIR-1 (CD305), which can be incorporated into chimeric antigen receptor constructs, for example, to serve as hinge or spacer elements. These domains can be positioned between an extracellular antigen-binding domain (e.g., scFv) and a transmembrane domain of a CAR, and can be designed to enhance receptor flexibility, antigen accessibility, and functional activation.

[0192] In some embodiments, a hinge region is a LAIR-1 hinge region. LAIR-1 is a type I transmembrane protein expressed on various immune cells and contains an extracellular immunoglobulin-like domain. In the CAR context, the extracellular domain or a portion thereof is repurposed as a hinge region. A LAIR hinge domain provides structural separation between the antigen-recognition and membrane- anchoring components of the CAR, allowing the binding domain to more effectively engage epitopes that are close to the target cell membrane or located in spatially constrained environments.

[0193] The use of a LAIR-derived hinge domain confers advantages over conventional hinges (e.g., those derived from CD8a or IgG), including altered length, rigidity, or glycosylation patterns, which can be tailored to improve CAR stability, reduce immunogenicity, and / or modulate signal strength. In some embodiments, the LAIR hinge domain includes the full extracellular domain of LAIR- 1 ; in other embodiments, a truncated or engineered version is used.

[0194] In some embodiments, a LAIR hinge domain comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 14. In some embodiments, a LAIR hinge domain comprises an amino acid sequence having at least 95% to the amino acid sequence of SEQ ID NO: 14. In some embodiments, a LAIR hinge domain comprises an amino acid sequence having at least 98% identity to the amino acid sequence of SEQ ID NO: 14. In some embodiments, a LAIR hinge domain comprises an amino acid sequence having 100% identity to the amino acid sequence of SEQ ID NO: 14.

[0195] 2. CD28 Hinge Domains

[0196] In some embodiments, a hinge region is a CD28 hinge region. In the context of the present disclosure, a CD28 hinge domain includes flexible spacer regions derived from the extracellular portion of the CD28 protein, which is incorporated into an engineered receptor, such as a CAR) to serve as a hinge or spacer domain, for example. These domains can bepositioned between an antigen-binding domain (e.g., an scFv) and a transmembrane domain and have a role in the spatial configuration and functionality of the receptor.

[0197] CD28 is a co-stimulatory receptor naturally expressed on T cells and plays a key role in T cell activation and survival. The extracellular domain of CD28, or a portion thereof, can be used in CAR design as a hinge domain because of its suitable length, flexibility, and compatibility with other CAR components. The CD28 hinge domain allows for proper positioning and mobility of the antigen-binding domain, improving its ability to engage target epitopes — particularly those that are membrane-proximal or sterically shielded.

[0198] The CD28 hinge domain can influence several aspects of CAR biology, including antigen recognition, receptor stability, surface expression, and signal transduction. It may also impact immune synapse formation and the strength or duration of downstream signaling. In some embodiments, a hinge domain comprises a full extracellular domain of CD28, while in other embodiments, a hinge domain includes only a truncated or engineered version designed to retain structural flexibility and minimize potential immunogenicity.

[0199] C. Transmembrane Domains

[0200] The transmembrane domain typically comprises a hydrophobic alpha-helical segment of approximately 20-25 amino acids, which is sufficient to traverse the lipid bilayer. It plays a role in maintaining receptor stability, membrane localization, and proper assembly of the receptor complex. In addition to its anchoring function, the transmembrane domain can influence receptor dimerization or multimerization and can impact signaling strength and duration.

[0201] Transmembrane domains used herein can be derived from various naturally occurring transmembrane proteins, including but not limited to CD3(^, CD8a, CD28, or ICOS. The choice of transmembrane domain can affect the expression level, surface trafficking, and functional performance of a CAR, for example, in engineered immune cells.

[0202] In some embodiments, a transmembrane domain is derived from CD28 or CD8a to promote optimal receptor assembly and signaling in T cells, while in other embodiments, the CD3(^ transmembrane domain is used to facilitate association with endogenous T cell receptor complexes. A transmembrane domain can also be modified to improve the therapeutic performance of a receptor in specific cellular or disease contexts.

[0203] D. Intracellular Signaling Domains

[0204] An intracellular signaling domain, in some embodiments, includes one or more signaling motifs derived from immunoregulatory proteins. In CAR constructs, for example, this domain generally comprises: (a) primary activation domain, most commonly derivedfrom the CD3(^ chain, which contains immunoreceptor tyrosine-based activation motifs (ITAMs) necessary for initiating T cell receptor-like signaling; and one or more costimulatory signaling domains, such as those derived from CD28, 4-1BB (CD137), or 0X40 (CD 134), which enhance T cell activation, expansion, and persistence.

[0205] The combination of activation and co-stimulatory domains can determine the generation or design of the CAR (e.g., second-generation CARs typically include CD3(^ plus one co-stimulatory domain; third-generation CARs include CD3(^ and two co-stimulatory domains).

[0206] An intracellular signaling domain converts antigen binding at the extracellular surface into a functional intracellular response, and its composition can be tailored to optimize therapeutic outcomes, including cytotoxic activity, memory formation, or reduced exhaustion in engineered immune cells.

[0207] V. Exemplary Sequences and Identity Thresholds

[0208] Some aspects of the technology relate to a bicistronic vector comprising (a) a contiguous 10-40 nucleotide sequence reverse complementary to a RASAL1 gene, wherein the RASAL1 gene comprises the nucleotide sequence of SEQ ID NO: 22, and (b) a transgene encoding a polypeptide comprising a sequence having at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to the amino acid sequence of SEQ ID NO: 14 (LAIR hinge domain). In some embodiments, a transgene encoding a polypeptide comprising a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 14. In some embodiments, a transgene encoding a polypeptide comprising a sequence having at least 98% identity to the amino acid sequence of SEQ ID NO: 14. In some embodiments, a transgene encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 14.

[0209] In some embodiments, a polypeptide further comprises a sequence having at least at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to the amino acid sequence of SEQ ID NO: 6. In some embodiments, polypeptide further comprises a sequence having at least at least 95% identity to the amino acid sequence of SEQ ID NO: 6. In some embodiments, polypeptide further comprises a sequence having at least at least 98% identity to the amino acid sequence of SEQ ID NO: 6. In some embodiments, polypeptide further comprises the amino acid sequence of SEQ ID NO: 6.

[0210] In some embodiments, a polypeptide further comprises a sequence having at least at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identityto the amino acid sequence of SEQ ID NO: 16. In some embodiments, a polypeptide further comprises a sequence having at least at least 95% identity to the amino acid sequence of SEQ ID NO: 16. In some embodiments, a polypeptide further comprises a sequence having at least at least 98% identity to the amino acid sequence of SEQ ID NO: 16. In some embodiments, a polypeptide further comprises the amino acid sequence of SEQ ID NO: 16.

[0211] In some embodiments, a polypeptide further comprises a sequence having at least at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to the amino acid sequence of SEQ ID NO: 17. In some embodiments, a polypeptide further comprises a sequence having at least at least 95% identity to the amino acid sequence of SEQ ID NO: 17. In some embodiments, a polypeptide further comprises a sequence having at least at least 96% identity to the amino acid sequence of SEQ ID NO: 17. In some embodiments, a polypeptide further comprises the amino acid sequence of SEQ ID NO: 17.

[0212] In some embodiments, a polypeptide further comprises a sequence having at least at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to the amino acid sequence of SEQ ID NO: 21. In some embodiments, a polypeptide further comprises a sequence having at least at least 95% identity to the amino acid sequence of SEQ ID NO: 21. In some embodiments, a polypeptide further comprises a sequence having at least at least 98% identity to the amino acid sequence of SEQ ID NO: 21. In some embodiments, a polypeptide further comprises the amino acid sequence of SEQ ID NO: 21.

[0213] In some embodiments, a polypeptide comprises a sequence having at least at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to the amino acid sequence of SEQ ID NO: 23. In some embodiments, a polypeptide comprises a sequence having at least at least 95% identity to the amino acid sequence of SEQ ID NO: 23.1n some embodiments, a polypeptide comprises a sequence having at least at least 96% identity to the amino acid sequence of SEQ ID NO: 23. In some embodiments, a polypeptide comprises the amino acid sequence of SEQ ID NO: 23.

[0214] VI. Vector Backbones and Regulator Elements

[0215] In some embodiments, a bicistronic vector comprises a vector backbone sequence from viral vector. A viral vector is a genetically engineered virus used to deliver genetic material into cells. These vectors are modified to remove their pathogenicity while retaining their ability to enter target cells and deliver transgenes. Non-limiting examples of viral vectors include adenoviral vectors, which can transduce dividing and non-dividing cells; adeno-associated viral (AAV) vectors, which are known for their low immunogenicity;lentiviral vectors, derived from HIV, which can stably integrate into the host genome; and retroviral vectors. In some embodiments, a vector backbone sequence is from an AAV vector. . In some embodiments, a vector backbone sequence is from a lentiviral vector. In some embodiments, a vector backbone sequence is from a retroviral vector. In some embodiments, a vector backbone sequence is from a herpes viral vector. In some embodiments, a vector backbone sequence is from an adenoviral vector.

[0216] One or more open reading frames of a bicistronic vector can be operably linked to a promoter. A promoter includes a specific DNA sequence located upstream of a gene that serves as a binding site for RNA polymerase and other transcription factors to initiate transcription. It functions as a regulatory element that controls when, where, and how much a gene is expressed. Promoters typically contain core elements, such as the TATA box, which help position the transcriptional machinery, as well as regulatory sequences that respond to signals from the cellular environment. Promoters herein can be constitutive, driving continuous gene expression in most or all cell types, or inducible, allowing gene expression to be turned on or off in response to specific stimuli.

[0217] Non-limiting examples of promoters include the cytomegalovirus immediate-early (CMV) promoter, elongation factor 1 alpha (EFla) promoter, CAG promoter (a hybrid comprising the CMV enhancer, chicken beta-actin promoter, and rabbit beta-globin splice acceptor), phosphoglycerate kinase (PGK) promoter, and ubiquitin C (UBC) promoter. These promoters may be selected based on the desired expression profile, target cell type, and vector system employed.

[0218] Other regulatory elements can be included in the bicistronic vectors of the disclosure. In some embodiments, an shRNA and CAR expression cassettes are separated by regulatory sequences such as insulators, polyadenylation signals, or viral elements designed to prevent transcriptional interference. The two transcriptional units can be expressed from distinct promoters (dual-promoter configuration) or from a single promoter using a bicistronic expression strategy, such as incorporation of an internal ribosome entry site (IRES) or a selfcleaving 2A peptide (e.g., P2A), to facilitate coordinated expression of both genetic elements in the same host cell.

[0219] Transgene regulatory elements include DNA sequences that control the expression of a transgene by influencing the timing, location, and / or level of transcription and translation, for example. In addition to promoters, regulatory elements include enhancers, insulators, polyadenylation signals, untranslated regions (UTRs), and introns. Enhancers are cis-acting elements that can increase transcriptional activity from a distance and may function in atissue-specific or stimulus-responsive manner. Insulators, such as the chicken P-globin HS4 insulator, can block the influence of neighboring regulatory sequences, helping to maintain stable and predictable transgene expression. Polyadenylation signals, such as the bovine growth hormone (bGH) or simian virus 40 (SV40) polyA signals, facilitate proper termination and stabilization of mRNA transcripts. Untranslated regions (5' and 3' UTRs) can modulate mRNA translation efficiency and stability. Additionally, inclusion of introns, such as the SV40 or rabbit P-globin introns, can enhance transgene expression by promoting efficient mRNA processing. These elements can be strategically combined in a bicistronic vector to achieve desired expression patterns, stability, and regulatory control.

[0220] VII. Host Cells

[0221] The present disclosure also provides host cells comprising (e.g., expressing) one or more bicistronic vectors described herein. In some embodiments, a cell is an immune cell. An immune cell includes a specialized cell that plays a role in the body’s defense against infections, cancer, and other foreign or abnormal substances. Immune cells originate primarily from hematopoietic stem cells in the bone marrow and circulate through the blood, lymphatic system, and tissues to detect and respond to pathogens or cellular abnormalities. Non-limiting examples of immune cells include T cells, B cells, and natural killer (NK) cells. Additional examples include macrophages, dendritic cells, and neutrophils. Each immune cell type has distinct functions but often works in coordination with others to mount an effective immune response.

[0222] In some embodiments, a cell is a T cell. A T cell is a type of immune cell that plays a role in adaptive immunity by recognizing and responding to specific antigens. Naturally occurring T cells develop in the thymus and are characterized by the expression of a T cell receptor (TCR) on their surface, which enables them to recognize peptide antigens presented by major histocompatibility complex (MHC) molecules. There are several subsets of T cells, each with distinct functions. CD8+ cytotoxic T lymphocytes (CTLs) directly kill virus-infected or tumor cells by releasing cytotoxic granules. CD4+ helper T cells support the immune response by secreting cytokines that activate other immune cells, such as B cells, macrophages, and cytotoxic T cells. Regulatory T cells (Tregs) suppress immune activation and maintain tolerance to self-antigens, preventing autoimmune responses. Additional specialized subsets include T follicular helper cells (Tfh), which assist B cells in antibody production, and gamma delta (y8) T cells, which have innate-like properties and respond to stress signals without requiring antigen presentation by MHC. Each of these T cell subsetscontributes to a coordinated and highly specific immune response. In some embodiments, a host cell is a CTL comprising (e.g., expressing) a bicistronic vector of the disclosure. In some embodiments, a host cell is a CTL comprising (e.g., expressing) a bicistronic vector of the disclosure.

[0223] In some embodiments, a cell is an NK cell. A natural killer (NK) cell is a type of innate immune cell that plays a role in the early defense against virally infected cells and tumor cells. Unlike T cells and B cells, NK cells do not require prior sensitization to recognize and eliminate abnormal cells. They identify target cells through a balance of activating and inhibitory receptors, allowing them to detect cells with reduced expression of major histocompatibility complex class I (MHC I), a common feature of infected or transformed cells. NK cells mediate cytotoxicity primarily by releasing perforin and granzymes, which induce apoptosis in target cells. In addition to their cytotoxic function, NK cells produce cytokines such as interferon-gamma (IFN-y), which enhances the activity of other immune cells. NK cells are also involved in antibody-dependent cellular cytotoxicity (ADCC) through Fc receptor engagement, further linking innate and adaptive immunity.

[0224] In some embodiments, a cell is a dendritic cell. A dendritic cell is a specialized antigen-presenting immune cell that plays a role in initiating and regulating the adaptive immune response. Dendritic cells function as sentinels of the immune system, residing in peripheral tissues where they continuously sample the environment for pathogens or abnormal cells. Upon encountering antigens, dendritic cells undergo maturation and migrate to lymphoid organs, where they present processed antigen fragments on major histocompatibility complex (MHC) molecules to T cells. This antigen presentation, along with co- stimulatory signals, activates naive T cells and the generation of antigen- specific immune responses. There are several types of dendritic cells, including conventional dendritic cells (eDCs), which are efficient at activating T cells, and plasmacytoid dendritic cells (pDCs), which are key producers of type I interferons during viral infections.

[0225] In some embodiments, a cell is a stem cell. A stem cell includes an undifferentiated cell capable of both self-renewal and differentiation into one or more specialized cell types. Stem cells serve as the foundational units for tissue development, maintenance, and repair. They are broadly classified based on their potency and origin. Embryonic stem cells (ESCs) are pluripotent, meaning they can give rise to all cell types of the body, and are derived from the inner cell mass of the blastocyst. In contrast, adult stem cells, such as hematopoietic stem cells (HSCs) from bone marrow or mesenchymal stem cells (MSCs) from connective tissue, are typically multipotent, meaning they can differentiate into a limited range of cell typeswithin a specific tissue lineage. In some embodiments, a stem cell is an induced pluripotent stem cells (iPSC), which is generated by reprogramming adult somatic cells to a pluripotent state through the expression of defined transcription factors.

[0226] VIII. Methods of Use

[0227] The bicistronic vectors described herein can be used, in some aspects, to produce immune cell therapies, such as CAR T cell therapies, engineered to recognize and eliminate target cells expressing a specific antigen, such as CD 19 or GD3. In CAR T cell therapy, for example, autologous or allogeneic T cells can be isolated, activated, and transduced ex vivo with a bicistronic vector of the disclosure encoding an shRNA and a CAR construct. The CAR, in some embodiments, comprises an antigen-binding domain, such as a single-chain variable fragment (scFv) derived from an antibody that binds specifically to CD19, GD3, or another tumor-associated antigen, linked via a LAIR hinge domain and transmembrane domain to one or more intracellular signaling domains that mediate T cell activation. The modified T cells are expanded and infused into a subject, where they seek out and destroy antigen-expressing cells. This approach allows for the redirection of T cells to recognize targets in an MHC-independent manner, enabling robust cytotoxic responses against tumor cells or other pathological cells expressing the designated antigen.

[0228] The engineered immune cells (e.g., CAR T cells) of the disclosure can be used, for example, to treat hematologic malignancies, particularly B cell-derived cancers such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), by targeting CD 19. CAR constructs may be designed to target alternative antigens, including BCMA, CD22, or CD123, for use in treating multiple myeloma, other hematologic malignancies, or solid tumors.

[0229] The engineered immune cells (e.g., CAR T cells) of the disclosure can also be used, for example, to treat neuroectodermal malignancies, particularly GD3-expressing cancers such as melanoma, neuroblastoma, and glioblastoma, by targeting GD3. CAR constructs targeting GD3 may be combined with RASAL1 shRNA knockdown and / or a LAIR1 hinge domain, as described herein, to enhance tumor infiltration, reduce T-cell exhaustion, and achieve superior tumor regression relative to conventional GD3-targeted CAR T-cell approaches.

[0230] In some embodiments, immune cells expressing a bicistronic vector of the disclosure may be co-administered with lymphodepleting agents (e.g., cyclophosphamide and fludarabine) to improve their engraftment and therapeutic efficacy. Additional enhancementsmay include the use of safety switches, inducible promoters, or logic-gated receptor systems to improve control over immune cell (e.g., CAR T cell) activity and minimize off-target toxicity.

[0231] IX. Mechanistic Basis for Antigen-Independent Enhancement of CAR T-Cell Efficacy by RASAL1 Knockdown

[0232] RASAL1 functions as a GTPase-activating protein that negatively regulates H-Ras, K-Ras, and N-Ras and physically associates with ZAP-70 within the TCR / CD3 complex, where it exerts a dual inhibitory role: direct suppression of ZAP-70 catalytic activity through its C1 / C2 domains, and GAP-mediated inactivation of p21ras downstream. Both inhibitory functions operate on components shared by all CAR signaling architectures incorporating CD3(^ and CD28 signaling domains. RASAL1 does not interact with, bind to, or influence any extracellular antigen-binding domain. Its inhibitory function is engaged only after antigen-CAR binding has occurred and the intracellular signaling cascade has been activated. The downstream pathway engaged following antigen recognition is therefore substantially identical across all CAR constructs sharing CD3(^ and CD28 intracellular domains, regardless of extracellular antigen-binding domain identity.

[0233] The experimental data confirm antigen-independent effects across multiple distinct tumor models. RASAL1 knockdown consistently produced increased CAR T-cell tumor infiltration, reduced PD-1, TIM-3, CD101, and CX3CR1 exhaustion marker expression, expanded TCF1+ progenitor stem-like CD8+ TIL populations, enhanced IFN-y and TNF-a production, and elevated granzyme B and FasL expression across EL4-CD19, EL4-GD3, B16 F10-CD19, and EL4-OVA tumor models. These phenotypic changes reflect cell-intrinsic properties of the T cell that are not governed by the identity of the tumor antigen targeted. Additionally, RASAL1 knockdown in regulatory T cells impaired their suppressive function as measured by reduced suppression of CD8+ T-cell proliferation across all tested Treg-to-responder ratios under polyclonal anti-CD3 stimulation, a result that is by definition antigenindependent. The RASAL1 shRNA cassette expressed without any CAR construct was itself sufficient to reduce tumor growth (FIG. 31), confirming that RASAL1 knockdown potentiates T-cell function upstream of and independent from any specific antigen recognition event.X. Mechanistic Basis for the Antigen-Independent Cooperative Effect of RASAL1 Knockdown and the LAIR Hinge Domain

[0234] RASAL1 knockdown and the LAIR hinge domain act through mechanistically distinct and non-overlapping pathways. RASAL1 knockdown acts entirely intracellularly, relieving ZAP-70 inhibition and reducing GAP-mediated Ras-ERK suppression downstream of CD3(^ phosphorylation. The LAIR hinge domain acts extracellularly through collagen binding. Experimental data demonstrate that deletion of collagen-binding sites from the LAIR hinge, producing the truncated tLAIR domain, reduced tumor control to levels statistically comparable to the CD28 hinge CAR (FIG. 8), confirming that collagen binding is the operative mechanism of LAIR hinge superiority. Collagen deposition is present in the tumor microenvironments of all tumor types associated with the antigens described herein, including breast, pancreatic, colorectal, lung, ovarian, prostate, melanoma, neuroblastoma, and hematologic malignancies. The LAIR hinge therefore tethers CAR T cells within the tumor stroma through an interaction with the extracellular matrix that is entirely independent of which antigen-binding domain the CAR carries.

[0235] The cooperative effect of combining these two components was demonstrated using anti-CD19 and anti-GD3 antigen-binding domains (a transmembrane glycoprotein antigen on hematologic tumors and a glycolipid antigen on solid neuroectodermal tumors, respectively) which differ substantially in molecular structure, epitope chemistry, membrane presentation, and tumor context. The RASAL1 shRNA4-CD19-LAIR hinge CAR achieved significantly greater tumor control than either the RASAL1 shRNA4-CD19-CD28 hinge CAR or the scrambled-CD19-LAIR hinge CAR (FIG. 30A), and the RASAL1 shRNA-GD3-LAIR hinge CAR achieved statistically significant tumor reduction where the GD3-LAIR hinge CAR alone did not (FIG. 34). The intracellular constraints on which RASAL1 knockdown acts (ZAP-70 inhibition and Ras-ERK suppression) are engaged by CD3(^ phosphorylation following any antigen engagement event. The extracellular constraint addressed by the LAIR hinge (insufficient tumor retention through collagen binding) is present in the tumor microenvironment independently of which antigen is targeted. Because these two constraints are operative for any CD3< CD28-containing CAR functioning in a collagen-rich tumor microenvironment, the cooperative benefit of RASAL1 knockdown and the LAIR hinge extends to CAR constructs incorporating any of the antigen-binding domains described herein.XI. Additional Embodiments:

[0236] 1. A bicistronic vector encoding a short hairpin RNA (shRNA) that binds specifically to RASAL1 mRNA and a means for binding specifically to a tumor-associated antigen selected from CD19, CD20, CD22, CD33, CD123, HER2 (ERBB2), EGFR, CEA (carcinoembryonic antigen), PSMA (pro state- specific membrane antigen), MUC1, mesothelin, GD2, GD3, WT1 (Wilms tumor 1), NY-ESO-1, PRAME (preferentially expressed antigen in melanoma), BCMA (B-cell maturation antigen), R0R1, and IL13Ra2.

[0237] 2. The bicistronic vector of paragraph 1, wherein the tumor-associated antigen is CD 19 or GD3.

[0238] 3. A bicistronic vector encoding a short hairpin RNA (shRNA) that binds specifically to RASAL1 mRNA and a chimeric antigen receptor comprising a leukocyte-associated immunoglobulin-like receptor (LAIR) hinge domain and a means for binding specifically to a tumor-associated antigen selected from CD19, CD20, CD22, CD33, CD123, HER2 (ERBB2), EGFR, CEA (carcinoembryonic antigen), PSMA (pro state- specific membrane antigen), MUC1, mesothelin, GD2, GD3, WT1 (Wilms tumor 1), NY-ESO-1, PRAME (preferentially expressed antigen in melanoma), BCMA (B-cell maturation antigen), R0R1, and IL13Ra2, preferably wherein the tumor-associated antigen is CD19 or GD3.

[0239] 4. A bicistronic vector comprising: (a) a contiguous 10-40 nucleotide sequence reverse complementary to a RASAL1 gene, wherein the RASAL1 gene comprises the nucleotide sequence of SEQ ID NO: 22; and (b) a nucleotide sequence encoding a chimeric antigen receptor that comprises a LAIR hinge domain and a means for binding specifically to a tumor-associated antigen selected from CD19, CD20, CD22, CD33, CD123, HER2 (ERBB2), EGFR, CEA (carcinoembryonic antigen), PSMA (pro state- specific membrane antigen), MUC1, mesothelin, GD2, GD3, WT1 (Wilms tumor 1), NY-ESO-1, PRAME (preferentially expressed antigen in melanoma), BCMA (B-cell maturation antigen), ROR1, and IL13Ra2, preferably wherein the tumor-associated antigen is CD19 or GD3, and optionally wherein the contiguous 10-40 nucleotide sequence is reverse complementary to a coding sequence of the RASAL1 gene.

[0240] 5. A bicistronic vector comprising: (a) a contiguous 10-40 nucleotide sequence reverse complementary to a RASAL1 gene, wherein the RASAL1 gene comprise the nucleotide sequence of SEQ ID NO: 22; and (b) a nucleotide sequence encoding a polypeptide comprising (i) a means for binding CD 19 and (ii) a LAIR hinge domain, optionally whereinthe contiguous 10-40 nucleotide sequence is reverse complementary to a coding sequence of the RASAL1 gene.

[0241] 6. The bicistronic vector of paragraph 4 or 5, wherein the contiguous 10-40 nucleotide sequence encodes the sequence of SEQ ID NO: 25 or 26.

[0242] 7. The bicistronic vector of any preceding paragraph, wherein the vector is a viral vector.

[0243] 8. The bicistronic vector of any preceding paragraph, wherein the bicistronic vector comprises a vector backbone sequence selected from a retroviral vector, a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, or a herpes viral vector.

[0244] 9. The bicistronic vector of any preceding paragraph, wherein the short hairpin RNA (shRNA) targeting RASAL1 comprises a sequence having at least 90%, at least 95%, or 100% identity to a sequence that binds to mRNA encoded by the sequence of SEQ ID NO: 22, optionally wherein the shRNA targeting RASAL1 comprises a sequence having at least 90%, at least 95%, or 100% identity to the sequence of SEQ ID NO: 25 or SEQ ID NO: 26.

[0245] 10. The bicistronic vector of any of paragraphs 3-9, wherein the LAIR hinge domain comprises an amino acid sequence having at least 90%, at least 95%, or 100% identity to the amino acid sequence of SEQ ID NO: 14.

[0246] 11. The bicistronic vector of any of paragraphs 3-10, wherein the chimeric antigen receptor comprises an amino acid sequence having at least 90%, at least 95%, or 100% identity to the amino acid sequence of SEQ ID NO: 23.

[0247] 12. A cell comprising the bicistronic vector of any preceding paragraph.

[0248] 13. The cell of paragraph 12, wherein the cell is selected from immune cells.

[0249] 14. The cell of paragraph 13, wherein the immune cells are selected from T cells, B cells, Natural Killer (NK) cells, and dendritic cells.

[0250] 15. The cell of paragraph 14, wherein the cell is a T cell.

[0251] 16. The cell of paragraph 12, wherein the cell is selected from stem cells.

[0252] 17. The cell of paragraph 16, wherein the stem cells are induced pluripotent stem cells (iPSCs).EXAMPLES

[0253] In one embodiment, the hinge region of the CAR is replaced with a domain of the surface receptor LAIR with binding sites for collagen and Clq of complement cascade. Many solid tumors have an increased expression of extracellular matrix proteins with increased collagen deposition. A CAR T-cell engineered with the collagen-binding domain of LAIR exhibits enhanced binding to the tumor microenvironment (TME), leading to better tumor infiltration and retention of the therapeutic cells at the site of action. The inclusion of the collagen-binding domain of LAIR in the hinge region allows the T-cells to not only target the tumor- specific antigen via the scFv but also simultaneously bind to the collagen-rich TME. This strengthens the overall interaction of the CAR T-cell with the tumor and its surroundings, leading to more stable and prolonged engagement. In other words, the binding to the ECM helps anchor the CAR T-cells, preventing them from easily diffusing away and increasing their local concentration for more effective killing. In some cases, interaction with the ECM components might facilitate the migration of CAR T-cells through the dense tumor stroma. In addition, in terms of the heterogeneous nature of tumors, where antigen expression is variable, the ability of the CAR T-cell to also bind to a more consistently expressed component of the TME like collagen provides a degree of antigen-independent tumor association, ensuring that even cells with low antigen expression are targeted.

[0254] LAIR- 1 is known to bind to collagen and proteins containing collagen-like domains The defining structural feature of collagen is the triple helix, characterized by a repeating Gly-X-Y sequence, where Glycine is at every third position, and X and Y are often Proline or Hydroxyproline. Type XVII collagen is a known ligand for LAIR-1, while other transmembrane collagens might also possess extracellular domains with collagen motifs accessible for LAIR-1 binding. In principle, the presence of collagen binding site also allows for binding to collagen-containing proteins such as surfactant protein D (SP-D) and mannose-binding lectin (MBL), which possess collagen-like domains. SP-D has been shown to induce programmed cell death (apoptosis) in various cancer cell lines, including lung, pancreatic, ovarian, and prostate cancer cells. This can occur through both intrinsic (p53-dependent) and extrinsic (Fas-mediated) pathways. SP-D acts as a pattern recognition molecule, potentially recognizing altered selfstructures on tumor cells and flagging them for immune clearance, it has been shown to polarize macrophages towards an Ml (anti-tumor) phenotype in prostate cancer models. SP-D acts as a pattern recognition molecule, potentially recognizing altered self- structures on tumor cells and flagging them for immune clearance.Secondly, the interaction of the LAIR domain with Clq on tumor cells might influence the complement cascade in the vicinity of the CAR T-cell. This allows the CAR to engage a second mode of tumor killing via complement-dependent cytotoxicity (CDC). In this way, the second pathway of killing ensures that even cells with low antigen expression are targeted via the CAR T-cell's cytotoxic activity. Incorporating a functional domain like the LAIR collagen / Clq binding domain into this region adds an extra layer of functionality without disrupting the primary antigen recognition. When the CAR binds to Clq, it initiates the classical pathway of the complement system. This leads to the formation of the membrane attack complex (MAC), which creates pores in the tumor cell membrane, causing cell lysis and direct killing of the tumor cells. The binding of the CAR to Clq can also facilitate the recruitment and activation of immune effector cells, such as natural killer (NK) cells and macrophages. These effector cells can then recognize the bound Clq and initiate ADCC, leading to the phagocytosis and destruction of the tumor cells. The CDC mechanism provides direct cytotoxicity, while the ADCC mechanism recruits and amplifies the immune response against the tumor cells. When the CAR binds to Clq, it initiates the classical pathway of the complement system and leads to the deposition of complement proteins (such as C3b and iC3b) on the surface of the target tumor cells. These deposited complement proteins act as opsonins, which can be recognized by complement receptors expressed on the surface of immune effector cells, such as natural killer (NK) cells, macrophages, and neutrophils.

[0255] Complement receptors include CR1 (CD35), CR3 (CDllb / CD18), and CR4 (CDllc / CD18). When these receptors bind to the complement proteins deposited on the target tumor cells, they can trigger intracellular signaling cascades that lead to the activation and cytotoxic functions of the effector cells. Similarly, certain complement proteins, such as C5a, that are generated during the complement cascade, can act as potent chemo-attractants. They can recruit and direct the migration of immune effector cells, like neutrophils, macrophages, and NK cells, towards the site of complement activation, where the tumor cells are located.

[0256] In another embodiment, using bicistronic vectors, we have generated a second promoter driven expression of si / shRNA for various regulatory intracellular proteins such as the GAP Rasall. In a bicistronic construct, such as the pMKO.l-GFP retroviral vector, that contains an internal ribosome entry site (IRES) that allows for the co-expression of GFP and a gene of interest. This bicistronic design enables researchers to monitor the expression of the introduced gene by tracking the co-expressed GFP signal. The vector also includes necessary viral elements for packaging and integration into the host cell genome, facilitating stable long-term gene expression studies. Iln this and bicistronic lentiviral vectors used in CAR-T cell therapy contain a promoter sequence driving the expression of the chimeric antigen receptor (CAR) gene and aselection marker gene, separated by an internal ribosome entry site (IRES) that enables the translation of both genes from a single mRNA transcript. These vectors enable the co-expression of the CAR and the selection marker, facilitating the identification and enrichment of successfully transduced T cells for therapeutic applications. The CAR gene encodes the extracellular antigenbinding domain, hinge, transmembrane domain, and intracellular signaling domains, while the selection marker gene typically encodes a fluorescent protein or an antibiotic resistance gene. In our systems, we use shRNA or CRISPR technology to reduce the expression of intracellular signaling proteins such as Rasall (RAS protein activator like 1), a protein that functions as a GTPase-activating protein (GAP) for the Ras family of small GTPases. We showed it interacts and inhibits ZAP-70 of the antigen-receptor on T-cells, as well as the p21ras-ERK pathway and reduces the activation of T-cell proliferation and development of effector T-cells in the immune system. Other proteins include ADAP (adhesion and degranulation-promoting adapter protein) and SKAP1 (src kinase-associated phosphoprotein 1) are adaptor proteins that play roles in T-cell activation and function. ADAP is involved in integrin-mediated adhesion, conjugation with antigen-presenting cells, and T-cell receptor (TCR) signaling. ADAP is also necessary for the activation of NFkb transcription factor in T-cells while ADAP and SKAP1 play key roles in the activation of integrin adhesion used for the adhesion to antigen presenting cells and in the control of T-cell motility. Another key regulatory molecule is GSK-3 (glycogen synthase kinase-3), a serine / threonine protein kinase that regulates various cellular processes, including glycogen metabolism, cell cycle progression, and apoptosis. Lastly, another key adaptor is SLP-76 (SRC homology 2 domain-containing leukocyte protein of 76 kDa), which is an adaptor protein in T-cell receptor (TCR) signaling. The K56R mutation in the SLP-76 protein disrupts its binding to RanGAPl, a component of the nuclear pore complex. This mutation causes impaired nuclear import of transcription factors NF AT and NfkB but not GATA3 for Th2 development. The net result is that the TCR signaling pathway is dysregulated, resulting in a skewed differentiation of CD4+ T cells towards the Th2 phenotype, characterized by increased production of Th2 cytokines like IL-4, IL-5, and IL- 13.

[0257] To date, we have shown that the expression the downregulation of Rasall synergises with the expression of the conventional and LAIR CARs to eradicate the presence of a solid tumor, while the down-regulation of SKAP1 causes a major increase in T-cell motility and tumor infiltration, while the downregulation of GSK-3alpha and beta greatly increases the generation of TCF1+ progenitor T-cells in the reduction in tumor size of multiple different tumors, while the expression of SLP-76 K56E causes T-cells to become TH2 like, a property that can be beneficial in therapies for conditions such as allergic disorders, where promoting a Th2 response may helpcounteract excessive Th 1 -mediated inflammation. Additionally, Th2 responses play a role in promoting humoral immunity and antibody production, which can be advantageous in vaccine development or immunotherapies targeting pathogens that require a strong antibody response, such as extracellular bacteria, helminth infections, and certain viruses.

[0258] Example 1. CARS with LAIR1 hinge outperform conventional CARs

[0259] A CAR targeting mouse CD19, based on the 1D3 antibody, was constructed by cloning the CD19-specific scFv into the pMKO.l-GFP retroviral vector. The construct includes a Flag tag (DYKDDDDK), a hinge domain, the CD28 transmembrane and intracellular regions, and the CD3(^ signaling domain. Various hinge lengths were evaluated, including a 36-amino-acid CD28 hinge and a 123-amino-acid LAIRl-based hinge (FIG. 1). In some cases, it is also referred to as a LAIR or LAIR1 hinge. Retrovirus was produced by co-transfecting HEK-293T cells with pMKO.l-GFP constructs and the pCL-eco packaging plasmid using Lipofectamine 2000. Viruscontaining supernatants were collected at 48 and 72 hours post transfected and stored at -80°C.

[0260] Mouse splenic T cells were activated with anti-CD3 (2 pg / ml) and anti-CD28 (2 pg / ml) for 24 hours. Activated cells were then transduced via spinoculation with viral supernatant and Polybrene (8 pg / ml) mix, followed by incubation. The next day, cells were split and cultured in fresh cytokine- supplemented media (containing IL-7 and IL-15). CAR expression was assessed on day 3 by anti-FLAG staining and flow cytometry. Cultures were maintained by splitting cells and refreshing cytokine-containing media every two days until in vivo use. For in vivo tumor work, mice were injected subcutaneously with 3xl06cells / mice EG7-CD19 lymphoma tumor cells and allowed 7 days for the tumors to grow. After this period, IxlO6cells / mice chimeric antigen receptor (CAR) cells were injected intraperitoneally into the tumor-bearing mice. The tumors were then harvested between days 14-20 after the initial tumor cell injection to study the effects of the CAR cell treatment. In certain experiments, CAR T-cells isolated from wild-type C57BL / 6 mice (CD45.2) or OT-1 transgenic mice were injected into SJL-M6 mice, which have a different genetic background (CD45.1). This allowed tracking of the injected CAR T-cells and analysis of their interactions with the host's immune system in the context of an allogeneic transplant model. Each of the CAR constructs showed similar transduction efficiency in mouse spleen T cells, averaging around 40% expression as detected with anti-Flag antibody (FIGs. 2A-2D).

[0261] We next evaluated the efficacy of CD28 and LAIR hinge-based CARs in controlling the growth of the EL4-CD19 tumor cells (FIGs. 3A-3B). Our findings revealed that the canonical CD28-based CAR (e.g., scr-scFv CD19-CD28-CD3z) reduced tumor growth over a 14-day periodpost-implantation, as measured by tumor volume. (FIG. 3A). By day 8, the mean tumor size in the untreated control group reached 230 mm3. By day 14, the untreated control tumor volume had increased to 1050 mm3, while the tumor volume in the group treated with the canonical scr-scFv CD19-CD28-CD3z CAR was 210cmm3. In contrast, the mean tumor volume in the group treated with the scr-scFv CD19-LAIR-CD3z CAR was reduced to less than 50 mm3as early as day 8 post-injection, and this reduction was sustained until day 14.

[0262] In a separate experiment, the results showed that 9 days post-implantation, while the conventional CD28-hinge CAR (scr-scFv CD19-CD28-CD3(^ CAR) was able to reduce tumor size, the LAIR-containing CAR (scr-scFv CD 19-LAIR-CD3(^ CAR) demonstrated superior antitumor effects, reducing tumor size to below 50 mm3 (FIG. 3B). These data indicate that replacing the CD28 signaling domain with the LAIR domain in the chimeric antigen receptor significantly improved its ability to control and inhibit the growth of CD 19-positive EL-4 lymphoma tumors compared to the conventional CD28-hinge CAR construct.

[0263] The most striking difference between the two CAR therapies was observed in their ability to clear the solid EL-4 CD 19 tumors implanted in mice. Visual examination and photographs taken at day 14 revealed that in the control group of 4 untreated mice, 3 mice had developed large tumors, while the 4th mouse had to be euthanized before day 14 due to excessive tumor burden. As expected, the mice treated with the conventional scr-scFv CD19-CD28-CD3(^ CAR therapy showed considerably smaller tumors across all 4 animals compared to the control group (FIG. 4). However, the scr-scFv CD 19-LAIR I -CD3(^ CAR therapy demonstrated remarkable tumor clearance, with 3 out of the 4 treated mice showing complete elimination of their tumors. The remaining mouse in this group had one of the smallest tumor sizes observed across all treatment groups. These findings, further quantified in a bar graph representation (FIG. 5), underscore a distinction - unlike the conventional CD 19-CD28-CD3(^ CAR which cannot effectively eliminate the tumors, the CD 19-LAIR I -CD3(^ CAR exhibited a unique ability to achieve complete clearance of the solid EL-4 tumors. Overall, these observations are consistent with an enhanced synergistic anti-tumor response mediated by the LAIR1 signaling domain in the CAR construct.

[0264] To further investigate the mechanisms underlying the enhanced anti-tumor effects of the CD 19-LAIR I -CD3(^ CAR therapy, we examined the phenotype of tumor-infiltrating lymphocytes (TILs) isolated from the tumors. TILs were extracted from the tumors and analyzed by flow cytometry, staining for the markers CD8 (cytotoxic T cell marker), granzyme B (GZMB) (cytolytic killer molecule), and Ki67 (cell cycle and proliferation marker). The analysis revealed an increased percentage of CD8+ CAR T cells among the TILs in mice treated with the CD 19-LAIR I -CD3(^ CAR compared to those treated with theconventional CD19-CD28-CD3(^ CAR (FIG. 6A), suggesting a higher infiltration of cytotoxic CAR T cells in the LAIR1 CAR group.

[0265] A higher percentage of CD8 CAR TILs expressing GZMB (FIG. 6B), and Ki67 in mice was observed in mice treated with the CD 19-LAIR I -CD3(^ CAR relative to the CD19-CD28-CD3(^ CAR group (FIG. 6C). These data indicate that the CD19-LAIR1-CD3( CAR T cells tend to exhibit enhanced proliferative capacity and expansion as well as a higher cytolytic potential within the tumor microenvironment compared to the canonical CD19-CD28-CD3(^ CAR T cells, which may contribute to their superior anti-tumor efficacy.

[0266] Another key finding from the analysis of TILs was related to the expression of exhaustion markers. Specifically, the researchers observed that CD19-LAIR1-CD3^ CAR T cells displayed significantly lower levels of programmed cell death protein 1 (PD-1) expression compared to CD19-CD28-CD3(^ CAR T cells (FIGs. 7A-7B). PD-1 is a cell surface receptor involved in regulating T cell activation and is upregulated upon chronic antigen exposure, leading to T cell exhaustion and dysfunction. To a further degree, the marker CD 101 represents a subset of the most terminally exhausted population of CD8+ T cells. The lower PD-1 and CD 101 expression in CD19-LAIR1-CD3^ CAR T cells, despite undergoing more cell division as indicated by higher Ki67 levels, suggests that these cells are less likely to experience exhaustion-related events compared to the conventional CD19-CD28-CD3(^ CAR T cells. This contributes to their sustained anti-tumor activity and improved tumor clearance observed in the study.

[0267] An analysis of the LAIR1 domain sequence and structure (data not shown) confirmed that the truncated tLAIR domain used in the CD19-LAIR1-CD3^ CAR T cell construct retains the ability to bind to collagen molecules, which are components of the extracellular matrix (ECM). Tumor cells often exhibit increased expression and deposition of collagen and other ECM proteins in their microenvironment, facilitating tumor growth, invasion, and metastasis.

[0268] By incorporating the collagen-binding LAIR1 domain into the CAR construct, the design aimed to enhance the binding and retention of the CD19-LAIR1-CD3^ CAR T cells within the tumor microenvironment. The interaction between the LAIR1 domain and the collagen-rich ECM surrounding tumor cells act as an additional anchoring mechanism, potentially stabilizing the CAR T cells at the tumor site and facilitating more effective tumor cell recognition and killing.

[0269] Moreover, the full-length LAIR1 domain, though not present in the truncated version used in this study, is also known to bind to the complement component IQ (Clq). Thisbinding capability engages an additional tumor-killing pathway mediated by the complement system. Upon binding to Clq, the LAIR1 domain triggers the activation of the classical complement cascade, leading to the formation of membrane attack complexes and ultimately causing complement-mediated lysis of tumor cells.

[0270] Therefore, the collagen-binding property of the LAIR1 domain in the CAR construct is hypothesized to enhance tumor retention and cytotoxicity, while the potential Clq-binding ability (though not present in the truncated version) further potentiates anti-tumor effects through complement-mediated mechanisms.

[0271] The truncated tLAIR domain used in the study is missing the binding sites for collagens, Clq, SP-D, and ADP.

[0272] To further test the hypothesis that the collagen-binding capability of the LAIR1 domain contributes to the enhanced anti-tumor efficacy of the CD19-LAIR1-CD3^ CAR T cells, the researchers evaluated the ability of these cells, as well as the CD19-tLAIRl-CD3^ CAR T cells (which lack the collagen-binding sites), to reduce tumor growth in vivo (FIG. 8).

[0273] The control scr-scFv CD19-CD28-CD3(^ CAR T cells were able to reduce tumor growth from an initial size of 1200 mm3to approximately 320 mm3by day 14. In contrast, the scr-scFv CD 19-LAIR I -CD3(^ CAR T cells, containing the full-length LAIR1 domain, exhibited superior tumor growth inhibition, reducing the tumor size from 1200 mm3to only 40 mm3at the same time point.

[0274] Notably, the scr-scFv CD 19-tLAIR l-CD3(^ CAR T cells, which express the truncated tLAIR 1 domain lacking the collagen-binding sites, showed a reduced ability to control tumor growth, with the tumor size decreasing to only 280 mm3by day 14. This level of tumor growth inhibition was statistically comparable to that achieved by the control scr-scFv CD19-CD28-CD3(^ CAR T cells.

[0275] These data support the notion that the collagen-binding sites present in the full-length LAIR1 domain contribute significantly to the enhanced anti-tumor efficacy observed with the CD19-LAIR1-CD3^ CAR T cells. The ability to bind to collagen in the tumor microenvironment likely facilitates better retention and persistence of the CAR T cells at the tumor site, enabling more effective tumor cell recognition and killing.

[0276] Methods

[0277] Cell line and tumor transplant.

[0278] Mouse splenic T cells were activated using anti-CD3 and anti-CD28 antibodies. Following activation, the cells were transduced via spinoculation with a viral supernatant inthe presence of a transduction enhancer, then incubated. The next day, the cells were split and cultured in fresh cytokine- supplemented media containing IL-7 and IL- 15. The media was RPMI 1640 with 10% fetal calf serum (FCS), 2 mM L-glutamine, penicillin and streptomycin. The concentrations of IL-7 and IL- 15 generally used to maintain mouse CAR-T cells in culture are typically in the range of 5-20 ng / mL for each cytokine. CAR expression was evaluated by anti-FLAG staining and flow cytometry after a short culture period. Cell cultures were maintained through regular splitting and media replacement until they were used in vivo. For tumor studies, mice were subcutaneously injected with EL4-CD19 lymphoma cells and allowed to develop tumors prior to administration of chimeric antigen receptor (CAR) T cells via intraperitoneal injection. Tumors were harvested at later timepoints to assess the effects of CAR T cell therapy. In certain experiments, CAR T cells derived from wild-type C57BL / 6 (CD45.2) or OT-1 transgenic mice were transferred into SJL-M6 mice, which possess a distinct genetic background (CD45.1).

[0279] Cell preparation.

[0280] Organs were collected from mice within a defined age range. Inguinal lymph nodes (LN) were mechanically disrupted using a cell strainer and a syringe plunger. The resulting suspension was washed with a buffered solution containing PBS, EDTA, and serum (FACS buffer). Tumors were similarly processed on strainers using cold RPMI medium. The tumor lysate was centrifuged and resuspended in PBS, then layered onto a lymphocyte separation medium to isolate tumor-infiltrating lymphocytes (TILs) by density gradient centrifugation. Spleens were mechanically dissociated in a multi-well plate containing red blood cell lysis buffer. Lysis was stopped by adding PBS, and the resulting cell suspension was filtered and centrifuged. Cell pellets from lymph nodes, tumors, and spleens were resuspended in FACS buffer, and viable cells were counted using a hemocytometer and Trypan blue exclusion.

[0281] Flow cytometry.

[0282] Isolated cells from spleen, lymph nodes, and tumors were stained with a fixable viability dye and subsequently blocked using a solution containing PBS, EDTA, serum, and anti-CD16 / CD32 antibody. After washing, cells were stained with a panel of fluorochrome-conjugated antibodies targeting surface markers, including CD3, CD4, CD8a, CD44, CD62L, TIM-3, CX3CR1, PD-1, CD101, and FLAG.

[0283] Subsequent to surface antigen labeling, cells underwent fixation and permeabilization to facilitate intracellular staining, employing a commercially available nuclearpermeabilization reagent kit. The permeabilized cells were then incubated with fluorochrome-conjugated antibodies targeting intracellular epitopes, including P-catenin, TCF1 / TCF7, Ki-67, Granzyme A, B, Foxp3, interferon-y, and TNF-a. For certain targets, an indirect immunofluorescence approach was utilized, necessitating the addition of a secondary antibody conjugate. Following incubation and washing steps, cells were resuspended in staining buffer and acquired on either a flow cytometer for fluorescence-based phenotypic analysis or a mass cytometer for cytometric time-of-flight (CyTOF) analysis. Quantification of mean fluorescence intensity (MFI) and marker expression within T cell subsets was performed using FlowJo data analysis software.

[0284] Cell Lysis and Immunoblotting

[0285] Cells were pelleted by centrifugation at 300 x g for 5 minutes and lysed on ice for 30 minutes in 10% triton based buffer (150 mM NaCl, 1% Triton X-100, 50 mM Tris pH 8.0) supplemented with protease and phosphatase inhibitor cocktails (Thermo Scientific). Cell lysates were centrifuged at 10,000 x g for 10 minutes at 4°C to pellet nuclear debris and insoluble material. For immunoprecipitation, 500 pg of each lysate was incubated with 2 pg of antibody overnight at 4°C with gentle rotation. Protein G Sepharose beads (GE Healthcare) were added and incubated for 2 hours to capture the antibody-antigen complexes. Beads were washed 3 times in lysis buffer before eluting immunoprecipitates in 2X Laemmli sample buffer.

[0286] For direct western blotting, lysates were diluted 1:1 in 2X Laemmli sample buffer. Immunoprecipitated samples and lysates were heated at 95 °C for 5 minutes then separated by SDS-PAGE on 4-20% Tris-glycine gels (Invitrogen) and transferred to 0.45 pm nitrocellulose membranes by semi-dry transfer. Membranes were blocked for 1 hour in 5% non-fat milk in TBS-T (20 mM Tris pH 7.6, 137 mM NaCl, 0.1% Tween-20) then incubated overnight at 4°C with primary antibodies against Rasall or ZAP-70 or P-actin (Sigma #A5441, 1:5000) diluted in blocking buffer. After washing, membranes were incubated for 1 hour with HRP-conjugated anti-rabbit (Cell Signaling #7074, 1:5000) or anti-mouse (Cell Signaling #7076, 1:5000) secondary antibodies diluted in blocking buffer. Membranes were washed again and protein bands were visualized using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) and exposure to autoradiography film. Where necessary, membranes were stripped in Restore Western Blot Stripping Buffer (Thermo Scientific) for 15 minutes, re-blocked, and re-probed with additional primary antibodies.PCR analysis

[0287] For real-time qPCR, RNA was isolated using the RNAeasy kit (Qiagen) and converted to cDNA using the cDNA reverse transcription kit (Applied Biosystem).

[0288] Killing Assay

[0289] Target cells were cultured and labeled with a tracking dye. Afterward, they were pulsed with antigenic peptide. Effector splenocytes were isolated and activated using anti-CD3 and anti-CD28 in the presence of cytokines. These cells were then electroporated with either gene- specific or control siRNA and cultured in supplemented media. The following day, target and effector cells were co-cultured at a defined effector-to-target (E:T) ratio. After incubation, the percentage of dead target cells was assessed by flow cytometry using a viability dye. An alternative approach to assess cytotoxicity involves quantifying the release of lactate dehydrogenase (LDH) into the culture medium after a 4-hour co-culture period, with varying effector-to-target cell ratios. This method measures the cytosolic LDH enzyme released by target cells upon membrane damage induced by effector cells, providing a quantitative measure of target cell lysis. Lactate dehydrogenase release was assayed after 4 h incubation at 37°C by removal of 50 pl supernatant from each well and incubation with substrate provided for 30 min and the absorbance read at 490 nm using the Thermomax plate reader (Molecular Devices). Percentage cytotoxicity = [(experimental

[0290] effector spontaneous ~ target spontaneous) / ( targetmaximum ~ target spontaneous)] x 100.

[0291] Quantification and Statistical Analysis

[0292] Assumptions of normal distribution and equal variance were verified prior to statistical testing. Data are shown as mean ± SEM along with individual data points unless otherwise specified. Results from independent experiments were pooled for analysis.

[0293] Statistical testing was performed using appropriate software, typically involving an unpaired t-test unless stated otherwise. A P- value below a defined threshold was considered significant, with notation indicating varying levels of significance.

[0294] Example 2. Rasall based CARs

[0295] We next evaluated the efficacy of a bicistronic chimeric antigen receptor (CAR) approach by co-expressing an shRNA targeting the GTPase-activating protein Rasall along with a CAR targeting either CD19 or the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The schematic illustrates the construction of a CAR targeting mouse CD 19, based on the 1D3 antibody, by cloning the CD19-specific single-chain variable fragment (scFv) into the pMKO.l-GFP retroviral vector. The bicistronic pMKO.l-GFP retroviral vector is also designed to co-express an shRNA sequence for Rasall driven by the U6 promoter and an anti-CD19 CAR driven by the same promoter but utilizing an internal ribosome entry site (IRES) for translation initiation. It also contains a green fluorescent protein (GFP) reporter gene downstream of the IRES for visualization and tracking of transduced cells. This vector system therefore enables simultaneous Rasall RNA interference and CAR expression. However, the vector could be another retroviral or lentiviral system, such as lentiviral vectors derived from HIV-1 (e.g., pLenti-EFla, pLVX-EFla), murine leukemia virus (e.g., pMX, pMSCV), or gammaretroviral vectors (e.g., pQCXIH, pMSCV) (FIGs. 9A-9B). Examples of the murine shRNA sequences explored include shRNAl-mRASALl (SEQ ID NO: 25) and shRNA4-mRA.SAL / (SEQ ID NO: 26).

[0296] The CAR construct includes a CD19-specific single-chain variable fragment (scFv), a Flag tag (DYKDDDDK), a hinge domain, the CD28 transmembrane and intracellular regions, and the CD3(^ signaling domain. Different hinge lengths can be evaluated, such as a 36-amino-acid CD28 hinge, a 123-amino-acid leukocyte-associated immunoglobulin-like receptor 1 (LAIRl)-based hinge, the shorter tLAIRl hinge or other hinges. Additionally, alternative transmembrane or intracellular signaling domains, such as 4- IBB, 0X40, ICOS, and other signaling molecules, can be incorporated into the CAR design. The vector could be another retroviral or lentiviral system, such as the lentiviral vectors derived from HIV-1 e.g., pLenti-EFla, pLVX-EFla), murine leukemia virus (e.g., pMX, pMSCV), or gammaretroviral vectors (e.g., pQCXIH, pMSCV). These vectors can employ scFvs against various tumor antigens in mouse or human models, including GD2 (disialoganglioside), GD3 (trisialoganglioside), HER2 (human epidermal growth factor receptor 2), mesothelin, and others.

[0297] In the case of expression in human cells, one can use the bicistronic lentiviral vector pHIV-EGFP (Addgene# 18121; http: / / n2t.net / addgene:18121; RRID: Addgene_18121). In this vector, the U6 promoter drives the expression of the shRNA, while the elongation factor 1 alpha (EFla) promoter drives the expression of the CAR. The upstream U6 promoter drives Rasall hRNAs that include as an example, the GAGTGAAGGTACGCCTGATTG (SEQ ID NO: 27) sequence.

[0298] It is important to note that Rasall (Ras protein activator like 1) is different from other GAPs (GTPase- activating proteins) such as Rasa2 (ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2). Rasall (RAS protein activator like 1) is a GAP that specificallyinactivates the Ras proteins H-Ras, K-Ras, and N-Ras by stimulating their intrinsic GTPase activity, thereby promoting the conversion of active GTP-bound Ras to the inactive GDP-bound state. In a similar vein, NF1 (Neurofibromin 1) is a well-known tumor suppressor gene that encodes the neurofibromin protein, which also acts as a GAP for Ras proteins. Mutations in the NF1 gene are associated with the development of neurofibromatosis type 1, a genetic disorder characterized by the formation of benign tumors called neurofibromas. Similarly, pl20GAP (RASA1) also known as RASA1 (RAS p21 protein activator 1), is another member of the GAP family that specifically targets and inactivates Ras proteins. It plays a crucial role in regulating Ras-mediated signaling pathways, and its dysregulation has been implicated in various types of cancer.

[0299] By contrast, RASA2 (RAS p21 protein activator 2) (also known as GAP1IP4BP) is a distinct GAP that does not target the same group of intracellular mediators as Rasall (54). While Rasall specifically regulates Ras proteins, Rasa2 primarily targets and inactivates the Rap family of small GTPases, including Rapl, Rap2, and certain Rho GTPases like RhoA, Rael, and Cdc42, which are involved in different cellular processes, such as cell adhesion and migration.

[0300] Following transduction, FACs plots showing the expression of the various CARs in T-cells, cells were stained with tagged anti-Flag and subjected to analysis by flow cytometry (FIG.

[0301] 10). Each of CARs were expressed at 37-43%. These cells were subsequently sorted by FACs to derive populations of cell cultures expressing some >95% CAR+ T-cells.

[0302] Rasall expression in T-cells was down-regulated by CARs expressing shRNAl or shRNA4 targeting Rasall (FIGs. 11A-11B). After one week, the cells were stained intracellularly with a FITC-labeled a ti- Rasall antibody and analyzed by flow cytometry. Both the shRNAl-CD19 CAR and shRNA4-CD19 CAR showed reduced Rasall expression compared to the scrambled control (scr-CD19 CAR) (FIG. 11 A). Further, immunoblot analysis confirmed the downregulation of Rasall protein levels (FIG. 1 IB). Transduced T-cells were lysed in 1% Triton lysis buffer, and lysates were denatured, separated by SDS-PAGE, transferred to nitrocellulose, and blotted with anti-Rasall antibody (upper panel) or anti-beta-actin loading control (lower panel). The Rasall band intensity was reduced in lysates from shRNAl -CD 19 CAR and shRNA4-CD19 CAR expressing cells compared to non-transduced and scr-CD19 CAR control cells. Similar results were obtained with CARs expressing different scFv regions

[0303] The cytolytic potential of the CARs (Chimeric Antigen Receptors) was tested using both in vitro (laboratory) and in vivo (living organism) assays. For in vitro killing experiments, CAR T cells were expanded and maintained in culture by providing either interleukin 2 (IL-2) orinterleukin-7 (IL-7) and interleukin- 15 (IL- 15), which are important cytokines for T cell proliferation and survival (FIGs. 12A-12B). After this ex vivo expansion step, the CAR T cells were co-cultured with their target cancer cells for 4 hours. Subsequently, the cytotoxic activity of the CAR T cells against the target cells was evaluated by measuring the release of lactate dehydrogenase (LDH), an enzyme present in the cytosol of cells. When cells are damaged or lysed, LDH is released into the surrounding medium, allowing quantification of cell death. FIG.

[0304] 12A: The Rasall Sh4-scFv CD19-CD28-CD3z CAR was superior to the scr-scFv CD19-CD28-CD3z CAR in killing target EL4-CD19 cells at all CAR-to-target ratios. At 5:1 and 2.5:1 ratios, the Rasall Sh4-scFv CD19-CD28-CD3z killing was 2-fold greater than the scr-scFv CD19-CD28-CD3z CAR. As seen in FIG. 12B, another experiment also showed that Rasall shRNAl-scFv ID3-CD28-CD3z CARs are more effective in killing EL4-CD19 cells than scr-scFv ID3-CD28-CD3z CARs. ID3 is a synthetic antibody engineered to specifically target the mouse CD 19 antigen. However, in this case, a control CAR lacking the intracellular cytoplasmic domains CD28ex failed to mediate killing. This indicates that the superior killing of targets by Rasall shRNAl-scFv CD19-CD28-CD3z is dependent on the presence of the cytoplasmic signaling domain of the CAR. RasallRasalRLa y , as seen in FIG. 12C, the Rasall shRNA 1-scFv CD19-CD28-CD3z and Rasall shRNA4-scFv CD19-CD28-CD3z CARs taken from tumors showed an unexpected synergistic augmentation in the expression of the effector cytokine IFN-y. IFN-y can directly induce apoptosis (programmed cell death) in tumor cells, enhance antigen presentation by increasing MHC class I expression on tumor cells (making them more visible to cytotoxic T lymphocytes), and activate macrophages to enhance their cytotoxic activity against tumor cells. The data presented in FIG. 12D demonstrates that the Rasall shRNA CAR exhibited a more significant upregulation of granzyme B (GZMB) expression, which is a crucial effector molecule required for the elimination of tumor targets. Furthermore, as depicted in FIG. 12E, the Rasall shRNA 1-scFv CD19-CD28-CD3z CAR displayed a more pronounced increase in FasL (Fas Ligand) (also known as CD95L or CD178) expression compared to the Rasall shRNA4-scFv CD19-CD28-CD3z CAR. FasL plays a critical role in inducing apoptosis (programmed cell death) in target cells by binding to its receptor, Fas. These findings indicate that the knockdown (KD) of Rasall potentiates the cytolytic program of CARs, providing a mechanism for enhancing their ability to effectively eliminate tumor targets.In terms of in vivo killing, FIGs. 13A-13B illustrates the ELCD 19 tumor growth curves in mice treated with Rasall KD CARs. Tumor volumes (mm3) were monitored, and the tumors were harvested on day 18 (FIG. 13A) or day 8 (FIG. 13B) post-injection. While the scr-scFv CD19-CD28-CD3z showed a trend to reduce tumor growth, the Rasall Shl-scFvCD19-CD28-CD3z and Rasall Sh4-scFv CD19-CD28-CD3z CARs had significant and more potent effects in limiting tumor growth. In a second example, the Rasall Shl-scFv CD19-CD28-CD3z and Rasall Sh4-scFv CD19-CD28-CD3z CARs reduced tumor growth while the scr-scFv CD19-CD28-CD3z had no effect. These findings indicate that two different Rasal shRNAs (shRNAl and shRNA4) in the knockdown (KD) of Rasall showed a significantly enhanced ability to eliminate EL4-CD19 tumor targets.

[0305] Remarkably, knocking down Rasall expression in CD 19 CAR T cells led to unexpected tumor clearance and improved survival, as shown in FIGs. 14A-14B. Mice bearing EL4-OVA tumors received CD 19 CAR T cell transfers on day 7, and tumor clearance and survival were monitored until day 20. FIG. 14 demonstrates that Rasall shRNA CD19 CARs cleared tumors effectively, while conventional CD 19 scFv CD28 CARs did not. Specifically, 1 out of 4 mice treated with Rasall shRNAl CD 19 CARs and a remarkable 3 out of 4 mice treated with Rasall shRNA2 CD 19 CARs became tumor-free. This was an unexpected result based on previous evidence which only partially reduced the size of tumors but did not mediate tumor clearance (53).

[0306] Consistent with the tumor clearance, Rasall shRNA CD 19 CARs also promoted 100% survival in tumor-bearing mice (FIG. 15). While no wild-type mice survived beyond day 15, 50% of mice treated with scrambled control CD 19 scFv CD28 CARs survived until day 20. Remarkably, 100% of mice treated with either Rasall shRNAl CD19 scFv CD28 CARs or Rasall shRNA4 CD 19 scFv CD28 CARs survived until day 20. These data indicate that reducing Rasall expression in CAR T cells provides a synergistic advantage, leading to enhanced tumor clearance and improved survival in tumor-bearing mice.

[0307] In terms of the composition of TILs in tumors, FAC profiles showed an increase in CAR T-cell filtration of tumors with the concurrent downregulation of Rasall (FIG. 16). As before, mouse splenic T cells were activated with anti-CD3 (2 pg / ml) and anti-CD28 (2 pg / ml) for 24 hours. Activated cells were then transduced via spinoculation with viral supernatant and Polybrene (8 pg / ml) mix, followed by incubation. CAR-T cells were then injected into mice that had previously been injected SC with EG7 tumor cells. The extracted TILs at day 18 were then assessed for the presence CD45.2 and GFP, both markers for injected CARs. While mice injected with scr-scFv CD19-CD28-CD3z were found to comprise 10.7 of TILs, Rasall Shl-scFv CD19-CD28-CD3z comprised 22.1 and Rasall Sh4-scFv CD19-CD28-CD3z made up 36 percent of TILs.

[0308] Further, the extracted CD45.2 CD8+ TILs at day 18 were also assessed for the expression of CD44 and CD62L (FIG. 17). While mice injected with scr-scFv CD19-CD28-CD3z were found to comprise 4.65 of TILs, Rasall Shl-scFv CD19-CD28-CD3z comprised 9.48 and Rasall Sh4-scFv CD19-CD28-CD3z made up 12.3 percent of TILs. The KD of Rasall therefore increased the presence of memory TILs which are vital to long term immunity. There was nothing in prior experiments that would have suggested that the downregulation of Rasall would have led to long-term immunity against cancer cells.

[0309] Further, when stained for TIM-3 and PD-1 expression, mice injected with scr-scFv CD19-CD28-CD3z were found to comprise 46.3 of TIM3+PD1+ TILs, Rasall Shl-scFv CD19-CD28-CD3z comprised 18.8 and Rasall Sh4-scFv CD19-CD28-CD3z made up 15.4 percent of TILs (FIG. 18). Similarly, while mice injected with scr-scFv CD19-CD28-CD3z showed a marked increase in the presence of PDlhlTIM3+ TILs, Rasall Shl-scFv CD19-CD28-CD3z and Rasall Sh4-scFv CD19-CD28-CD3z showed much fewer exhausted TILs at levels similar to the levels in controls (FIG. 19). The KD of Rasall therefore decreased the presence of CD8+ exhausted TILs. The decrease in the presence of exhausted TILs would be of benefit because exhausted TILs have reduced ability to target and eliminate cancer cells effectively. Exhausted TILs exhibit diminished cytotoxic activity, reduced cytokine production, and decreased ability to eliminate cancer cells. Their functionality is compromised, rendering them less effective in mounting an effective anti-tumor response. Consequently, a decrease in the presence of exhausted TILs could lead to the following potential benefit of enhanced tumor immunity, improved responses to immunotherapies and a reduced immunosuppressive microenvironment.

[0310] In addition, in keeping with reduced exhaustion, FAC profiles showing that Rasall shRNA increases the presence of in the CD8+ Ki67+ TCF1+ TILs in tumors (FIG. 20). CAR-T cells were injected into mice that had previously been injected subcutaneously (SC) with EG7 tumor cells. The extracted PD-1+ CD45.2 CD8+ tumor-infiltrating lymphocytes (TILs) at day 18 were then assessed for the expression of the cell cycle marker Ki67 and the progenitor stem cell marker TCF1. While mice injected with scrambled control (scr-scFv CD19-CD28-CD3z) CAR-T cells comprised 3.96% of Ki67+TCF1+ TILs, Rasall knockdown (Rasall Shl-scFv CD19-CD28-CD3z) CAR-T cells comprised 6.19%, and Rasall knockdown (Rasall Sh4-scFv CD19-CD28-CD3z) CAR-T cells made up 16.5% of Ki67+TCF1+ TILs. Similarly, the mice injected with scr-scFv CD19-CD28-CD3z CAR-T cells comprised 10.0% of Ki67-TCF1+ TILs, Rasall Shl-scFv CD19-CD28-CD3z CAR-T cells comprised 14.4%, and Rasall Sh4-scFv CD19-CD28-CD3z CAR-T cells made up 22.5% of Ki67-TCF1+ TILs. The knockdown of Rasall increased the presence of dividing (Ki67+) and non-dividing (Ki67-) TCF1+ progenitor stem-like CD8+ CARs from tumors.FIG. 21 shows that the viSNE (visual Stochastic Neighbor Embedding) profiles that illustrate the expression patterns of different markers in CAR-T cells derived from tumors. These CAR-T cells were extracted from EL4-CD19 tumors and analyzed using multi-dimensional viSNE analysis. The viSNE analysis revealed distinct clusters or "islands" of expression, denoted as i, ii, and iii. Cluster i exhibited an enrichment of CD45.2+ TILs, indicating the presence of a specific subset of lymphocytes. Notably, this cluster also showed an increased prevalence of Rasall Shl-scFv CD19-CD28-CD3z and Rasall Sh4-scFv CD19-CD28-CD3z CAR-T cell subsets compared to the scrambled control (scr-scFv CD19-CD28-CD3z) subset. Additionally, cluster i displayed elevated expression levels of CD69, Ki67 (a marker of cell proliferation), and the progenitor stem cell marker TCFl.In summary, the viSNE analysis demonstrate that the knockdown of Rasall in CAR-T cells leads to an enrichment of a distinct subset of TILs (cluster i) characterized by increased overlapping expression of stem cell-like and proliferative markers, such as TCF1 and Ki67. This finding shows that the downregulation of Rasall in CAR-T cells enhances their stem cell-like and proliferative properties, potentially improving their therapeutic efficacy.Further, Rasall shRNA impacted the production of effector cytokines in CD8+ tumorinfiltrating lymphocytes (TILs) in tumors (FIG. 22). CAR-T cells were injected into mice previously inoculated with EG7 tumor cells. On day 18, the extracted CD45.2+ CD8+ TILs were analyzed for intracellular expression of IFN-y and TNF-a. RasallRasallRasallVn e. findings suggest that the knockdown of Rasall in CAR-T cells increased the presence of CD8+ CAR TILs expressing the effector cytokines IFN-y and TNF-a within the tumor microenvironment, indicating an enhanced anti-tumor immune response.

[0311] Lastly, another possible mechanism could involve Rasall shRNA (short hairpin RNA) in chimeric antigen receptor (CAR)-T cells enhancing the recruitment of endogenous T-cells to the tumor. This could be advantageous due to the amplification of the anti-tumor immune response. CAR-T cells are engineered to specifically target and eliminate cancer cells. However, their efficacy can be limited by the tumor's immunosuppressive microenvironment and the eventual exhaustion or depletion of the CAR-T cells themselves. By recruiting endogenous T-cells, including CD8+ cytotoxic T lymphocytes (CTLs) and helper CD4+ T cells, to the tumor site, the anti-tumor immune response could be amplified and sustained over a longer period. Further, the recruited endogenous T-cells can work synergistically with the CAR-T cells, enhancing their cytotoxic activity and potentially overcoming tumor escape mechanisms. The combined efforts of CAR-T cells and endogenous T-cells could lead to more effective tumor elimination and a lower risk of relapse. Moreover, it would potentially broaden the antigen recognition repertoire and enhance the response by inducing alternate mechanisms such as increased effector functions.Lastly, it could help by overcoming immunosuppression. The tumor microenvironment is often immunosuppressive, which can impair the function of both CAR-T cells and endogenous T-cells. However, the combined presence of CAR-T cells and recruited endogenous T-cells could potentially overcome this immunosuppression through the release of pro-inflammatory cytokines, disruption of inhibitory signaling pathways, and the promotion of a more favorable immune environment.

[0312] FIGs. 23-24 show FAC profiles showing that Rasall shRNA CAR-T cells are unexpectedly potent in being able to promote the presence of endogenous T-cells within the EL4-CD19 tumor. The scFv CD19-CD28-CD3z CAR (CD45.2) were injected into SJL mice (CD45.1) that had been previously inoculated with EL4-CD19 tumor cells for 7 days. The extracted CD45.1+CD8+ T cells represent endogenous TILs. At day 18, TILs were assessed for the expression of CD44 and CD62L on CD45.1+CD8+ T cells. Any effect on CD45.1+CD8+ T cells would indicate a trans-regulatory effect where the CARs alter the endogenous T cells in the tumor. FIG. 23 shows Rasall shRNA-expressing CARs Rasall Shi and Sh4) increased the presence of CD8+ endogenous T cells in the TIL population relative to control scrambled shRNA (Scr) CARs. FIG.24 Rasall shRNA reduces the endogenous memory T cell population while increasing the presence of endogenous CD45.1 effector CD8+ T cells. While mice injected with Scr CARs had 27.1% CD45.1+CD44+ CD62L+ memory CD8+ TILs, those receiving Rasall Shi and Sh4 CARs had markedly reduced memory CD44+CD62L+ populations (5.56% and 5.10%, respectively) and increase in endogenous CD8+CD44+CD62L- CD45.1+ effector cells (from 12.7% in scFv CD19-CD28-CD3z CAR (CD45.2) treated mice to 93.3 and 94% in tumor from Rasall Shl-scFv CD19-CD28-CD3z (CD45.2) and Rasall Sh4-scFv CD19-CD28-CD3z (CD45.2) treated mice.

[0313] Rasall Rasall Rasall Rasall xmWw observations involving the ability of Rasal shRNA CARs to clear tumors was seen using a different tumor model. FIG. 25 depicts Rasall knockdown enhances the anti-tumor efficacy of CD19 scFv CD28 CAR T cells against B 16 F10 CD19 solid tumors. shRNA4-CD19 scFv CD28 CAR T cells, with reduced Rasall expression, eradicated 4 out of 5 tumors by day 18. In contrast, the conventional scr-CD19 scFv CD28 CAR T cells failed to clear any tumors. These results demonstrate that downregulating Rasall with conventional CD28 CARs leads to an unexpected CAR-T complete elimination of B16 melanoma solid tumors, an outcome not observed with the standard CAR T cell therapy.

[0314] Cytokine release syndrome (CRS) is a potentially life-threatening complication that can occur during CAR T-cell therapy, characterized by an excessive and uncontrolled releaseof inflammatory cytokines. Strategies to mitigate CRS risk and manage its symptoms, such as anti-IL6 cytokine blockade and corticosteroid administration, are crucial for improving the safety profile. However, this introduced the question whether the Rasal Shi or sh4 CARs might be associated with lower production of inflammatory cytokines. Interleukin-6 (IL-6) is considered one of the primary cytokine drivers of cytokine release syndrome (CRS), playing a pivotal role in amplifying the inflammatory cascade. FIG. 26 shows that Rasall Sh4-scFv CD19-CD28-CD3z CARs exhibit reduced IL-6 production compared to conventional scr-scFv CD19-CD28-CD3z CARs, possibly mitigating the cytokine release syndrome (CRS) that frequently accompanies CAR T-cell therapy. Transduced CARs were sampled from culture and assessed by PCR for the expression of IL-6 in blood, lung and liver tissue. The Sh4-scFv CD19-CD28-CD3z CARs showed significantly less IL-6 production than the scr-scFv CD19-CD28-CD3z CARs expressing cells.

[0315] To further demonstrate Rasall' s role in tumor rejection, we created a mutant mouse Rasall -c-mut). Using CRISPR technology (FIGs. 27A-27E), they deleted 481 base pairs in the Rasall gene, removing exons 4-5. This resulted in an altered amino acid sequence after residue 41 and a premature stop codon 14 amino acids later. Sequencing confirmed the loss of the Cl domain and partial loss of the C2 domain. T-cells from these Rasall -c-mut mice exhibited a loss of binding to ZAP-70 (FIG. 27B). When spleen T-cells were stimulated with anti-CD3 and then immunoprecipitated with anti-ZAP-70, Rasall co-precipitated from wildtype T-cells but not from Rasall-c-mnt T-cells (upper panel). Importantly, ZAP-70 was precipitated equally from both wild-type and Rasall -c-mut T-cells (middle panel), and actin was not precipitated by the control antibody (lower panel). These data indicated that the loss of the Cl / 2 domains in Rasall prevented its ability to associated and inhibit ZAP-70.

[0316] Our investigation into the role of Rasall in tumor rejection revealed that genetically modified mice lacking functional Rasall (Rasall -c-mut) exhibited a compromised ability to control tumor growth. Functionally, in vivo studies demonstrated a significant reduction in the growth of both MC38 colon adenocarcinoma and B16 F10 melanoma tumors in Rasall-c-nmt mice compared to wild-type controls (FIGs. 27C and 27D). These findings, consistent with the observed efficacy of Rasall shRNA CAR cells in tumor regression, underscore the critical role of Rasall as a negative mediator of immune cell function where its presence as a defective GAP can potentiate the ability of immune cells to mediate effective anti-tumor immune responses Specifically, we observed a greater abundance of CD8+ T-cells in B16-F10 melanoma tumors of Rasall-c-nmt mice (FIGs. 27E), and these cells displayed elevated levels of the proliferation marker Ki67 (FIGs. 27F). Furthermore, the expression of cytolyticeffector molecules GZMA (FIGs. 27G) and GZMB (FIGs. 27H) was significantly higher in CD8+ tumor- infiltrating lymphocytes isolated from Rasall -c-mut mice, indicating a more cytotoxic anti-tumor immune response consistent with a greater control over tumor growth observed in these animals.

[0317] Another possible mechanism to account for the markedly improved anti-tumor response leading to an unexpected clearance of tumors, the Rasall knockdown (KD) could impair the suppressive function of CD4 regulatory T-cells (Tregs) on CD8+ T-cell proliferation (FIGs. 28A-23B). Tregs play a crucial role in maintaining immune tolerance and preventing autoimmunity by suppressing excessive immune responses. Their function is to modulate and control the activity of effector T cells, including CD8+ cytotoxic T lymphocytes (CTLs), which are crucial for tumor elimination. To examine this, CD4+CD25+ Tregs were isolated and added to cultures of wildtype CD8+ T-cells (pre-labeled with cell tracker Tagit) stimulated with anti-CD3 (2C11) at 0.5 pg / ml in vitro for 72 hours. Cell divisions were assessed. Wild-type T responder cells underwent multiple divisions (grey peaks). Addition of wild-type Tregs suppressed the proliferative response, as seen by a reduced number of peaks shifted to the left. In contrast, addition of Rasall knockdown Tregs failed to suppress proliferation to the same extent as wild-type Tregs. Further, increasing numbers of Tregs relative to T responder cells were titrated to assess suppression. At lower Treg:Tresponder ratios of 1:1 to 1:8, suppression was less pronounced. The 1:1 ratio showed higher suppression, while the 1:2 ratio exhibited less suppression. At all ratios, Rasall knockdown Tregs were less suppressive than wild-type Tregs.

[0318] Immune checkpoint blockade with anti-PD- 1 has transformed the treatment of many cancers. A question was therefore whether anti-PD- 1 can cooperate with impaired Rasall to limit tumor growth. In other words, does active Rasall normally act to limit the efficacy of anti-PD- 1 immunotherapy. We found that anti-PD 1 alone limited tumor B 16 F10 melanoma, as did the implantation in Ras al 7c mutmice. However, the use of anti-PD- 1 in Ras al 7c mutmice was most effective (FIG. 29A). Further this was associated with a significant cooperative increase in the presence of CD8+ TILs (FIG. 29B), the expression of the activation marker CD44 (FIG. 29C) together with a reduction in T-cell exhaustion as shown by a reduction in PD-1 (FIG. 29D), TIM-3 (FIG. 29E ) and CX3CR1 (FIG. 29F) expression. Consistent with the reduced exhaustion was an increase the percentage of PD1+CD8 cells expressing the progenitor markers SLAMF6+ (FIG. 29G). SLAMF6 (Signaling Lymphocytic Activation Molecule Family member 6) is a surface marker that identifies progenitor or naive CD8+ T cells with enhanced self-renewal capacity and the potential to differentiate into effector and memory subsets. FIG. 29H shows an unexpected synergistic increase in the number ofPD1+TCF1+ CD8 TILs from anti-PDl treated Ras al Jc mutmice. Overall, in Rasallc~dommice, anti-PDl therapy increased the percentage of PD1 -expressing stem-like CD8+ TILs as well as reducing both transitory and terminally exhausted CD8+ TILs.

[0319] Having demonstrated that efficacy of the LAIR1 hinge and the use of bicistronic Rasall shRNA, we next assessed whether Rasall shRNA could cooperate more effectively with the LAIR1 hinge than the conventional CD28 hinge CAR. Indeed, the Rasall shRNA4-scFv CD19-mLAIRl-CD3z CAR was found to be more effective than the Rasall shRNA4-scFv CD19-mCD28-CD3z CAR in limiting EL4-CD19 (FIG. 30A). Rasall shRNA4-scFv CD19-mLAIRl-CD3z CAR was found to reduce tumor growth as soon as 6 days postinjection, while the Rasall shRNA4-scFv CD19-mCD28-CD3z CAR acted to temporarily prevent tumor growth without a reduction followed by an increase in growth 10 days postinjection.

[0320] Consistent with this, Rasall shRNA4-scFv CD19-mLAIRl-CD3z CARs showed greater % of CD8 CARs in the tumor (FIG. 30B), the expression of Ki67 which is indicative of more cell proliferation (FIG. 30C), and reduced PD-1 expression (FIG. 30D), suggestive of less exhaustion. These data indicate that Rasall shRNA can cooperate with the LAIR1 hinge to generate a CAR that is most effective in limiting tumor growth.

[0321] In addition, the use of the single nRasall cassette to transduce mouse splenocytes resulted in a more effective tumor rejection of EL4 CD19 tumors (Fig. 31). Whether this approach or the use of CARs operates selectively through the transduction of spleen T-cells is unclear. The culturing of transduced cells with anti-CD3 / CD28 in the presence of IL-2 or IL-7 / IL-15 certainly would be expected to favor the propagation and expansion of CAR-T-cells, and indeed, the majority of transduced cells stained positively for CD3. The presence of NK cells and natural killer T (NKT) cells is also expected. NKT cells express a semi-invariant T cell receptor (TCR) that recognizes lipid antigens presented by the non-classical major histocompatibility complex (MHC) class I molecule CD Id. Further, spleen contains CD4+ helper and cytolytic T cells as well as regulatory T cells, B lymphocytes and host antigen-presenting cells (APCs), such as dendritic cells and macrophages as well as innate lymphoid cells (ILCs). Further, myeloid cells, including neutrophils, eosinophils, and basophils, are present and participate in inflammatory processes and immune defense mechanisms.

[0322] Additionally, specialized stromal cells, such as follicular dendritic cells and marginal metallophilic macrophages, provide structural support and create distinct microenvironments within the spleen's white pulp, facilitating efficient immune surveillance and responses.Lastly, the shRNA for human Rasall in the context of a human CAR. Human CARs were generated from cells were isolated from peripheral blood from human donor volunteers, as previously described (Guo et al., 2021 iScience 24, 103295), Bicistronic lentiviral vectors were used that simultaneously drive the expression of both shRNA and a chimeric antigen receptor (CAR) in T cells for use in CAR-T cell therapy. FIG. 32 shows that the presence of human LAIR1 as hinge increased the potency of the CAR to kill the 293-ACE2 cells were loaded with the RBD peptide followed by washing and incubation with CAR-Ts for 4-5 h prior to a measure of killing. CAR-Ts were co-cultured with 293-ACE2-RBD cells at a 10:1 effector to target ratio for 4shs for the assessment of killing. While the \\Rascill shRNAl-scFv CR3022 -hCD28-CD3z killed 82% of target cells, the scr-scFv CR3022 -hCD28-CD3z killed 59% of targets. This indicate that the human Rasall shRNA can improve the killing efficiency of human CARs against target cells expressing an antigen.

[0323] Methods

[0324] Cell line and tumor transplant

[0325] Mouse splenic T cells were activated with anti-CD3 (2 pg / ml) and anti-CD28 (2 pg / ml) for 24 hours. Activated cells were then transduced via spinoculation with viral supernatant and Polybrene (8 pg / ml) mix, followed by incubation. The next day, cells were split and cultured in fresh cytokine- supplemented media (containing IL-7 and IL- 15) (FIG.

[0326] 4). CAR expression was assessed on day 3 by anti-flag staining and flow cytometry. Cultures were maintained by splitting cells and refreshing cytokine-containing media every two days until in vivo use. For in vivo tumor work, mice were injected subcutaneously with EG7-CD19 lymphoma tumor cells and allowed 7 days for the tumors to grow (FIG. 5). After this period, chimeric antigen receptor (CAR) cells were injected intraperitoneally into the tumorbearing mice. The tumors were then harvested between days 14-20 after the initial tumor cell injection to study the effects of the CAR cell treatment. In certain experiments, CAR T-cells isolated from wild-type C57BL / 6 mice (CD45.2) or OT-1 transgenic mice were injected into SJL-M6 mice, which have a different genetic background (CD45.1).

[0327] Cell preparation

[0328] All organs were taken from 8- to 16-week-old mice. Inguinal lymph nodes (LN) were mechanically disrupted onto a 70um strainer using the plunger of a 5mL syringe. Stainer was wash with 5ml of PBS (Coming # MT21040CV) / 2mM EDTA (Sigma # E5134) + FBS 2% (FACS buffer). Tumors were smashed on 70 um strainers in RPMI (VWR # CA45000-396)on ice. Tumor lysate was spined down at 350g for 5min and resuspended in PBS. PBS containing tumor lysate was add to lymphocytes separation medium (Fisher Scientific # MT25072CV) and TILs were separated and isolated after centrifugation at 2000 rpm for 20 min at RT. Spleen were pressed in a 6 wells plate containing 2ml of red blood lysis buffer (Biolegend # 420302) and 2 more ml were added and then incubated 5min at RT. Lysis was stopped with 20ml of PBS and the solution was filtered on a 70pm membrane and then centrifuged 5min at 350g. Pellets from LN, tumor and spleen cells were resuspended in 1ml of FACS buffer and alive cells were counted on a Neubauer counting chamber with Trypan blue.

[0329] Ex-vivo activation

[0330] Cells from spleen were isolated as describe in the specific section. Then, T cells were isolated with magnetic kit (Stemcell Technologies # 19848RF), and 2.106cells were seed in 1ml of activation media; RPMI+L-glutamine+ FBS 10%+ HEPES IM (Fisher Scientific #MT25060C) + P-mercaptoetanol 0,1% (Fisher Scientific #44-420-3250ML) in a 48 wells pate media and activated with lug / ml with anti-CD3e (Biolegend #100340) for 24h at 37°C.

[0331] Flow cytometry

[0332] Isolated cells from spleen, LN, and tumor were stained with Fixable Viability Dye eFluor™ 780 (dilution: 1 / 1000; ebioscience # 65-0865-18) 20min at 4°C and then blocked with lOOpl of PBS / 2mM EDTA + FBS 5% + 2,5 ng / ml purified rat anti-mouse CD16 / CD32 (BD Biosciences #553141) 20min at 4°C. Cells were then centrifuged 5min at 350g and stained with primary antibodies for 30min at 4°C. The fluorochrome-conjugated antibodies were as follows for flow cytometry: BV605 Rat Anti-Mouse CD4 (RM4-5 / RM4-4;

[0333] Biolegend #116027), PE-Cy™7 Rat Anti-Mouse CD8a (53-6.7 ; BD Biosciences #552877), Alexa Fluor® 700 Hamster anti-Mouse CD3e (500A2; BD Biosciences #557984), PerCP-Cy™5.5 Rat Anti-Mouse / human CD44 (IM7; Biolegend #103032), Brilliant Violet 650™ anti-mouse CD62L Antibody (MEL- 14; Biolegend #104453), PE-Cyanine5.5 KLRG1 Monoclonal Antibody (2F1; Invitrogen #35-5893-80), PE CD127 Monoclonal Antibody (A7R34; Invitrogen #12-1271-81), Alexa Fluor® 488 Anti-Glucose Transporter GLUT1 antibody (EPR3915; abeam #abl95359), BD OptiBuild™ BUV395 Mouse Anti-Mouse Ly-108 (13G3; BD Biosciences #745730), BD Horizon™ BUV737 Hamster Anti-Mouse CD69 (H1.2F3; BD Biosciences # 612793), BD OptiBuild™ BV605 Mouse Anti-Mouse CD366 (TIM-3) (5D12; BD Biosciences #7476241), PE-eFluor™ 610 CD39 Monoclonal Antibody(24DMS1; Invitrogen #61-0391-82), Brilliant Violet 510™ anti-mouse CD279 (PD-1) Antibody (29F.1A12; Invitrogen ; 35-5893-80), PE-Cyanine7 CD101 Monoclonal Antibody (MoushilOl; Biolegend #100742), Alexa Fluor® 700 anti-mouse CD90.2 (Thy-1.2) Antibody (30-H12; Invitrogen #25-1011-80), FITC anti-mouse CD127 (IL-7Ra) Antibody (A7R34; 105319) and as follow for cytof Anti-Mouse CD4 (RM4-5; Fluidigm # 13145002B)-145Nd, Anti-Mouse CD45 (30-F11; Fluidigm # 3089005B)-89Y, Anti-Mouse TCRb (H57-597; Fluidigm # 3169002B)-169Tm, Anti-Mouse CD3e (145-2C11; Fluidigm # 3165020B)-165Ho, Anti-Mouse CD8a (53-6.7; Fluidigm # 3151007B)-146Nd, Anti-Mouse CD25 (3C7; Fluidigm # 3151007B)-151Eu. Cells were fixed with 2% PAF (Coming #14-959-1A) 15min at 4°C, washed 2 times in PBS / 2mM EDTA +FBS 2% and then nuclear permeabilized with FOXP3 kit (Thermofisher #00-5523-00) for 30 min at 4°C. Cells were stained with antibodies targeting intracellular protein for 50min at RT and diluted in PBS / 2mM EDTA + FBS 5%. The fluorochrome-conjugated antibodies were as follows for flow cytometry: PE beta Catenin Monoclonal Antibody (15B8; ebioscience #12-2567-41), Alexa Fluor® 647 ConjugateTCFl / TCF7 Rabbit mAb (C63D9; Cell signaling # 6709), Alexa Fluor® 488 anti-mouse / human Ki-67 Antibody (11F6 ; Biolegend# 151204), PE anti-human / mouse Granzyme B Recombinant Antibody (QA16A02; Biolegend # 135008), Granzyme F / CCP4 (GZMF) (polyclonal; antibodiesonline.com # AA 748-761), FITC Rabbit anti-Goat IgG (H+L) Secondary Antibody (Invitrogen # 31509), eFluor™ 450 Granzyme A Monoclonal Antibody (GzA-3G8.5; ebiosciences # GzA-3G8.5), PE / Cy7 anti-mouse Granzyme C Antibody (SFC1D8; Biolegend # 150808), eFluor 660 EOMES Monoclonal Antibody (Danllmag; ebiosciences # 61-4875-82), APC anti-mouse Perforin Antibody (S16009B; Biolegend# 154404), PE anti-Bcl-2 Antibody (BCL / 10C4; Biolegend # 633507) and as follow for cytof : Anti-Mouse Foxp3 (FJK-16s; Fluidigm # 3158003A)-158Gd. Cells were washed 2 times in PBS / 2mM EDTA +FBS 2%. BD FacsFortessa was used for cell phenotyping and intracellular detection. Mean fluorescence intensity (MFI) of specific markers was quantified on T cell subpopulations using FlowJo. Results were analyzed using Flow Jo (Tree Star, Ashland, USA).

[0334] Cell lysis, and Immunoblotting

[0335] CD8+ T cells were isolated (Stemcell Technologies # 19853A). Cell lysates were prepared by resuspension of spleen-purified CD8+ T cells in 1% TBS-T lysis buffer (Fisher Scientific # BP24711), followed by a 30-min incubation on ice. Lysates were centrifuged at 14,000 rpm for 30 min at 4°C and the nuclear-free supernatants were subjected to SDS-PAGE on a 10 % polyacrylamide gel. Proteins from the gel were electroblotted onto nitrocellulose membranes at 100V for 75 min, followed by 1 h of blocking with 3% BSA (Bio-technein # 5217) TBST at RT. The nitrocellulose membranes were then incubated in the presence of the indicated primary Abs: GSK-3a / p Rabbit mAb (D75D3; Cell signaling # 5676), P-Actin Rabbit mAb (13E5; Cell signaling # 93473) followed by incubation with HRP-conjugated secondary Abs; Mouse Anti-rabbit IgG (Conformation Specific) mAb (HRP Conjugate) (L27A9; Cell signaling # 5127S). Immunoreactive protein bands were visualized using an ECL reagent (BioRad #103576-100) and autoradiography. Whenever required, nitrocellulose membranes were stripped by incubation in stripping buffer for 20 min at RT, followed by 1 h incubation with blocking buffer (3% BSA in TBST).

[0336] Killing assay

[0337] EL4 cells (Target) were cultivated in RPMI + 10%FBS and incubated at RT for 25 min with Tag-it (Biolegend # 425101) 1 / 1000. Then, EL4 cells were pulsed with 1 pg / ml of OVA peptide (anaspec #AS-60193-1) at 37 °C for 1 hour. OT1 splenocytes (Effector) were isolated as previously described and activated with Anti-CD28 2ug / mL (Biolegend #102116) + IL-25ng / mL (Biolegend #575402) and anti-CD3e 2ug / mL in activation media for 1 day at 37°C. Effector cell were electroporated with 125nM of GZM siRNA or Ctrl siRNA (Santa Cruz Biotechnology #sc- 105412, #sc- 105413) and cultivated overnight in RPMI+20% FBS+2%L-Glutamine+anti-CD3 (2ug / mL) and anti-CD28 (2ug / mL) + IL2 (5ng / mL). Next day, cells were spin down at 300g for 5min, resuspended at the concentration of 106 / mL and cultivated for 24h in activated media + IL2 (50IU / mL). Next day 25000 of target cell were colcultured for 6 days in activation media with 250000 effector electroporated cells; Ration (E:T)=10:l and dead percentage of target cell (Tag-it +) were analysed in flow cytometry using a viability dye.

[0338] Quantification and statistical analysis

[0339] Respect of the assumptions of normal distribution of residuals and homoscedasticity was verified, and data were presented as mean + SEM as well as individual values, unless otherwise indicated. Data from independent experiments were pooled for analysis in each data panel, unless otherwise indicated. Statistical analyses were performed using Prism 8 (GraphPad Software). Unpaired t test was performed unless otherwise indicated in the figure legends. We considered a P-value lower than 0,05 as significant. N.S.: P>0,05; *: P<0,05; **: P<0,01; ***: P<0,001; ****P<0,0001.Example 3. Rasall shRNA Enhances Anti-Tumor Efficacy of T Cells Expressing Anti- GD3 CARs

[0340] We next evaluated whether the beneficial effects of Rasall knockdown on CAR T-cell function extend beyond the anti-CD19 target antigen to include anti-GD3 chimeric antigen receptors. GD3 (trisialoganglioside) is a disialoganglioside antigen expressed on neuroectodermal tumors such as neuroblastoma and melanoma, making it an attractive target for CAR T-cell therapy in solid tumors. To test this, a Rasall -targeting shRNA was cloned into the pMKO.1 GFP retroviral vector, either alone or in combination with an anti-GD3 scFv-CD28-CD3^ CAR, indicating the relative positions of each expression cassette (FIG.

[0341] 33A).

[0342] Primary splenic T cells isolated from C57BL / 6 mice were activated with soluble anti-CD3 (1 pg / mL; clone 2C11) and anti-CD28 (1 pg / mL; clone 37.51) antibodies for 24 hours in RPMI 1640 medium supplemented with 10% FBS, MEM non-essential amino acids, sodium pyruvate, HEPES buffer, and 2-mercaptoethanol. Activated T cells were transduced with retroviral supernatant derived from HEK 293T packaging cells in the presence of Polybrene (1 pg / mL). Transduced cells were expanded for 5 days in the presence of interleukin-7 (IL-7; 10 ng / mL) and interleukin- 15 (IL- 15; 10 ng / mL). For in vivo tumor studies, C57BL / 6 mice were implanted subcutaneously with 1 x 106EL4-GD3 lymphoma cells and tumors were allowed to establish for 5 days until palpable. Mice then received adoptive transfer of 3 x 106expanded T cells transduced with either Rasall shRNA alone or anti-GD3 scFv-CD28-CD3^ CAR alone. Tumor growth was monitored over a 6-day period (FIG. 33B).

[0343] Mice receiving Rasall shRNA-transduced T cells exhibited a statistically significant reduction in tumor growth compared to both the untreated control and the anti-GD3 scFv-CD28-CD3(^ CAR group. By day 4 post-injection, the Rasall shRNA group showed tumor volumes significantly lower than the anti-GD3 CAR group (**P<0.01), and by day 6, the difference from control was highly significant (****P<0.0001). In contrast, the anti-GD3 scFv-CD28-CD3^ CAR alone did not significantly reduce tumor growth compared to control at the day 6 endpoint. These data demonstrate that the mere Rasall shRNA knockdown alone amongst activated spleen cells which are adoptively transferred to mice is sufficient to enhance T-cell-mediated anti-tumor activity for tumor mass rejection.

[0344] We next assessed whether Rasall shRNA could also cooperate with the anti-GD3 scFv-LAIR l-CD28(^ CAR — incorporating the LAIR1 hinge domain previously shown to enhance anti-tumor efficacy (Example 1) — to provide additive or synergistic anti-tumoreffects. Rasall shRNA was co-expressed with the anti-GD3 scFv-LAIR l-CD28(^ CAR in the same pMKO.l GFP retroviral vector. Transduced T cells were prepared and transferred as described above, and tumor growth was monitored over 6 days (FIG. 34).

[0345] The anti-GD3 scFv-LAIR l-CD28(^ CAR alone demonstrated a modest reduction in tumor growth that did not reach statistical significance compared to untreated controls at day 6. In marked contrast, co-expression of Rasall shRNA with the anti-GD3 scFv-LAIR 1-CD28(^ CAR resulted in a substantial and statistically significant reduction in tumor volume compared to both control (****P<0.0001) and CAR alone (****P<0.0001), with tumors reduced to approximately 180-250 mm3at day 6. This synergistic improvement was unexpected given that the anti-GD3 scFv-LAIR 1 -CD28(^ CAR alone was insufficient to control tumor growth at this timepoint. Within the same experiment, the Rasall shRNA knockdown alone did reduce tumor growth as mentioned (FIG. 33); however, the level of inhibition seen for the combination of Rasall shRNA knockdown and anti-GD3 scFv-LAIR l-CD28(^ CAR was unexpected and synergistic given that the inhibition by anti-GD3 scFv-LAIRl-CD28^ CAR alone was insufficient to control tumor growth.

[0346] Taken together, these results demonstrate that Rasall shRNA functionally cooperates with both the LAIR1 hinge domain and the anti-GD3 antigen-targeting domain to substantially improve anti-tumor efficacy. These findings are consistent with, and extend, the observations made with anti-CD19 CAR constructs (Examples 1 and 2), and support the generalizability of Rasall knockdown as a strategy to enhance CAR T-cell function across different tumor antigens and hinge domain configurations.

[0347] Example 4. Synergistic Cooperation Between Rasall Suppression and the LAIR1 Hinge Domain, Human CAR Efficacy, and Collagen-Mediated CAR-T Cell Activation Synergistic Cooperation Between Rasall Suppression and the LAIR1 Hinge To directly evaluate the combined effects of Rasall suppression and LAIR1 hinge incorporation on CAR-T cell cytotoxic function, primary effector T cells were engineered using a bicistronic vector system encoding anti-CD19 CAR constructs containing either a conventional CD28 hinge domain or a LAIR1 -derived hinge domain, with or without concurrent expression of shRNA targeting Rasall. CAR-modified effector cells were evaluated in an in vitro cytotoxicity assay against CD19-expressing EG7 target cells. LDH-loaded CD 19+ EG7 target cells were incubated with anti-CD19 CAR effector cells under a standardized 1:2 effector-to-target ratio for 3 hours, after which target cell lysis wasquantified by measuring lactate dehydrogenase (LDH) release into the culture supernatant using a colorimetric LDH detection assay according to the manufacturer’s protocol (FIG. 35).

[0348] Control cells lacking CAR expression exhibited minimal baseline cytotoxicity. AntiCD 19 CARs with the CD28 hinge domain mediated detectable killing of CD 19+ EG7 target cells, while addition of Rasall shRNA to the CD28 CAR produced no meaningful enhancement in vitro relative to the CD28 CAR alone. In contrast, incorporation of the LAIR1 hinge domain substantially increased CAR-mediated cytotoxicity relative to CD28-hinge CARs, demonstrating an independent functional advantage conferred by the LAIR1 platform. Unexpectedly, concurrent Rasall suppression in the LAIRl-hinge CAR context produced a markedly greater enhancement than observed with either modification alone or with Rasall suppression in the CD28-hinge CAR context, generating the highest level of target cell killing (synergistic) among all groups tested.

[0349] These findings demonstrate a previously unrecognized and disproportionate functional cooperation between LAIR1 hinge incorporation and Rasall suppression that exceeds the incremental effects predicted by either strategy independently. The preferential enhancement observed in the LAIRl-hinge context indicates that Rasall suppression both improves CAR function generally and interacts unexpectedly with LAIR1 hinge- dependent structural and / or signaling properties to generate a distinct and superior CAR platform. This cooperative interaction supports the use of combined LAIR1 hinge incorporation and Rasall suppression as a novel modular engineering strategy for improving CAR-T cell cytotoxicity, cellular fitness, and therapeutic performance.

[0350] Human LAIR1 Hinge CARs Exhibit Superior Killing of Human Tumor Targets Human versions of the anti-CD19 LAIR1 hinge CAR were constructed containing either a conventional CD28 hinge domain or a LAIR 1 -derived hinge domain, both incorporating CD28 transmembrane and costimulatory domains and a CD3(^ signaling domain (FIG. 36A). Primary mouse T cells were retrovirally transduced with the human CAR constructs and expanded for three days in RPMI 1640 supplemented with 10% FBS, 1% Pen / Strep, IL-7 and IL- 15 (5 ng / mL each). CAR expression was assessed via flow cytometry using a BV421 -conjugated anti-FLAG antibody, showing comparable surface expression levels (18.5% for CD28-CAR and 14.4% for LAIR1-CAR) (FIG. 36B). NALM6 human B-cell lymphoma cells were confirmed to express high levels of human CD19 (98.1%) by PE-conjugated anti-human CD 19 staining (FIG. 36C).

[0351] Mouse T cells transduced with human CAR constructs were co-cultured with NALM6 human B-cell lymphoma cells at a 2: 1 effector-to-target ratio. Cytotoxicity was assessedusing a standard 3-hour LDH release assay. LAIR 1 -hinge CAR T cells demonstrated significantly superior killing of NALM6 target cells (-30%) compared to CD28-hinge CAR T cells (-20%) and non-transduced control T cells (-10%), as measured by specific lysis calculated from LDH release normalized to spontaneous and maximum release controls (FIG.

[0352] 36D). These results demonstrate that the human LAIR1 hinge domain confers enhanced antitumor cytotoxicity against human tumor cells, extending the findings from murine systems to a human CAR platform relevant to clinical application.

[0353] The LAIR1 Hinge Domain Enhances CAR-T Cell Viability and Reprograms Phenotypic and Functional State During Ex Vivo Expansion

[0354] Primary splenic T cells from C57BL / 6 mice were activated for 24 hours in complete RPML1640 supplemented with soluble anti-CD3 (1 pg / mL; clone 2C11) and anti-CD28 (clone PV-1), together with 10% FBS, MEM non-essential amino acids, sodium pyruvate, HEPES, and 2-mercaptoethanol. Activated T cells were subsequently retrovirally transduced with CD28-hinge or LAIR 1 -hinge CAR constructs using HEK293-derived viral supernatants in the presence of polybrene (1 pg / mL). Following transduction, CAR-T cells were expanded in the presence of IL-7 and IL- 15 (5-10 ng / mL each).

[0355] At day 3 following transduction and expansion, cells were stained using Fixable Viability Dye eFluor 780 (eBioscience LIVE / DEAD Near-IR). CD28-hinge CAR expression was associated with a marked reduction in viable cell frequency relative to non-transduced controls (78.6% viable in control vs. 41.5% in CD28 CAR cells). ShRasall-CD28 CAR cells showed similarly reduced viability (41.8%). Incorporation of the LAIR1 hinge significantly increased viable cell frequencies in both ShRasall-LAIRl CAR cells (61.7%) and LAIR1 CAR cells (66.1%) (FIG. 37). These data demonstrate that inclusion of the LAIR1 hinge domain confers a reproducible survival advantage during CAR-T cell generation and ex vivo expansion, independent of Rasall suppression, consistent with an intrinsic pro-survival or fitness-enhancing property provided by the LAIR1 hinge.

[0356] Following expansion, comprehensive phenotypic analysis demonstrated that LAIR1 hinge incorporation reprograms multiple dimensions of CAR-T cell biology (FIG. 38).

[0357] Despite broadly comparable CAR surface expression across constructs (51-61% CAR+), LAIRl-hinge CAR T cells showed distinct biological properties compared to CD28-hinge controls. Specifically, LAIR1 incorporation was associated with decreased CD69 expression (47.5% for LAIR1 CAR vs. 74.4% for CD28 CAR), indicating reduced activation-induced cell death risk, while CD1 la (LFA-1) and CD25 expression levels were broadly maintained. Analysis of differentiation markers (CD62L vs. CD44) showed that LAIR1 hinge constructspromoted a shift away from canonical central memory programming toward a more activated or transitional state (FIG. 38B).

[0358] Functional and exhaustion-associated profiling further demonstrated LAIR 1 -hingedependent remodeling of proliferative and activation programs (FIG. 38C). LAIR1 CAR T cells showed a reduction in the percentage of cells co-expressing PD-lhi and TIM-3 (4.40% for LAIR1 CAR vs. 10.5% for CD28 CAR), indicating reduced T-cell exhaustion during in vitro expansion. Concurrent Rasall knockdown in the LAIRl-hinge context further reduced PD-lhi TIM-3+ co-expression to 4.14%. Proliferative capacity as measured by Ki67 was selectively reduced in LAIR 1 -containing constructs (59.4% for LAIR1 CAR vs. 64.4% for CD28 CAR; 52.6% for ShRaraZJ-LAIRl CAR vs. 64.0% for ShRasall-CD28 CAR), consistent with reduced activation-induced exhaustion. Despite reduced proliferative drive, all CAR T cell populations retained substantial effector competence, as demonstrated by preserved polyfunctional cytokine production (IFNy and TNFa). These data indicate that the LAIR1 hinge reprograms CAR-T activation into a distinct functional state that combines altered differentiation and activation marker expression with preserved effector output, supporting the LAIR1 hinge as a broadly applicable platform for engineering next-generation CARs with enhanced therapeutic fitness.

[0359] The LAIR1 Hinge Domain Mediates Collagen Binding and Transduces Collagen-Dependent Regulatory Signals

[0360] To evaluate extracellular matrix (ECM) interactions of the LAIR1 hinge domain, primary splenic T cells from C57BL / 6 mice were activated for 24 hours in supplemented RPML1640 containing anti-CD3 (1 pg / mL; clone 2C11) and anti-CD28 (clone PV-1) antibodies. Following activation, T cells were retrovirally transduced with CD28-hinge or LAIRl-hinge CAR constructs using HEK cell-derived viral supernatants in the presence of 1 pg / mL polybrene and expanded for five days in the presence of IL-7 and IL- 15 (5 ng / mL each). CD3+ T-cell purity post-expansion was confirmed at 95-97% by flow cytometry using anti-CD3 (clone 2C11) conjugated to Alexa Fluor 700A (FIG. 39A).

[0361] Microtiter plates were pre-coated overnight with 20 pg / cm2of either Collagen I or Collagen IV in PBS. Non-transduced control T cells, CD28-hinge CAR T cells, and LAIRl-hinge CAR T cells were incubated on the coated plates in the absence of CD 19+ B cells to isolate hinge- specific binding to collagen independently of scFv domain binding to antigen. Following incubation, non-adherent cells were removed by washing (2 times) with 37 °C RPMI media, and adherent cells were visualized by bright-field microscopy and quantified.LAIR 1 -hinge CAR T cells exhibited significantly higher adhesion to Collagen I-coated surfaces (-4,000 cells / well) compared to both non-transduced and CD28-hinge controls (p<0.01), with negligible binding observed in all groups on uncoated control surfaces (FIG. 39B). Similarly, LAIRl-hinge CAR T cells demonstrated markedly superior adhesion to Collagen IV-coated surfaces (-9,000 cells / well) compared to both control populations (p<0.01) (FIG. 39C). The specificity of the LAIR1 hinge-collagen interaction was further supported by the lack of significant adhesion in CD28-hinge CAR T cells, which share an identical scFv domain, thereby excluding residual CD 19+ B cells as a mediator of the observed binding.

[0362] To assess functional consequences of collagen engagement, CAR T cells were cultured for 3 days on uncoated plates or plates coated with Collagen I or Collagen IV at 20 pg / cm2and analyzed by flow cytometry for surface CD69 expression and intracellular Ki-67 staining (FIG. 39D). Neither non-transduced controls nor CD28-hinge CARs demonstrated substantial CD69 upregulation following exposure to either collagen substrate. In contrast, LAIRl-hinge CAR T cells exhibited marked collagen-dependent activation, with CD69 expression increasing from 3.47% on uncoated surfaces to 23.5% on Collagen I and 31.7% on Collagen IV. Correspondingly, LAIRl-hinge CAR T cells showed substantial reductions in Ki-67 expression upon collagen binding, decreasing from 63.6% on uncoated plates to 29.9% on Collagen I and 28.4% on Collagen IV, indicating that collagen interactions can directly alter CAR-T cell proliferative programming.

[0363] Collectively, these data demonstrate that the LAIR1 hinge domain within the CAR functions not merely as a structural spacer but as a biologically active signaling module capable of: (1) mediating selective adhesion to Collagen I and Collagen IV independently of antigen engagement; (2) transducing collagen-triggered activation signals resulting in CD69 upregulation; and (3) modulating CAR-T cell proliferative programming upon collagen engagement. These properties are consistent with the established role of native LAIR-1 as a collagen receptor and support the concept that the LAIR1 hinge enables CAR platforms to sense and respond to collagen-rich tumor microenvironments. The LAIR1 hinge therefore provides a structurally active platform component capable of improving CAR-T cell tumor retention, activation, and therapeutic performance, particularly within solid tumor microenvironments where collagen deposition is prevalent.SEQUENCE TABLE

[0364] Construct SEQ ID Sequence

[0365] element NO:

[0366] CD8a Signal MALPVTALLLPLALLLHAARP 1 peptide

[0367] CD4 Signal MNRGVPFRHLLLVLQLALLPAATQG 2 peptide

[0368] CD28 Signal MLRLLLALNLFP S I QVTG 3 peptide

[0369] MPPPRLLFFLLFLTPMEVRPEEPLWKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKL SLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGELFRWNVSD LGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSLNQSLSQDLTMAP GSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMWVMETGLLLPRATAQDA CD 19 (isoform 1) GKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYLIFCLCSLVGILHLQRALVLR 4

[0370] RKRKRMTDPTRRFFKVTPPPGSGPQNQYGNVLSLPTPTSGLGRAQRWAAGLGGTAPSYGNPSSD VQADGALGSRSPPGVGPEEEEGEGYEEPDSEEDSEFYENDSNLGQDQLSQDGSGYENPEDEPLG PEDEDSFSNAESYENEDEELTQPVARTMDFLSPHGSAWDPSREATSLGSQSYEDMRGILYAAPQ LRSIRGQPGPNHEEDADSYENMDNPDGPDPAWGGGGRMGTWSTR MPPPRLLFFLLFLTPMEVRPEEPLWKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKL SLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGELFRWNVSD LGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSLNQSLSQDLTMAP GSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMWVMETGLLLPRATAQDA CD 19 (isoform 2) GKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYLIFCLCSLVGILHLQRALVLR 5

[0371] RKRKRMTDPTRRFFKVTPPPGSGPQNQYGNVLSLPTPTSGLGRAQRWAAGLGGTAPSYGNPSSD VQADGALGSRSPPGVGPEEEEGEGYEEPDSEEDSEFYENDSNLGQDQLSQDGSGYENPEDEPLG PEDEDSFSNAESYENEDEELTQPVARTMDFLSPHGSAWDPSREATSLAGSQSYEDMRGILYAAP QLRSIRGQPGPNHEEDADSYENMDNPDGPDPAWGGGGRMGTWSTR MALPVTALLLPLALLLHAARPEIVTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQA PRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSRFTFGPGTKVDIK CD19scFv (full GSTSGSGKPGSGEGSTKGQVQLVQSGAEVKKPGSSVKVSCKDSGGTFSSYAISWVRQAPGQGLE 6 length) WMGGIIPIFGTTNYAQQFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREAVAADWLDPWG QGTLVTVSS CD19scFv (HC SYAIS (based on Kabat numbering) 7 CDR1)

[0372] CD19scFv (HC GIIPIFGTTNYAQQFQG (based on Kabat numbering) 8 CDR2)

[0373] CD19scFv (HC EAVAADWLDP (based on Kabat numbering) 9 CDR3)

[0374] CD19scFv (LC RASQSVSSSYLA (based on Kabat numbering) 10 CDR1)

[0375] CD19scFv (LC GASSRAT (based on Kabat numbering) 11 CDR2)

[0376] CD19scFv (LC QQYGSSRFT (based on Kabat numbering) 12 CDR3)

[0377] FLAG Tag DYKDDDDK (based on Kabat numbering) 13 QEEDLPRPSISAEPGTVIPLGSHVTFVCRGPVGVQTFRLERESRSTYNDTEDVSQASPSESEAR LAIR hinge FRIDSVSEGNAGPYRCIYYKPPKWSEQSDYLELLVKETSGGPDSPDTEPGSSAGPTQRPSDNSH 14 domain NEHAPASQGLKAEHLY

[0378] Truncated LAIR LLVKETSGGPDSPDTEPGSSAGPTQRPSDNSHNEHAPASQGLKAEHLY 15 (tLAIR) hinge

[0379] CD28 transmembrane (TM) FWVLWVGGVLACY SLLVTVAF 11 FWV 16 domain

[0380] CD28

[0381] intracellular (IC) YMNQPAWHHHHHHQEDGSVYGRVYYQCYF 17

[0382]

[0383] domainConstruct SEQ ID Sequence

[0384] element NO:

[0385] CD28 hinge IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP 18 region

[0386] CD28 costimulatory RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS 19 domain

[0387] CD3 intracellular RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 20 (IC) domain

[0388] CD3 coRDDRVYQALKDSGGPRSAKSRDAGGGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKD

[0389] stimulatory KMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 21 domain

[0390] GTGTTTAACTGGAAACTAGAACGAGATGGAAGGGGATGTTCAAGGCCCCTCCCTTGACTCTGAA CGGACCCCCAGGGAACATGCGACCCTCTCTCTGGCGACGCCTCCCACCCACCACTAATACTTGC TCCTGGACCGGGGGGCGCGGAGGTTGGAGAGAGGAGCTACCCGGGTCTCGGACAGGCGGCACTG GGACCACGAGGCAGGGAGCCAGGCTTGAAGCAGGTGACATGTAGACGTCCCCTGGTCCAGCCTC GGAACCTGAGCGCCCTTCTGCCTGGAAAGTTTGTGGCTAGGCGCCATGGCCAAGAGCAGCTCCC TGAATGTTCGCGTGGTGGAGGGCCGCGCGCTGCCTGCCAAGGACGTGTCTGGGAGCAGCGACCC CTACTGCCTAGTGAAAGTGGACGACGAGGTGGTGGCCAGGACAGCTACTGTCTGGAGGAGCCTG RASAL1 gene GGCCCCTTCTGGGGGAGGAGTACACGGTGCACCTGCCTCTGGATTTCCACCAGCTGGCCTTCTA HGNC: 9873 CGTGCTGGATGAGGACACTGTCGGGCACGACGACATCATCGGCAAGATCTCGCTGAGCAGGGAG GCGATTACAGCCGACCCCCGAGGGATTGACAGCTGGATTAACTTGAGCCGAGTGGACCCAGATG NCBI Gene: 8437 CAGAAGTGCAGGGTGAGATCTGCCTGTCAGTGCAGATGCTGGAGGATGGGCAGGGCCGCTGCCT Ensembl: ENSGO TCGCTGCCATGTGCTTCAGGCCAGGGACCTGGCTCCCAGAGACATCTCTGGCACATCTGACCCA TTTGCACGTGTGTTTTGGGGCAGCCAGAGCTTGGAGACCTCAACCATCAAGAAGACTCGCTTCC 22 0000111344

[0391] CGCACTGGGATGAAGTGCTGGAGCTGCGGGAGATGCCAGGTGCCCCGTCCCCACTGCGGGTGGA OMIM®: 604118 GCTCTGGGACTGGGACATGGTGGGCAAGAATGACTTCTTGGGCATGGTGGAGTTCTCTCCAAAG UniProtKB / Swiss ACCCTCCAGCAGAAGCCACCTAAAGGCTGGTTCCGCCTCCTGCCCTTTCCCAGAGCCGAGGAGG -Prot: 095294 ATTCTGGGGGGAACCTGGGTGCCCTGCGAGTGAAGGTACGCCTGATTGAGGACCGCGTCCTGCC CTCCCAGTGCTACCAGCCTCTCATGGAGCTGCTCATGGAGTCTGTGCAGGGGCCAGCAGAGGAG GACACTGCTAGCCCCTTGGCTTTGCTGGAAGAGCTGACCTTGGGGGACTGCCGCCAGGACCTTG CCACCAAGCTGGTGAAACTCTTTCTTGGCCGGGGACTGGCTGGGCGCTTTCTGGACTATCTCAC CCGGCGTGAGGTGGCTCGGACCATGGACCCCAACACCCTCTTCCGTTCTAACTCCCTGGCATCC AAGTCGATGGAACAGTTTATGAAGCTCGTGGGCATGCCCTACCTGCACGAGGTCCTGAAGCCTG TGATTAGCCGTGTCTTTGAGGAGAAGAAGTACATGGAGCTGGATCCCTGCAAGATGGACCTGGG CCGCACCCGGAGGATCTCCTTCAAAGGCGCACT MALPVTALLLPLALLLHAARPEVQLVESGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGK GLEWMGGFDPEDGETMYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATSTAVAGTPD LFDYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVMTQSPLSSPVTLGQPASISCRSSQS LVHSDGNTYLSWLQQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYY

[0392] 4A8-LAIR1-28Z CTQATQFPYTFGQGTKVDIKDYKDDDDKQEEDLPRPSISAEPGTVIPLGSHVTFVCRGPVGVQT

[0393] 23 peptide FRLERESRSTYNDTEDVSQASPSESEARFRIDSVSEGNAGPYRCIYYKPPKWSEQSDYLELLVK ETSGGPDSPDTEPGSSAGPTQRPSDNSHNEHAPASQGLKAEHLYFWVLWVGGVLACYSLLVTV AFIIFWVRSKRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQG QNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGER RRGKGHDGLYQGLSTATKDTYDALHMQALPPR MALPVTALLLPLALLLHAARPEVQLVESGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGK GLEWMGGFDPEDGETMYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATSTAVAGTPD LFDYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVMTQSPLSSPVTLGQPASISCRSSQS

[0394] tLAIRl-28Z LVHSDGNTYLSWLQQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYY CTQATQFPYTFGQGTKVDIKDYKDDDDKLLVKETSGGPDSPDTEPGSSAGPTQRPSDNSHNEHA 24 peptide

[0395] PASQGLKAEHLYFWVLWVGGVLACYSLLVTVAFIIFWVRSKRSRGGHSDYMNMTPRRPGPTRK HYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGK PRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR

[0396] shRNAl- CCCTCAACCATTGTTCGAGAATTCAAGAGATTCTCGAACAATGGTTGAGGGTTTTT 25 mRASALl

[0397] shRNA4- GCTCTTCCTCTCTCTTATATTCAAGAGATATAAGAGAGAGGAAGAGCTTTTT 26 mRASALl

[0398] GAGTGAAGGTACGCCTGATTG

[0399]

[0400] U6 promoter 27Construct SEQ ID Sequence

[0401] element NO:

[0402] Human GD3 QVQLVE SGGGWQPGRS LRLS CAAS GFTF SNFGMHWVRQAP GKGLEWVAY I S S GGS S INYADTVK 28 GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGGTGTRSLYYFDYWGQGTTVTV

[0403] Heavy Chain

[0404] Variable Region

[0405] Human GD3 DIQMTQSPSSLSASVGDRVTITCRASQDIGNFLNWYQQKPGKAPKLLIYYTSRLQSGVPSRFSG 29 SGSGTDYTLTISSLQPEDFATYYCQQGKTLPYTFGGGTKVEIK

[0406] Light Chain

[0407]

[0408] Variable Region

[0409] All references, patents and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, which in some cases may encompass the entirety of the document.

[0410] 5 The indefinite articles “a” and “an,” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one.” It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method 10 are recited.

[0411] In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” “composed of,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of’ and “consisting essentially 15 of’ shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.

[0412] The terms “about” and “substantially” preceding a numerical value mean ±10% of the recited numerical value.

[0413] Where a range of values is provided, each value between and including the upper and 20 lower ends of the range are specifically contemplated and described herein.

Claims

What is claimed is:CLAIMS1. A bicistronic vector encoding a short hairpin RNA (shRNA) that binds specifically to RASAL1 mRNA and a chimeric antigen receptor that binds specifically to a tumor-associated antigen.

2. The bicistronic vector of claim 1, wherein the tumor-associated antigen or neoantigen is selected from the group consisting of CD19, CD20, CD22, CD33, CD38, CD123, CLL-1, GPRC5D, HER2 (ERBB2), EGFR, EGFRvIII, CEA (carcinoembryonic antigen), PSMA (pro state- specific membrane antigen), MUC1, mesothelin, Claudin 18.2, GPC3, B7-H3, AXL, GD2, GD3, FAP, WT1 (Wilms tumor 1), NY-ESO-1, PRAME (preferentially expressed antigen in melanoma), MAGE-A3, MAGE-A4, AFP, BCMA (B-cell maturation antigen), R0R1, and IL13Ra2.

3. A bicistronic vector encoding a short hairpin RNA (shRNA) that binds specifically to RASAL1 mRNA and a chimeric antigen receptor comprising a leukocyte-associated immunoglobulin-like receptor (LAIR) hinge domain.

4. A bicistronic vector comprising (a) a contiguous 10-40 nucleotide sequence reverse complementary to a RASAL1 gene, wherein the RASAL1 gene comprises the nucleotide sequence of SEQ ID NO: 22, and (b) a transgene encoding a polypeptide comprising a sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 14, optionally wherein the contiguous 10-40 nucleotide sequence is reverse complementary to a coding sequence of the RASAL1 gene.

5. The bicistronic vector of claim 4, wherein the polypeptide further comprises a sequence having at least at least 90% identity to the amino acid sequence of SEQ ID NO: 6.

6. The bicistronic vector of claim 4 or 5, wherein the polypeptide further comprises a sequence having at least at least 90% identity to the amino acid sequence of SEQ ID NO: 16.

7. The bicistronic vector of any of claims 4-6, wherein the polypeptide further comprises a sequence having at least at least 90% identity to the amino acid sequence of SEQ ID NO: 17.

8. The bicistronic vector of any of claims 4-7, wherein the polypeptide further comprises a sequence having at least at least 90% identity to the amino acid sequence of SEQ ID NO:

9. The bicistronic vector of any of claims 4-8, wherein the polypeptide comprises a sequence having at least at least 90% identity to the amino acid sequence of SEQ ID NO: 23.

10. A bicistronic vector comprising: (a) a contiguous 10-40 nucleotide sequence reverse complementary to a RASAL1 gene, wherein the RASAL1 gene comprises the nucleotide sequence of SEQ ID NO: 22; and (b) a nucleotide sequence encoding a chimeric antigen receptor that comprises a LAIR hinge domain, optionally wherein the contiguous 10-40 nucleotide sequence is reverse complementary to a coding sequence of the RASAL1 gene.

11. A bicistronic vector comprising: (a) a contiguous 10-40 nucleotide sequence reverse complementary to a RASAL1 gene, wherein the RASAL1 gene comprise the nucleotide sequence of SEQ ID NO: 22; and (b) a nucleotide sequence encoding a polypeptide comprising a CD 19 antibody domain and a LAIR hinge domain, optionally wherein the contiguous 10-40 nucleotide sequence is reverse complementary to a coding sequence of the RASAL1 gene.

12. The bicistronic vector of any of claims 4-11, wherein the contiguous 10-40 nucleotide sequence encodes the sequence of SEQ ID NO: 25 or 26.

13. A bicistronic vector encoding: (a) a short hairpin RNA (shRNA) targeting RASAL1, and (b) a chimeric antigen receptor comprising (i) a CD 19 single-chain variable fragment (scFv) region and (ii) a LAIR hinge domain.

14. The bicistronic vector of any preceding claim, wherein the vector is a viral vector.

15. The bicistronic vector of any preceding claim, wherein the bicistronic vector comprises a vector backbone sequence selected from a retroviral vector, a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, or a herpes viral vector.

16. The bicistronic vector of any preceding claim, wherein the short hairpin RNA (shRNA) targeting RASAL1 comprises a sequence having at least 90%, at least 95%, or 100% identity to a sequence that binds to mRNA encoded by the sequence of SEQ ID NO: 22, optionally wherein the shRNA targeting RASAL1 comprises a sequence having at least 90%, at least 95%, or 100% identity to the sequence of SEQ ID NO: 25 or SEQ ID NO: 26.

17. The bicistronic vector of any of claims 13-16, wherein the CD19 scFv region comprises the sequence of SEQ ID NO: 6.

18. The bicistronic vector of any of claims 13-17, wherein the LAIR hinge domain comprises an amino acid sequence having at least 90%, at least 95%, or 100% identity to the amino acid sequence of SEQ ID NO: 14.

19. The bicistronic vector of any of claims 13-18, wherein the chimeric antigen receptor comprises an amino acid sequence having at least 90%, at least 95%, or 100% identity to the amino acid sequence of SEQ ID NO: 23.

20. A bicistronic vector encoding a short hairpin RNA (shRNA) targeting RASAL1 mRNA, a CD 19 scFv, a LAIR hinge domain, a CD28 transmembrane domain, a CD28 intracellular domain, and a CD3<^ intracellular domain.

21. The bicistronic vector of claim 20, comprising:a first nucleic acid comprising a first promoter, optionally a U6 promoter, operably linked to a coding sequence encoding the shRNA targeting RASAL1 mRNA; anda second nucleic acid comprising a second promoter, optionally an EFla promoter, operably linked to a coding sequence encoding a chimeric antigen receptor comprising the CD 19 scFv, LAIR hinge domain, CD28 transmembrane domain, CD28 intracellular domain, and CD3<^ intracellular domain.

22. A bicistronic vector encoding a short hairpin RNA (shRNA) targeting RASAL1 mRNA, a CD 19 scFv, a CD28 hinge domain, a CD28 transmembrane domain, a CD28 intracellular domain, and a CD3<^ intracellular domain.

23. The bicistronic vector of claim 22, comprising:a first nucleic acid comprising a first promoter operably linked to a coding sequence encoding the shRNA targeting RASAL1 mRNA; anda second nucleic acid comprising a second promoter operably linked to a coding sequence encoding a chimeric antigen receptor comprising the CD 19 scFv, CD28 hinge domain, CD28 transmembrane domain, CD28 intracellular domain, and CD3<^ intracellular domain.

24. A bicistronic vector encoding a short hairpin RNA (shRNA) targeting RASAL1 mRNA and a chimeric antigen receptor comprising an anti-GD3 single-chain variable fragment (scFv) region.

25. The bicistronic vector of claim 24, wherein the chimeric antigen receptor further comprises a LAIR hinge domain.

26. The bicistronic vector of claim 24 or 25, wherein the chimeric antigen receptor further comprises a CD28 transmembrane domain, a CD28 intracellular domain, and a CD3(^ intracellular domain.

27. A cell comprising the bicistronic vector of any preceding claim.

28. The cell of claim 27, wherein the cell is selected from immune cells.

29. The cell of claim 28, wherein the immune cells are selected from T cells, B cells, Natural Killer (NK) cells, and dendritic cells.

30. The cell of claim 29, wherein the cell is a T cell.

31. The cell of claim 27, wherein the cell is selected from stem cells.

32. The cell of claim 31, wherein the stem cells are induced pluripotent stem cells (iPSCs).

33. A method of modulating CAR-T cell signaling and / or function in a collagen-rich tumor microenvironment, comprising providing a T cell expressing a chimeric antigen receptor comprising a LAIR hinge domain, wherein the LAIR hinge domain binds to collagen in the tumor microenvironment and transduces an activation signal to the T cell.

34. The method of claim 33, wherein the activation signal results in upregulation of CD69 on the T cell.

35. A method of manufacturing CAR-T cells with enhanced viability, comprising introducing into T cells a nucleic acid encoding a chimeric antigen receptor comprising a LAIR hinge domain, and expanding the T cells ex vivo in the presence of IL-7 and IL- 15, wherein the T cells exhibit greater viability compared to T cells expressing a chimeric antigen receptor comprising a CD28 hinge domain under the same conditions.

36. The method of claim 35, wherein the nucleic acid further encodes a short hairpin RNA (shRNA) targeting RASAL1 mRNA.

37. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of T cells expressing a chimeric antigen receptor comprising a LAIR hinge domain and a short hairpin RNA (shRNA) targeting RASAL1 mRNA.

38. The method of claim 37, wherein the cancer is a hematologic cancer or a solid tumor.

39. The method of claim 36 or 37, wherein the chimeric antigen receptor further comprises an anti-CD19 scFv or an anti-GD3 scFv.

40. The method of any of claims 37-39, wherein the T cells exhibit synergistically enhanced cytotoxicity against tumor cells compared to T cells expressing a chimeric antigen receptor comprising a CD28 hinge domain with the same shRNA targeting RASAL1 mRNA.

41. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of T cells expressing the bicistronic vector of any one of claims 1-26.

42. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a population of cells comprising the cell of any one of claims 27-32.